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Abstract 
In metazoans, chromatin-mediated gene silencing phenomena fall into 
three main categories: Heterochromatin-mediated gene silencing, 
Telomeric gene silencing and Polycomb Group (PcG)-mediated 
silencing. The function of the Drosophila PcG system is best known at 
the homeotic gene clusters, where it keeps the transcriptional state of 
developmental regulators repressed, contributing to the maintenance of 
cell identity during embryo development. This system is also present at 
the TAS repeat sequences, which are responsible for Telomeric 
silencing in Drosophila, although the mechanisms may differ.  
Here I report on the discoveries from different approaches to study the 
function of PcG-regulated chromatin at two genomic locations: the bxd 
Polycomb Response Element, from the Ubx locus, and the TAS repeat 
sequences. I show that Zeste, one of the PRC1 PcG complex subunits, 
interacts specifically with the Polyhomeotic protein, likely as a dimer. 
Using an in vitro system with purified factors I show that the PRC1-
mediated chromatin compaction over a bxd sequence is enhanced by 
Zeste in a dimerization- and DNA binding- dependent way and that other 
factors known to interact with the PcG machinery also display an 
enhancement effect. These results are consistent with a targeting 
function and suggestive of a resilient mechanism for the targeting of 
PRC1 function. 
To study the less-characterized TAS sequences, I developed a 
biochemical purification procedure to identify proteins associated with 
the TAS loci. With this protocol, over 70 new candidates were identified 
and 5 were validated for direct physical association with TAS sequences. 
The Brahma complex was identified as a dominant modifier of Telomeric 
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Position Effect and three other factors were identified as potential 
modifiers. These findings have suggested a predominantly modifier 
dose-independent silencing mechanism at Drosophila telomeres and will 
allow a more directed study of the silencing mechanism mediated by 
TAS sequences. 
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Sumário 
Em organismos metazoários existem três categorias principais de 
silenciamento de genes pela  cromatina: silenciamento através da 
Heterocromatina, silenciamento Telomérico e silenciamento através de 
proteínas da família Polycomb (PcG). A função mais estudada das 
proteínas PcG em Drosophila é exercida nos complexos de genes 
homeóticos, onde mantêm a repressão destes reguladores do 
desenvolvimento, contribuindo para manter a identidade celular durante 
o desenvolvimento embrionário. Este sistema também está presente 
nas sequências repetitivas TAS, que são responsáveis pelo 
silenciamento Telomérico em Drosophila, apesar de os mecanismos 
poderem ser diferentes. 
Apresento aqui as descobertas feitas através de abordagens 
experimentais distintas ao estudo da cromatina regulada por proteínas 
PcG em duas regiões do genoma: o Elemento de Resposta a Polycomb 
bxd, do locus Ubx, e as sequências repetitivas TAS. Mostro que a 
proteína Zeste, um dos componentes do complexo PRC1 da família 
PcG, interage especificamente com o componente Polyhomeotic, 
provavelmente como um dímero. Através de experiências in vitro com 
componentes purificados, mostro que a actividade de compactação da 
cromatina associada à sequência do elemento bxd pelo complexo PRC1 
é potenciada pela proteína Zeste, com o envolvimento dos domínios 
proteicos de dimerização e de ligação ao ADN. Outras proteínas de que 
se conhece a associação à actividade das proteínas PcG apresentam 
um efeito de potenciação semelhante ao de Zeste. Estes resultados são 
interpretáveis à luz de uma função de Zeste e dos outros factores no 
direccionamento do complexo PRC1 para os alvos apropriados e 
sugerem um nível elevado de resiliência nesse mecanismo. 
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Para estudar as menos caracterizadas sequências TAS, desenvolvi um 
método bioquímico de purificação para identificar proteínas associadas 
aos loci TAS. Através deste protocolo, foram identificados mais de 70 
candidatos e a associação de 5 deles com as sequências TAS foi 
confirmada por outros métodos. O complexo Brahma foi identificado 
como um modificador dominante do Efeito Posicional Telomérico de 
silenciamento e outros três factores foram também identificados como 
potenciais modificadores. Estes resultados sugerem um mecanismo de 
silenciamento Telomérico em Drosophila predominantemente 
independente da dose dos modificadores e vão permitir um estudo mais 
direccionado do mecanismo de silenciamento mediado pelas 
sequências TAS. 
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Chromatin Structure in Eukaryotic Cells 
The confinement of the eukaryotic genome within nuclear boundaries 
poses very significant physical challenges. On the one hand, the 
structure needs to solve the packaging problem, by condensing the 
genetic material roughly 10,000-fold from its linear length to fit within the 
nuclear space, while managing the large amount of negative charge of 
the DNA molecule. On the other hand, packaging needs to be done in a 
plastic enough manner, to allow disassembly and re-assembly with cell 
cycle progression and during genome regulation.  
The levels of organization of the genome are likely several, and a 
common rule probably does not exist for every genomic region. It is 
consensual that the basic unit of organization of the genome is the 
nucleosome, formed by the wrapping of roughly 150 base pairs of DNA 
around a histone octamer, composed of two copies of each H2A, H2B, 
H3 and H4 histones (1). These basic proteins counter the negative 
charge of DNA, stabilizing the electrostatic potential inside the nucleus. 
At the same time, they provide a 5-fold stacking of the DNA molecule 
length, which is an important, if insufficient level of shrinking to solve the 
folding problem. Levels of organization above the nucleosome are 
contentious. The organization of a “beads-on-a-string” linear multi-
nucleosome fragment into the next predicted hierarchical level, the 30nm 
fiber, has been proposed to be done by a 2-start zig-zag model (2,3) or a 
1-start solenoid model (4,5), depending on the in vitro reconstitution 
conditions, the method used to determine the structure (X-ray 
crystallography, biochemical analysis or electron microscopy) or the 
presence of the linker histone H1.  
The 30nm fiber is proposed to organize into a 100nm chromonema and 
from here onto the highest organization level, the chromosome (6). 
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Criticism of these models has always been latent (7), due to the lack of 
in situ evidence and the un-physiological conditions of the in vitro data. 
Recent in situ cryo-EM studies of mitotic chromosomes have found no 
evidence for the existence of the 30nm fiber, or of any higher-order of 
organization beyond an 11nm structure, and have proposed an irregular 
fractal-like structure for chromatin in the nucleus (8,9), consistent with 
the recent analysis of chromatin interaction maps from human cells (10) 
and Drosophila embryos (11). Such “molten fractal” models are 
proposed to grant a higher fluidity to, and efficiency in the regulation of, 
the chromatin structure, which are in line with a contemporary view of 
chromatin as a dynamic structure, regulating access to genomic DNA 
and being regulated by a plethora of partner non-histone proteins, as 
opposed to the classical view of a more static frame of structural 
elements organizing the genome (12).  
The association of genomic DNA with histone and non-histone proteins, 
and their higher-order organization into more complex chromatin 
structures and nuclear sub-compartments, create a very intricate 
substrate for genome regulation. Transcription factors and other DNA-
binding proteins which recognize specific motifs in the DNA sequence 
display a different ability to access their substrate whether it is in a 
nucleosomal context or un-protected by the absence of histones (13). 
This access is regulated by various chromatin remodeling activities. On 
one extreme, these can involve the eviction of the whole histone 
octamer, or a part of it from the nucleosome (14), leaving the DNA 
accessible, or substituting one of the multiple histone variants with 
diverse properties (15) for the canonical histone form within the octamer. 
Subtler forms of regulation involve the breaking of contacts between 
histones and DNA, leading to the sliding, looping, or otherwise exposing 
of previously occluded portions of the DNA sequence. These remodeling 
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activities are carried out by a variety of protein complexes, at the 
expense of ATP hydrolysis (16). 
Moreover, DNA-binding proteins often act in the context of multi-protein 
complexes, or transiently associate with other proteins which, by virtue 
of their affinity for specific histone NH2-terminal tail covalent 
modifications at certain aminoacid residues, confer an extra level of 
specificity for target loci. The combination of DNA target presence, 
affinity and accessibility, histone tail covalent modifications, and the 
presence and amount of DNA-binding protein and interacting factors for 
each locus in the genome determines, to a great extent, the processes 
of genome regulation and cell identity. 
 
Chromatin Silencing Mechanisms 
Stable silencing of genes is a desirable property of genome regulation, 
be it for developmental reasons or to defend the cell from deleterious 
transcripts, such as transposons. It generally involves the creation of a 
compacted chromatin structure. The first mechanistic models of 
chromatin-mediated gene silencing came from yeast. In Saccharomyces 
cerevisiae, although no cytological features of heterochromatin are 
visible, specialized genomic structures at the silent mating loci (17), the 
Ribosomal DNA (18,19) and the telomeres (20), are found in a 
transcriptionally silent chromatin state. This repressive environment is 
stable and depends on histones, SIR proteins and on the relative 
position of the repressive loci (21). Transgenes inserted in the vicinity of 
these regions are subjected to the repressive chromatin environment 
and can be silenced to different extents. In higher eukaryotes, the 
amount of constitutive heterochromatin is much higher than in yeast, due 
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to the accumulation of non-coding sequences in the genome, particularly 
at the pericentromeric region. Translocation of a white gene into the 
vicinity of pericentric heterochromatin in Drosophila causes variegating 
expression of the white gene in the eye, due to stochastic silencing by 
the juxtaposed heterochromatin in primordial cells and clonal growth into 
the adult eye (22). This effect is mediated by the local chromatin 
structure (23) and factors that influence this structure control the extent 
of silencing. Mutants that cause an increase in the repression of white on 
this background are called Enhancers of Position Effect Variegation 
[E(PEV)], whereas mutants which alleviate silencing of white are called 
Suppressors of PEV [Su(PEV)]. Collectively, they can be referred to as 
Modifiers of PEV [Mod(PEV)]. In most cases studied, these mutants are 
dominant, i.e. mutation of one of the two copies in the diploid genome is 
enough to cause a phenotype (24). The dose-dependence of this 
phenomenon has led some to propose a mass-action model for the 
silencing of chromatin by specialized complexes (25).    
Unlike in yeast, the chromatin silencing mechanisms at the telomeric 
regions are not equivalent to other constitutive heterochromatic regions 
in Drosophila. Modifiers of PEV don’t show an effect on Telomere 
Position Effect (TPE), the variegating phenotype of white-bearing P-
element insertions at the telomeric regions (26). Furthermore, the 
silencing effect is conveyed by the Telomere-Associated Sequence 
(TAS) repeat loci, rather than the telomeres themselves, and has been 
shown to be regulated by the Polycomb-Group (PcG) of proteins (27), 
which are associated with developmental regulation in higher eukaryotes 
and are mostly found at nuclear regions cytologically classified as 
euchromatic (28,29). 
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Drosophila Development and PcG Protein functions 
A classic model for the study of cell identity phenomena is the 
developing embryo of Drosophila melanogaster. Within the first few 
hours of embryo development, patterns of homeotic master regulatory 
gene expression are formed along the anterior-posterior axis, leading to 
the establishment of the body segments which will result in the 
appropriate organ formation in the adult (30). These master regulatory 
genes are located in two genomic clusters on the Chromosome 3R: the 
Antennapedia Complex (ANT-C) and the Bithorax Complex (BX-C) 
[hereafter collectively called Homeotic Complex (HOM-C)]. Genes in 
these clusters are regulated through cis-acting sequences, relatively 
distant from gene promoters, and by trans-acting transcription factors 
which, depending on the position in the developing body plan, bind to 
regulatory regions in combinations that activate or repress these master 
regulatory identity genes. Such trans-acting transcription factors are 
classified as Gap, Pair-Rule and Segment-Polarity proteins (30) and they 
act sequentially to determine the appropriate pattern of homeotic gene 
expression. They are very short-lived, though, their transcripts decaying 
sharply after the first four hours of development. Concomitantly with their 
decline, another two families of factors – the Trithorax-Group (TrxG) and 
the PcG – replace them at the HOM-C and stably maintain the active or 
repressed states, respectively, of transcription previously established. 
The Drosophila Brahma complex is an example of a TrxG complex and it 
is the homolog of the human ATP-dependent chromatin remodeling 
complex Swi/Snf, which is one of the most ubiquitous chromatin 
remodeling enzymes. PcG proteins exist in the context of multi-protein 
complexes as well and their activities are varied. The Polycomb 
Repressive Complex 1 (PRC1) binds histone H3 methylated at residue 
K27 and is thought to be the main engine of silencing through chromatin, 
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due to its in vitro compaction activity (31). dRING-Associated Factors 
(dRAF) complex mono-ubiquitylates histone H2A at residue K119 and 
de-methylates histone H3 at residue K36 (32). PR-DUB de-ubiquitylates 
histone H2A, counteracting the activity of dRAF (33). PRC2 tri-
methylates histone H3 at residue K27 (34-36), and the Pcl-PRC2 variant 
carries the same activity, but more efficiently (37). Pho Repressive 
Complex (PhoRC) binds a specific sequence within PcG target sites and 
interacts with di-methylated histone H3 and histone H4 at residues K9 
and K20, respectively (38). All these complexes are found enriched at 
Polycomb Response Elements (PREs), which are cis-regulatory regions 
found at the HOM-C and elsewhere in the genome. Mutations in ANT-C, 
BX-C, Gap, Pair-Rule, Segment Polarity, TrxG, PcG or PREs all can 
lead to homeotic transformation, due to the loss of the appropriate cell 
identity. This suggests a highly inter-dependent regulation of the 
segmentation mechanism. 
PRE chromatin has been characterized by a list of structural features: 
the reduced accessibility of the underlying DNA to an exogenous 
methylase, in a PcG-dependent manner, suggestive of a condensed 
structure (39), the sensitivity to nucleases DNase I and MNase (40-42), 
the depletion in histones (42-44), and the low-density on a CsCl gradient 
(45). Besides these, there is a characteristic organization of DNA motifs 
recognized by a group of factors known or thought to recruit PcG 
proteins (46). The combination of these properties, along with a 
particular topology and genomic organization (47,48), is the basis of 
some of the functional readouts that identify these regions as PREs. 
Namely, the strong physical association with PcG proteins (49), the 
homing of P-elements containing a PRE sequence (50,51), or the 
Pairing-Sensitive Silencing (PSS) of an associated mini-white transgene 
(52). PSS is mediated by PcG proteins and different PREs have been 
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shown to also require the proteins Pleiohomeotic (Pho), GAGA (53), 
Zeste (54) and other unidentified factors (55). 
Some of this information has been used to predict the occurrence of 
PREs on the human homeotic (HOX) clusters, leading to the 
identification of a few elements that exhibit the hallmarks of Drosophila 
PREs (56); on the other hand, the DNA motifs recognized by proteins 
associated with PREs (GAGA, Zeste, Pho) were used to build algorithms 
for the in silico identification of clusters of these motifs, thus expanding 
the catalog of potential PREs in Drosophila (57,58). Both cases typify the 
strengths and weaknesses of predictive tools as, on the one hand, they 
allowed the discovery of the first human PREs and of new Drosophila 
PREs but, on the other hand, they probably missed most human PREs, 
while identifying a substantial number of probable false positive 
Drosophila PREs, as several studies have not found any PcG proteins 
bound at many of the in silico predicted PREs (59-61). 
  
Long-range communication in chromatin 
One of the most interesting features of the PcG machinery is the 
involvement with long-range communication between chromatin 
locations in cis and in trans. The PSS phenomenon is just one case 
where this feature is detected, but other communication events, such as 
chromatin fiber looping (62), PRE clustering (11,48) and transvection, 
depend on PcG function and, often, they also depend on PRE-binding 
proteins. 
Transvection has been extensively studied in Drosophila, but evidence 
from other organisms is very limited. This can be, in part, due to the long 
tradition of genetic studies in Drosophila, but in part it is also because 
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the genome of Drosophila is organized in a very peculiar way: the 
homologous chromosomes are extensively paired in interphase nuclei, 
allowing a physical proximity between the alleles throughout most of the 
genome (63). Given this organization, the distance between regulatory 
regions and promoters in the homologous chromosomes may be 
sufficiently short to allow cross-talk. This is the original concept that led 
to the coinage of the term “trans-vection”, in opposition to “cis-vection”, 
when regulation involves the promoters and regulatory regions in one of 
the chromosomes alone (64). This pairing phenomenon is likely made 
possible by the action of general chromatin structural proteins, such as 
Topoisomerases (63) and Condensins (65). But the close association of 
homologs by the action of general chromatin factors is not enough, 
though necessary, for transvection to occur. Many cases have been 
reported where the wild type function of the zeste gene product is 
needed. These are the cases of decapentaplegic (66), apterous (67), 
yellow (68), or eyes absent (69).  Several cases, though, such as 
vestigial (70), or men (71) don’t require wild-type zeste function. Due to 
the close association of homologous chromosomes in Drosophila nuclei, 
it has been suggested that transvection has evolved from cis-regulatory 
phenomena. It is thus interesting to find cases where zeste function is 
also required for enhancer-promoter communication in cis (72). 
At the BX-C, the dependence on zeste for transvection seems to be the 
predominant case at the Ubx locus (73,74), whereas transvection at 
Abd-A and Abd-B loci was shown to be independent of zeste in all cases 
studied. Interestingly, transvection at the iab-5, -6, and -7 within these 
locations is also independent of local chromosome pairing and indeed 
very difficult to disrupt (75,76), although this is not the case for 
transvection between Fab-7 and Abd-B promoters (77). These 
 Compositional and Functional Analysis of Polycomb Target Chromatin 
 
 
 18 
observations make it plausible that transvection effects operate in 
organisms without extensive homolog pairing. 
 
The study of Chromatin Processes 
Experimental approaches to study all of these genome regulation 
parameters have evolved in parallel for the past century, but technical 
developments in the last two decades have made progress in their 
understanding extremely fast. Genome-wide binding motifs for DNA-
binding proteins have become possible to identify with the development 
in genome sequencing technology. Likewise, the combination of 
microarray technology, and later of high-throughput sequencing, with 
Chromatin Immunoprecipitation (ChIP) allowed the identification of all 
genome sites where a particular protein is found in a specific cell or 
tissue type (78), and how differentiation, signaling, stress or mutations 
alter that protein localization. The computational analysis of these data 
has also allowed the discovery and refinement of DNA sequence motifs 
recognized by DNA/chromatin-binding factors. Finally, the high-
throughput sequencing analysis now available has combined with the 
Micrococcal Nuclease (MNase) mapping technology, to study the 
nucleosomal genome occupancy (79), while recent Chromosome 
Conformation Capture (3C) derivatives, such as Hi-C, started to offer 
insights into the higher-order chromatin structures and the principles of 
genome organization (10). 
All these innovations and breakthrough discoveries notwithstanding, 
there isn’t at the moment enough information to predict all the factors 
which associate with a defined genomic locus at a given time or 
physiological condition. The development of the Proteomics of Isolated 
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Chromatin segments (PICh) technology allowed the unbiased 
identification of chromatin-associated proteins at least for one locus (80), 
paving the way to expand the application of this tool to other loci. Of 
special interest in this regard are regulatory regions involved in 
developmental processes. The pattern of association of structural and 
regulatory proteins with such loci has the potential to provide deep 
insights into the mechanisms of development, cell identity and disease. 
 
Here I present and discuss the results of experiments on two projects. In 
Chapter 2, I show the biochemical analysis of the association of the 
PRE-binding factor Zeste with the PRC1 complex and the functional 
interaction of Zeste and other PRE-binding proteins with the chromatin 
compacting activity of PRC1. Activity assays and in vivo targeting 
experiments support a model of robust concentration of PRC1 activity at 
target loci, through multiple layers of interaction. 
In Chapter 3, I describe the technical optimization of the PICh technique 
and its application to the isolation of proteins associated with TAS 
sequences from Drosophila. This work has extended considerably the 
number of proteins known to associate with TAS sequences and 
provided an extensive list of further candidates. I discuss the implications 
of these findings for the mechanisms of TPE and other chromatin-
mediated regulatory phenomena. 
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Chapter 2 
Zeste interacts with Polyhomeotic and 
contributes to the recruitment of PRC1 to PRE 
sequences 
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Abstract 
Control of homeotic gene expression during early Drosophila embryo 
development involves an intricate web of interactions between 
transcription factors, Polycomb- and Trithorax-Group proteins and 
regulatory regions. The association of Polycomb-group proteins with the 
appropriate targets at the appropriate times is assured by a set of DNA-
binding factors which recognize specific sequences at target regions. 
Here we show that one of these factors, Zeste, physically associates 
with the PRC1 subunit Polyhomeotic, and that this interaction depends 
on the dimerization domain of Zeste. We further show that both the 
dimerization domain and the DNA-binding domain are required for 
stimulating the PRC1 chromatin compacting activity in vitro and that this 
apparent stimulation is probably due to a targeting effect. Other 
Polycomb targeting factors show a similar in vitro behavior. 
Overexpression of Zeste in cell cultures increased the occupancy of 
Polyhomeotic at legitimate targets, but did not create ectopic 
Polyhomeotic sites, suggesting the existence of a resilient mechanism 
for dynamically targeting Polycomb activity in vivo.  
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Introduction 
The crucial function of the PcG machinery during the early Drosophila 
embryo development is the maintenance of the silencing of target genes, 
such as the master regulators of the Antennapedia and Bithorax 
complexes, through the creation of a repressive chromatin structure. 
Due to its in vitro chromatin compaction activity, PRC1 is thus 
considered the main engine of PcG chromatin-mediated gene repression 
in Drosophila. 
The PRC1 complex is formed by the association of four PcG proteins – 
Posterior Sex Combs (PSC), Polyhomeotic (Ph), Polycomb (Pc) and Sex 
Combs Extra (SCE, or dRING) – with several TFIID general transcription 
factors and accessory proteins (82). A recombinant complex assembled 
with the four core components of PRC1 [Polycomb Core Complex 
(PCC)] maintains all of the in vitro activities of the whole multi-
Megadalton PRC1 complex, and indeed the PSC subunit alone 
conserves the compaction activity to a large extent (83-85).  
One of the accessory PRC1 proteins is Zeste, has been described as a 
sequence-specific transcriptional activator of the homeotic gene Ubx 
(86) and as a PRE-binding recruiter of the TrxG Brahma complex (87), 
with which it cooperates in the gene activating remodeling activity at 
promoter sequences (88). One of the most intriguing roles of Zeste, 
however, is its function on transvection (89). The most studied cases of 
transvection are at the Ubx locus, where Zeste is necessary for the 
activation of the Ubx promoter by an enhancer in trans, and the zeste1-
white interaction, in which the neomorphic zeste1 allele is responsible for 
silencing paired copies of white, in a PcG-dependent fashion. These 
opposing functions hint at a dual role in the control of activation and 
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silencing. Its stable association as a PRC1 subunit, thus, suggested a 
central role in the targeting of the PcG silencing activity.  
zeste-deleted adult flies without visible homeotic defects can be 
obtained, though (90). This observation suggested that the protein is part 
of a redundant mechanism, as an added layer of safety when other 
mutations are present at the Bithorax Complex, in which cases it can 
compensate through transvection. The notion of redundancy is 
reinforced by the fact that multiple sequence-specific DNA-binding 
factors associate with PRE sequences, and are thought to contribute to 
the recruitment of PcG proteins. Besides Zeste, GAGA (54), Dsp1 (91), 
Grainyhead (92), Pho (93), Pho-like (94), Pipsqueak (95) and Spps (96) 
have a recruitment function at PREs. Furthermore, Sex Comb on Midleg 
(SCM) (97), Polycomb-like (98) and the methylation mark at Lysine 27 of 
the histone H3 tail (99) were all proposed to be involved in the 
recruitment of PcG proteins.  
Nevertheless, Zeste appears to have a significant role in the 
maintenance of Ubx in a silenced state (100). And importantly, like 
GAGA, Zeste was shown to significantly increase the in vitro compaction 
activity of PCC (101), suggesting an important function in PcG 
regulation. 
Here we have dissected further the physical association between Zeste 
and PRC1 and analyzed their functional interaction in the compaction of 
a chromatin template. We have found that the dimerization domain of 
Zeste is required for the physical association with Ph and that Zeste and 
other PRE-binding factors are able to stimulate the compaction activity of 
PSC when target sequences are present. The failure of Zeste 
overexpression to recruit Ph to ectopic binding sites reveals a resilient 
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PcG targeting mechanism, likely dependent on multiple interaction 
surfaces. 
 
Materials and Methods 
Cloning 
Primer sequences can be found in the Annex Table X. The pFastBac 
baculovirus expression constructs for dRING-Flag, Flag-PSC, Flag-Ph, 
Flag-Pc, dRING, PSC, Pc (83), pVL1392-HA-Zeste and pVL1392-HA-
Zeste-Flag (88), pMT-Zeste tagged expression vector (102), GST-PhSAM 
(103) and His-PhSAM (104) were described. The pFB-Zeste∆DBD plasmid 
was constructed by amplifying the Zeste coding sequence downstream 
of the DNA-binding domain (starting at aminoacid 127) with primers 
NdeDBD X Zeste-CT and cloning into the NdeI X EcoRI sites of the pFB-
Zeste plasmid, maintaining the in-frame fusion with the N-terminal HA 
tag. The pFB-Zeste∆AD plasmid was built by amplifying the regions N-
terminal and C-terminal to the Activation domain with primers Zeste-NT 
X BssHII-N2 and Zeste-CT X BssHII-C, respectively, which introduced 
BssHII sites before and after the Activation domain. These were cloned 
with the Topo-TA cloning kit (Invitrogen) into the pCRII plasmid. 
Assembly into pFastBac was done in two steps, cloning the N-terminal 
fragment into the BamHI X EcoRI sites and then cloning the C-terminal 
fragment into the BssHII X EcoRI sites. The pFB-Zeste∆CT plasmid was 
built by cloning the Zeste sequence upstream of the BlpI site (aminoacid 
418) with the BlpCT X Zeste-NT primers into the BamHI X EcoRI sites 
on the pFastBac plasmid. The pFB-Zeste∆Pro plasmid was constructed by 
first introducing a PstI site to cleave at the sequence corresponding to 
the T429 aminoacid of the full-length Zeste sequence, with primers 
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ZPst429F and ZPst429R, using the Quickchange mutagenesis kit 
(Stratagene). The Leucine-Zipper region was then amplified with primers 
ZPstLeu and Zeste-CT and this fragment was cloned into the first 
plasmid, replacing the PstI X EcoRI fragment. For pFB-Zeste∆LZ, the 
Zeste sequence upstream of the Leucine-Zipper domain (aminoacid 
500) with the ProCT X Zeste-NT primers into the BamHI X EcoRI sites 
on the pFastBac plasmid. The pFB-Zeste1 plasmid was constructed by 
site-directed mutagenesis, using primers ZK425M2F and ZK425M2R 
and the Quickchange mutagenesis kit (Stratagene). For the pFB-
Zeste∆DBD–Flag, pFB-Zeste∆Pro–Flag and pFB-Zeste∆AD-Flag plasmids, 
the Zeste-CTFlag primer was used instead of the Zeste-CT primer. For 
pFB-Zeste∆LZ-Flag, primer ProFlag2 substituted for ProCT. For pFB-
Zeste∆CT -Flag, the BlpFlag2 primer substituted the BlpCT primer. Dsp1-
Flag, Psq-Flag, Pho-Flag and GAGA-Flag were cloned into pFastBac by 
amplifying the ORFs out of cDNA vectors obtained from the Drosophila 
Genomics Resource Center (DGRC), using the following primer pairs 
and cloning sites on pFastBac: Dsp1-NT X Dsp1Flag-CT into the EcoRI 
X XbaI site, Psq-NT X PsqFlag-CT into the SpeI X XhoI site, Pho-NT X 
PhoFlag-CT into the EcoRI X XbaI site, GAGA-NT X GAGAFlag-CT into 
the SpeI X XbaI site. The 5S-G5bxd array construct was built by first 
creating SalII and EagI restriction sites flanking the E4 central region of 
the 5S-G5E4 sequence, by site-directed mutagenesis with the 
Quickchange kit (Stratagene) and primer pairs G5E4mutSalIA X 
G5E4mutSalIB and G5E4mutEagIA X G5E4mutEagIB, respectively. The 
PB fragment of the bxd PRE (105) was amplified from genomic DNA 
with primers bxdSal and bxdEag and cloned into the SalII X EagI sites of 
the mutagenized p5S-G5E4 vector, replacing the E4 fragment, to create 
the p5S-G5bxd plasmid. The GST-ZesteLZ construct was made by 
amplifying the region corresponding to aminoacids 501-575 with primers 
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ZesteLZBam and ZesteLZEco and cloning into the BamHI X EcoRI sites 
of the pGEX-4T-1 vector.  
Protein Expression and Purification 
The baculovirus system was used to express proteins in Sf9 insect cells. 
pFastBac plasmids were transformed into DH10bac cells to produce the 
expression bacmid by recombination. Bacmids were isolated and 
transfected into Sf9 cells following the instructions of the Bac-to-Bac 
expression system (Life Technologies). For the expression of HA-Zeste 
and HA-Zeste-Flag, the baculovirus production was done using the 
Baculogold system (BD Biosciences), due to the difference in the donor 
vector backbone (pVL1392). Baculovirus amplification was done 
consecutively in 2cm, 10cm and 25cm tissue culture plates, by infecting 
70% confluent cultures with 1% volume of baculovirus from the previous 
amplification step. Amplification was carried out at 27ºC for 4 days, or 
until signs of infection were obvious (swelling of the cells and 
detachment from the plate). For protein production, individual or 
combinations of different baculoviruses at a Multiplicity of Infection of 
between 1 and 10 pfu/cell were added to suspension cultures of Sf9 
cells in the early to middle exponential growth phase (~5X105 cells/ml). 
Cultures were grown at 27ºC, in a shaking incubator at 100rpm for 40 hr. 
Nuclear protein extracts were prepared based on a previously described 
protocol (107): cells were washed with 1X PBS (137mM NaCl; 2.7mM 
KCl; 10mM Na2HPO4; 2mM KH2PO4; pH 7.4), then with Hypotonic buffer 
(10mM HEPES, pH 7.9; 1.5mM MgCl2; 10mM KCl; 0.2mM PMSF; 1mM 
DTT) and resuspended to 3 packed cell volumes (pcv) with Hypotonic 
buffer. Cells were swollen on ice for 10 min. and lysed with 10 strokes of 
a tight-fitting homogenizer pestle. Nuclei were collected by centrifugation 
and resuspended with 0.5 packed nuclei volumes (pnv) of Low-Salt 
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buffer (20mM HEPES, pH 7.9; 25% Glycerol; 1.5mM MgCl2; 20mM KCl; 
0.2mM EDTA; 0.2mM PMSF; 1mM DTT). An equal volume of High-Salt 
buffer (same composition as Low-Salt buffer, but with 1.2M KCl) was 
added dropwise, while vortexing, and the nuclear protein was extracted 
by incubating in a rotating platform for 45 min. Insoluble materials were 
removed by centrifugation and the cleared extracts were used for protein 
purification. All procedures were carried out at 4ºC or on ice. 
A 400µl volume of M2 agarose beads slurry (Sigma), equilibrated in BC 
buffer (20 mM HEPES, pH 7.9, 0.2 mM EDTA, 10% glycerol) with 0.3M 
KCl (BC300), was added to the nuclear extract per liter of originally 
infected Sf9 culture. The mixture was incubated on a rotating platform for 
4 hr., then poured onto an empty Econo-pac column (Bio-Rad) and the 
flow-through was discarded. Beads were washed sequentially with 20 
volumes of BC buffer containing 0.3, 0.6, 1.2, 2.0, 1.2, 0.6 and 0.3M of 
KCl, with a 20 min. incubation at the 2.0M step, to allow a more stringent 
wash. The protein was eluted from the beads by replacing the buffer with 
a 0.8mg/ml solution of the Flag peptide (DYKDDDDK) in BC300, 
incubating for consecutive elution steps of 30 min. and collecting 
eluates. All solutions contained 0.05% NP-40, 10µM ZnCl2, 1mM DTT, 
0.2mM PMSF and 1X cOmplete EDTA-free protease inhibitor cocktail 
(Roche). Protein concentration was determined by Bradford assay. 
The hSwi/Snf complex used in REA assays was purified from nuclear 
extracts of the Ini1-11 Hela cell line (108), using the same protocols as 
for Sf9 cells, but with a maximum of 0.6M KCl in the BC buffer washes. 
GST-pulldown 
pET-PhSAM (His-PhSAM construct) was transformed into BL21(DE3) 
pLysS bacteria and expression was induced at an OD600 of 0.6 with 1mM 
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IPTG and incubated for 3 hr. at 30ºC. Cells were resuspended with Lysis 
buffer [50 mM Tris-HCl, pH 8.0; 0.2M NaCl; 10 mM β-mercapto-ethanol 
(BME); 10 mM Imidazole, pH 7.5], lysed with five 10 sec. pulses of 
sonication, using a Misonix sonicator and the extracts were cleared by a 
15 min. centrifugation at 20,000g. Extract was applied to a Ni-NTA 
agarose resin (Qiagen) equilibrated with Lysis buffer and incubated on a 
rotating platform for 30 min. at 4ºC. The extract with resin was poured 
onto an Econo-column (Bio-Rad), washed with 20 resin volumes of Lysis 
buffer, 20 volumes of Lysis buffer with 50mM Imidazole, and the protein 
was eluted with 5 volumes of Lysis buffer with 0.5M Imidazole. Imidazole 
was removed from the eluate by dialyzing twice (4 hr., then overnight) 
against 100 volumes of Assay buffer (10 mM Tris-HCl, pH 8.0; 50 mM 
NaCl; 2 mM DTT).  
pGEX-ZesteLZ and pGEX-PhSAM were transformed and induced similarly 
to pET-PhSAM. Bacterial pellets were resuspended with 1X PBS 
containing 0.2mM PMSF, lysed by sonication and cleared by 
centrifugation as above. 0.05% NP-40 was added to the extracts before 
adding to Glutathione Sepharose 4 Fast Flow beads (Pharmacia) 
equilibrated in 1X PBS. Extracts were incubated 1 hr., rotating with the 
beads at 4ºC. Beads were collected by a 1 min. centrifugation at 1000g 
and washed 5 times with 20 bead volumes of 1X PBS, 5 min. each, 
collecting the beads between washes by centrifugation as above. 40µl of 
beads with bound fusion protein were added into each of 4 tubes. PBS 
or purified 10mg His-PhSAM, Ph or Zeste were added to the beads and 
incubated 30 min. at room temperature. Beads were collected and 
washed 5 times as above. Protein was eluted by adding 40µl of 2X 
reducing sample buffer (Thermo Scientific) and incubating 5 min. at 
95ºC. Samples were separated by SDS-PAGE and stained with Imperial 
Protein stain (Thermo Scientific). 
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Western Blot 
For Zeste interaction analysis, 0.1% Input chromatin was separated 
along with 0.01% of the purified protein by SDS-PAGE and transferred 
onto a PVDF membrane. Membrane was blocked for 1 hr. with 5% milk 
in PBST (1X PBS; 0.1% Tween-20), and incubated overnight with 
1:10,000 dilutions of rabbit anti-HA tag (Abcam) or mouse M2 anti-Flag 
(Sigma) antibodies in PBST-3% milk at 4oC. For Zeste protein levels in 
wild-type and transfected cells, the protein from 10,000 cells was 
separated by SDS-PAGE, transferred and blocked as above, and probed 
with the same anti-HA antibody or with rabbit anti-Zeste (1:1000). 
Membranes were washed 3 times, 15 min. each with PBST, and then 
incubated 1 hr. with a 1:10,000 dilution in PBST of HRP-conjugated 
secondary anti-rabbit (GE), or anti-mouse (GE) antibodies. Membranes 
were washed 3 times, 15 min. each with PBST, incubated 5 minutes with 
SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific), 
exposed and developed to Kodak Biomax film (PerkinElmer). Films were 
digitalized and images processed using Adobe Photoshop (Adobe 
Systems). 
Nucleosomal Template Assembly 
The 5S-G5bxd DNA template was excised from 2mg of the pG5bxd 
plasmid by digestion with 700U Asp718 and 480U ClaI (Roche), 180U 
DraIII and 450U DdeI (NEB) at 37ºC overnight. Digested DNA was 
purified by phenol:chloroform separation and precipitated with ethanol. 
DNA was re-suspended with TEN1000 (10mM Tris-HCl pH 8.0; 1mM 
EDTA, pH 8.0; 1M NaCl) and the 2.5Kb 5S-G5bxd fragment was 
separated from the digested backbone by sequential PEG-6000 
precipitation: 50% (w:v in 0.5M NaCl solution) PEG-6000 was added to 
reach a concentration of 3%, vortexed, incubated on ice for 15 min. and 
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centrifuged 10 min., at room temperature, 10,000g. The supernatant was 
recovered into a new tube and PEG-6000 solution was added to 
increase the concentration to 4%, repeating the previous procedure. 
Further PEG-6000 concentration steps of 5% and 6% were produced 
and the pellets of each centrifugation were re-suspended in TE buffer 
(10mM Tris-HCl, pH 8.0; 1mM EDTA, pH 8.0) and analyzed on an 
agarose gel, to determine the presence of the 2.5Kb fragment and 
contaminant bands. Typically, >90% of the fragment was on the 4% and 
5% PEG pellets, but complete separation from the smaller fragments 
was only achieved after 3 to 4 re-iterations of the precipitation protocol. 
80µg of the purified 5S-G5bxd fragment were end-labeled with 32P-
αdATP through a Klenow (NEB) fill-in reaction at the Asp718 site. The 
reaction was carried out for 50 min. at room temperature, followed by a 
clean-up spin through a Microspin G-25 column (Amersham-GE) to 
remove unincorporated nucleotides. Nucleosomal arrays were 
assembled with histone octamers purified from Hela cells (109) by 
gradient salt dialysis (110). Briefly, 10mg of labeled template DNA were 
added to the assembly reaction (20mM Tris-HCl, pH 7.7; 1mM EDTA, 
pH 8.0; 10mM DTT; 0.1mg/ml BSA; 0.5mM Benzamidine-HCl; 2M NaCl; 
in a 100µl reaction volume). To each assembly reaction, Hela histone 
octamer solution was added at varying weight ratios (typically 1:0.9, 1:1, 
1:1.1, but wider ratios need to be tested with new histone octamer 
batches, due to the frequently imprecise protein quantification). 
Assembly reactions were placed inside pre-boiled 6-8KDa MWCO 
dialysis membranes (Spectrum Labs) and into 200ml of High Salt 
assembly buffer (20mM Tris-HCl, pH 7.7; 2M NaCl; 1mM EDTA, pH 8.0; 
10mM DTT; 0.5mM Benzamidine-HCl). The gradient dialysis was set-up 
by establishing a constant flow rate, with a peristaltic Rabbit Pump 
(Rainin), of 200µl/min. from a Low-Salt assembly buffer (20mM Tris-HCl, 
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pH 7.7; 0.25M NaCl; 1mM EDTA, pH 8.0; 10mM DTT; 0.5mM 
Benzamidine-HCl) into the High-Salt assembly reaction, and from here 
to waste. The dialysis proceeded for 48 hr. (roughly until 1000ml of the 
Low-Salt assembly buffer was used), after which time the dialysis bags 
were transferred into 1000ml of TE-low (10mM Tris-HCl, pH 7.7; 0.25mM 
EDTA, pH 8.0; 1mM DTT) and dialyzed for an extra 12 hr. 
Restriction Enzyme Accessibility Assay 
Pre-incubation with PcG proteins was carried out at 30ºC for 60 min. in 
8.8µl reaction mixture [2ng (1.6nM) nucleosomal array; 4.5mM MgCl2; 
2.25mM ATP; 45mM KCl; 9mM HEPES, pH 7.9; 0.09mM EDTA, pH 8.0; 
9% Glycerol]. REA assay reactions were carried out at 30ºC for 60 min. 
in 10µl reaction mixture (4 mM MgCl2; 2mM ATP; 52mM KCl; 12% 
glycerol; 10 mM HEPES, pH 7.9; 0.1mM EDTA, pH 8.0; 1mM DTT) in 
the presence of 5U XbaI (NEB) and 100ng hSwi/Snf. Reactions without 
PcG proteins were supplemented with 2µM Bovine Serum Albumin 
(BSA). Reactions were stopped by the addition of 3µl of Stop buffer 
[6.7mg/ml Proteinase K (Roche); 67mM EDTA, pH 8.0; 33mM Tris-HCl, 
pH 7.7; 0.67% SDS; 17% Glycerol; Bromophenol Blue and Xylene 
Cyanol) and incubation at 55ºC for 40 min. Samples were separated on 
a 1% Agarose gel in 1X TAE (40mM Tris-HCl, pH 7.5; 20mM Acetic 
Acid; 1mM EDTA, pH 8.0), and the gel was dried in a gel drier (Bio-Rad) 
before exposing to a PhosphorImager screen and detecting in a 
Typhoon scanner (Molecular Dynamics - GE). Bands were quantified 
using the ImageQuant software (GE) and the inhibition of hSwi/Snf 
remodeling was determined using the equation: (% uncut with PcG protein and hSwiSnf −% uncut with hSwiSnf)(% uncut without hSwiSnf− % uncut with hSwiSnf)  X100 
To determine the effect of including PRE DNA-binding proteins (Zeste, 
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Pho, Dsp1, Psq, GAGA) in the PcG pre-incubation, the ratio of the levels 
of hSwi/Snf inhibition with and without such proteins was determined at 
each concentration point. 
Chromatin Immuno-precipitation 
Sg4 cells were grown in CCM3 medium (Hyclone), supplemented with 
Pen/Strep (Gibco) at 27ºC, in T-flasks. Zeste-Flag-HA tagged expression 
vector [pMK33-CFH-BD; (102)] was co-transfected with pCoBlast 
(Invitrogen) using the FuGENE HD Transfection Reagent (Qiagen), 
following the manufacturer’s protocol. 25µg/ml Blasticidin (Invivogen) 
was added to the culture medium 2 days after transfection. 24 hr. before 
crosslinking, transgene expression was induced by the addition of 1mM 
CuSO4 and ChIP was performed. ChIP experiments were performed 
essentially as described (111), with minor changes: All operations, 
unless otherwise noted, at 4oC. Cells were cross-linked at a density of 
5X106/ml for 10 min. with 1.8% Formaldehyde (Fisher), at room 
temperature, stopped with Glycine to 0.125M, washed with 1X PBS, re-
suspended and incubated 10 min. in ChIP Wash buffer A (10mM 
HEPES, pH 7.6; 10mM EDTA, pH 8.0; 0.5mM EGTA, pH 8.0; 0.25% 
Triton X-100), and repeated with ChIP Wash Buffer B (10mM HEPES, 
pH 7.6; 0.1M NaCl; 1mM EDTA, pH 8.0; 0.5mM EGTA, pH 8.0). Nuclei 
were isolated by a brief incubation with 1% SDS in TE buffer and, after 
washing extensively with TE, resuspended with TE-PMSF-SDS (TE; 
1mM PMSF; 0.1% SDS) at a density of 1x108 cells/ml. Chromatin was 
solubilized using a Misonix sonicator, to obtain a DNA length between 
200-400bp. Salt and detergent concentrations were corrected to 1% 
Triton X-100, 0.1% Na-Deoxycholate (DOC), 140mM NaCl, and the 
insoluble pellet removed by centrifuging 5 min. at maximum speed in a 
microcentrifuge. 0.5ml chromatin aliquots were pre-cleared for 1 hr. with 
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20µl Protein-A Sepharose (PAS) slurry (Thermo Scientific), and 
incubated overnight with 1.5µg of a rabbit polyclonal anti-HA antibody 
(Abcam), 1.5µg of rabbit polyclonal anti-Ph antibody (31), or with 1.5µg 
of rabbit control IgG (Abcam). Antibody was captured with 30µl PAS for 
3 hr., beads were washed 5 times, 10 min. each with 1ml of RIPA 
(140mM NaCl; 10mM Tris-HCl, pH 8.0; 1mM EDTA, pH 8.0; 1% Triton 
X-100; 0.1% SDS; 0.1% DOC), then once with 1ml of LiCl buffer (0.25M 
LiCl; 10mM Tris-HCl, pH 8.0; 1mM EDTA, pH 8.0; 0.5% NP-40; 0.5% 
DOC) and finally twice with 1ml of TE. Beads were then re-suspended in 
100µl TE, 50µg/ml RNase A (Qiagen), and incubated 30 min. at 37ºC; 
then added SDS to 0.5%, Proteinase K (Roche) to 0.5mg/ml and 
incubated overnight at 37ºC. Reversed the crosslinks at 65ºC for 6 hr., 
extracted DNA, Ethanol-precipitated and re-suspended the pellet in 
150µl ddH2O. qPCR analysis was performed with the IQ SYBR Green 
system (Bio-Rad), with the following primers: F5-fwd and F5-rev for bxd, 
F9-fwd and F9-rev for pUbx, F13-fwd and F13-rev for bx, F18-fwd and 
F18-rev for Fab-7, wp1 and wp2 for pWhite. These primers have been 
described before: F5-F18 (43), wp1 and wp2 (44). The immuno-
precipitated material was quantified against a calibration curve with 
dilutions of input DNA. 
 
Results 
Zeste associates physically with Polyhomeotic 
The transcriptional activator Zeste has been shown to be a stable 
component of the PRC1 complex (82) and to associate tightly with a 
core PRC1 complex (PCC) composed of its four PcG protein 
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constituents – PSC, Ph, Pc and dRING (101). To further dissect this 
interaction, we co-expressed Flag-tagged individual PCC components 
and HA-tagged full-length Zeste in Sf9 cells. Flag-tagged proteins were 
purified from nuclear extracts using an M2 anti-Flag resin, the isolated 
protein was separated by SDS-PAGE and the presence of Zeste 
determined by anti-HA Western blotting (Figure 2.1B). Ph was capable 
of retaining association with Zeste after stringent washing, unlike the 
other PCC components, showing that it is sufficient for the association of 
Zeste with PCC. A trimeric PSC-Pc-dRING complex (PCC∆Ph), purified 
through the Flag tag on PSC, was incapable of binding Zeste [Figure 
2.1B and 1C (middle)], showing that Ph is necessary for the association 
of Zeste with PCC. 
The Zeste protein is composed of several domains and regions with 
particular features (Figure 2.1D). The most prominent regions are the N-
terminal DNA-binding domain and the C-terminal Proline-rich region and 
Leucine-Zipper domain, with less characterized acidic Activation domain 
and Glutamine/Alanine stretches in between. We cloned deletion 
mutants spanning individual or multiple domains into baculovirus 
expression vectors and analyzed the domain requirements for the 
interaction of Zeste with Ph (Figure 2.1E). Sf9 cells were co-infected with 
baculoviruses for Flag-tagged Ph and HA-tagged Zeste mutants, and 
proteins were purified as described above. Deletion mutants eliminating 
the C-terminal Proline-rich region and the Leucine-Zipper domain 
(Z∆CT), or eliminating the Leucine-Zipper domain alone (Z∆LZ) abolish 
the interaction with Ph, indicating that this protein-protein interaction 
domain is required for the association. The Leucine-Zipper domain of 
Zeste thus appeared to be the docking site for Ph. To confirm this 
association, we expressed GST-fusions of the Leucine-Zipper of Zeste 
(GST-ZesteLZ) and of the Ph SAM domain (GST-PhSAM), bound the 
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fusion proteins to Glutathione beads and probed their capacity of 
interacting with candidate partners (Figure 2.1F). 
 
Figure 2.1: Zeste interacts specifically with Polyhomeotic. A. Cartoon depiction of the 
PCCZ complex; B. anti-HA (Zeste) Western blot of input and purified material from an 
M2 Flag affinity column, in association with each of the indicated Flag-tagged PCC 
components. (legend continued on next page) 
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GST-PhSAM was used as a positive control for binding Ph, as it is known 
to be the dimerization surface for the Ph protein (103). As expected, 
GST-PhSAM is capable of associating with a purified HIS-tagged version 
of itself (His-PhSAM), as well as with full-length Ph, while only very 
residual association is seen with Zeste (Figure 2.1F, left); GST-ZesteLZ, 
on the other hand, is capable of associating with full-length Zeste, but 
not with His-PhSAM or full-length Ph (Figure 2.1F, right). These results 
suggest that the Leucine-Zipper domain of Zeste is not sufficient for the 
direct interaction with Ph. This observation was intriguing, given the 
absolute requirement of the Leucine-Zipper for interaction with Ph 
(Figure 2.1D) and the previously reported sufficiency of this domain to 
retain association with the Brahma complex factor Moira (112). This 
might be explained by an overall structural defect caused in Zeste upon 
deletion of the Leucine-Zipper. The Zeste protein has been shown to 
multimerize and its activity was suggested to be dependent on this 
phenomenon (113,114). If the Leucine-Zipper deletion were to affect this 
self-association process, it might impact the interaction with partner 
proteins, with a functional outcome. To look directly at self-association, 
we again used the baculovirus/Sf9 system and co-infected cells with 
Flag-tagged deletion mutants and HA-tagged full-length Zeste.  
PCC∆Ph is a sub-complex of PCC, lacking the subunit Ph, and purified through the Flag 
tag on PSC; C. Coomassie stained gel of recombinantly reconstituted PCC (left), PCCZ 
(right), and PCC∆Ph. Flag tag on Ph (PCC, PCCZ) or on PSC (PCC∆Ph). Zeste 
(arrowhead) was included in the PCC∆Ph Sf9 cell co-infection, but did not co-purify with 
the other subunits. Asterisk indicates a non-specific endogenous Sf9 protein; D. Domain 
organization of the Zeste protein. DBD: DNA-binding domain, AD: acidic Activation 
Domain, QA: Glutamine- and Alanine-rich regions, Pro: Proline-rich region, LZ: Leucine-
Zipper domain; E. Zeste domain requirement for interaction with Ph. The indicated HA-
tagged mutants were co-expressed with Flag-Ph in Sf9 cells and purified over M2 
column. Western blot for HA on input and purified material; F. GST-PhSAM (left half) and 
GST-ZesteLZ (right half) were bound to a Glutathione column and incubated in the 
presence of the purified proteins indicated below. Stably interacting proteins were 
detected on a coomassie-stained gel. Arterisk indicates non-specific band; G. The Flag-
tagged indicated Zeste deletion mutants were co-expressed in Sf9 cells with full-length 
HA-tagged Zeste. The ability to recruit Zeste was tested on a coomassie-stained gel of 
the M2-purified protein, by the presence of the band for full-length Zeste (arrow). 
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Deletion of domains not involved in dimerization – ZesteAD, ZesteP ro – 
had no effect on the recruitment of full-length Zeste, but in the absence 
of the Leucine-Zipper domain the association with Zeste was completely 
lost (Figure 2.1G).This observation is consistent with the GST-ZesteLZ 
association with full-length Zeste (Figure 2.1F). These results show that 
the PRC1 subunit Ph is the direct interaction partner of Zeste within the 
complex, and suggest that an interaction surface is formed on Zeste 
upon dimerization of its Leucine-Zipper domain, which allows recruitment 
of Ph/PCC. 
 
Zeste functions involved in the interaction with PCC 
Functional interactions between Zeste and PcG proteins have been 
extensively suggested from genetic interaction studies (115) and 
biochemical studies, but the nature of this interaction with PRC1 is not 
understood completely. On the one hand, Zeste binding sites on the 
target chromatin substrate increase the activity of PCCZ (a reconstituted 
complex with the four PCC proteins plus Zeste), but even in the absence 
of such sites PCCZ inhibits chromatin remodeling more efficiently than 
PCC (101). These results suggest that there is both a targeting function, 
as well as structural alterations in PCC upon association with Zeste, 
making the complex more efficient at silencing chromatin. We used the 
Restriction Enzyme Accessibility (REA) (83) assay to characterize these 
activities further. For this biochemical assay, a 32P end-labeled 
polynucleosomal template (Figure 2.2A) is pre-incubated with varying 
amounts of purified PcG proteins before assaying the ability of the 
human ATP-dependent chromatin remodeler complex Swi/Snf to 
remodel one of the central nucleosomes. This remodeling event exposes 
a restriction enzyme site that is otherwise inaccessible, due to the 
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presence of the nucleosome. We reconstituted a nucleosomal array 
substrate based on the G5E4 array (116), with a portion of the bxd PRE 
replacing the E4 sequence in the central region (Figure 2.2A). C-terminal 
deletion mutants of Zeste don’t form a complex with PCC, so to allow 
comparison between the effects of Zeste and mutants we decided to 
purify PCC, Zeste and mutants separately (Figure 2.2B), and to compare 
the remodeling inhibition activities of PCC in the presence or absence of 
Zeste and mutants. This strategy also allows a more rigorous 
determination of the effects Zeste has in this mechanism, because the 
activity of different PCC complex preparations varies considerably, 
making it possible to under- or over-estimate the activity of PCCZ. By 
adding Zeste separately to each PCC preparation, we can determine the 
variation in activity from the basal level with PCC alone. We started by 
quantifying the Swi/Snf inhibition activity of purified Zeste protein alone. 
Zeste showed no Swi/Snf remodeling inhibition activity at the 
concentrations used, in sharp contrast with PCC (Figure 2.2D). When 
added to PCC in equimolar amounts, though, the mixture had a clearly 
higher activity than PCC alone (Figure 2.2E): Increasing amounts of 
PCC gradually inhibit cutting by the XbaI restriction endonuclease, 
leading to the accumulation of the uncut, full-length DNA template (upper 
band). The incorporation of Zeste in the PCC pre-incubation mixture 
causes an increase in the Swi/Snf inhibition profile. These effects seen 
with wild-type Zeste are more obvious at lower concentrations of PCC, 
with nearly identical Swi/Snf inhibition profiles detected at higher PCC 
concentrations. We next wanted to compare the effect of Zeste with that 
of mutants lacking the N-terminal DNA-binding domain (Zeste∆DBD) or the 
C-terminal protein interaction region (Zeste∆CT). Nucleosomal 5S-G5bxd 
arrays were pre-incubated with 16nM Zeste or mutant protein, along with 
varying amounts of PCC, before the remodeling reaction with Swi/Snf. 
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Pre-incubation of the arrays with either mutant reduced the PCC activity 
back to levels near those of PCC alone, when compared to PCC+Zeste 
(Figure 2.2F).  
 
Figure 2.2: Zeste increases the efficiency of PCC-mediated inhibition of Swi/Snf 
remodeling. A. Schematic of the 32P end-labeled 5S-G5bxd nucleosomal array substrate 
used in the remodeling assays (details on the text); B. Coomassie-stained gel of the 
protein preparations used in the assays. Asterisks indicate non-specific peptides co-
purified and arrowheads indicate the relevant bands on the Zeste mutant proteins; C. 
Experimental REA protocol for the analysis of PCC, Zeste effects on Swi/Snf remodeling; 
D. Swi/Snf inhibition by PCC (1-16nM) and Zeste (2-32nM). The bars represent the 
average for 3 independent preparations of PCC and 2 of Zeste, and error bars are the 
standard error. E. Representative gel of REA assays with varying concentration of PCC 
(left) or PCC and an equimolar amount of Zeste (right). PCC and Zeste concentrations 
range from 1nM to 16nM; F. Representative gel of REA assays with varying 
concentration of PCC (1-16nM) or PCC and a fixed 16nM concentration of Zeste or the 
indicated mutants (right). 
 
These results are consistent with a role for Zeste in mediating the 
contact between PCC and its target chromatin, with both the DNA-
binding and the protein-protein interaction functions being required for 
this effect. It is worth noting, though, that earlier studies have found that 
C-terminal mutants of Zeste have impaired DNA-binding activity (117), 
thus making it difficult to determine whether the defect in silencing 
observed here is due to the lack of binding to PCC or to a DNA-binding 
impairment. 
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Zeste interacts functionally with Ph and PSC 
Most of the in vitro chromatin compaction activity studies on PRC1 have 
been done with either PCC or with PSC alone (83,118,119). This has 
been the case due to the concentration of the Swi/Snf inhibition activity 
of PRC1 on the PSC subunit. PRC1 activity has recently been linked to 
the existence of positively charged proteins in the complex (120). ~3/4 of 
the basic character of Drosophila PCC is conferred by PSC, but most of 
the remaining charge is due to Ph (Figure 2.3A). The +25.8 charge of Ph 
is well above the +10.4 threshold determined for active PcG proteins 
(120), so we hypothesized that Swi/Snf inhibition could be carried out by 
the Ph subunit and that Zeste could interact specifically with this activity, 
given the physical interaction observed between these proteins. In fact, 
Ph has detectable transcriptional silencing activity in vitro (84), albeit 
considerably lower than that of PSC. In order to compare the effects of 
Zeste on Ph and on PSC activities, we purified individual proteins 
(Figure 2.3B) and used them on the REA assay. Both Ph (Figure 2.3C, 
left) and PSC (Figure 2.3D, left) have activity on their own, although, as 
expected, the activity of PSC is higher. To quantify the effect of Zeste on 
their activities, we determined their inhibition rates in the presence or 
absence of Zeste and calculated the ratio (PcG+Zeste:PcG) at each PcG 
concentration point. Though Zeste leads to a more efficient inhibition of 
remodeling by Ph (the average ratio is always above 1), the poor 
biochemical stability of Ph leads to high variability in the assay (Figure 
2.3E). Surprisingly, a clear increase in PSC activity is also seen in the 
presence of Zeste, in a DNA-binding domain-dependent manner (Figure 
2.3D, 2.3F). This effect appears to be less pronounced than is seen with 
the whole PCC, although the trend is similar, suggesting that the strong 
interaction between Ph and Zeste is not absolutely required for a 
synergistic effect on remodeling, or at least that, in this reconstituted 
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system, weaker interactions with PSC can substitute for the strong 
interaction with Ph in vivo.  
 
 
Figure 2.3: Functional interaction between Zeste, Ph and PSC. A. Net charge of the 
Drosophila PCC complex and of the individual constituent proteins; B. Recombinant 
purified proteins used on the assays, on coomassie-stained gel; C. Representative gel of 
REA assay with 1-16nM Ph (left) or 1-16nM Ph in the presence of 16nM Zeste (right); D. 
Representative gel of REA assays with 0.6-20nM PSC alone (left), or in the presence of 
16nM Zeste (middle), or 16nM Zeste∆DBD (right); E. Variation in Swi/Snf inhibition 
between Ph+Zeste and Ph. Values correspond to the ratio between the percent inhibition 
of Swi/Snf remodeling in the presence and absence of Zeste at each concentration point. 
Values above 1.0 represent an increase in the inhibition by PCC upon addition of Zeste; 
F. Variation in Swi/Snf inhibition between PSC+Zeste and PSC, or between 
PSC+Zeste∆DBD and PSC. The shaded area covers the concentration range where over 3 
molecules of PSC are present for each nucleosomal array molecule. 
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The effects of Zeste on inhibition by PSC are particularly visible at lower 
concentrations of PSC. If we calculate the molarity ratios between the 
nucleosomal substrate and PSC molecules, it becomes obvious that the 
effects of Zeste are particularly pronounced at below the 3:1 PSC:array 
ratio (Figure 2.3F), the point at which the chromatin is expected to be 
saturated with PSC molecules, at 1 PSC molecule per 4 nucleosomes 
(118). This observation suggests a targeting effect, whereby at sub-
saturation levels of PSC, Zeste concentrates the available molecules at 
the targets where Zeste DNA-binding sites are found (the central region 
of the array, where the XbaI site also resides). 
 
PSC activity is modulated by PRE-binding factors 
We next wanted to know whether the apparent targeting effect could be 
seen with other PRE-binding proteins as well. The engineered 5S-G5bxd 
nucleosomal array template accommodates 2 central nucleosomes, 
covering a sequence with 5 Gal4 binding sites and the BP fragment of 
the bxd PRE (105), respectively (Figure 2.4A). The first nucleosome 
occludes the XbaI site assayed by the REA assay and a cluster of Zeste 
binding sites; the second nucleosome region contains binding sites for 
Zeste, GAGA/Pipsqueak (Psq) and Pleiohomeotic (Pho). These 
described sequences are the only regions on the template where binding 
sites for these factors are found; the remaining 10 nucleosomes cover 
5S positioning sequences where no binding sites are present. Also, no 
binding sites for Dsp1, another PRE-binding factor are found on this 
template. Previous studies have implicated some of these factors on the 
bridging between target chromatin and PRC1 components (101,121). 
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We purified each of these individual proteins (Figure 2.4B) and 
determined their intrinsic Swi/Snf inhibition profiles. None of these 
proteins reach the +10.4 charge threshold for active silencing factors 
(Figure 2.4C) and, consistently, none have appreciable levels of 
remodeling inhibition at the concentrations tested (Figure 2.4D).  
 
Figure 2.4: Influence of various PRE-binding proteins on the activity of PSC. A. 
Schematic of the 5S-G5bxd nucleosomal array, with detail of the central region. The 2 
central nucleosomes (grey) form over a hybrid sequence composed of the G5 region of 
the parental G5E4 array (left oval) and the BP fragment of the bxd PRE (105) (right oval). 
The XbaI site is indicated, as well as the positions of the binding sites for Zeste, 
GAGA/Psq and Pho (upper line); B. Coomassie-stained gel of the recombinant proteins 
used in these experiments; C. Net charge of the proteins used in these experiments; D. 
Swi/Snf inhibition activity of the indicated proteins, at the concentrations used in the 
assays with PSC: 8nM Dsp1, 4nM Pho, 8nM Psq, 8nM GAGA, 16nM Zeste; E.  Variation 
in Swi/Snf inhibition between either PSC+Pho, PSC+GAGA, PSC+Psq or PSC+Zeste 
and PSC. Analysis and shaded area as in Figure 3; E. Variation in Swi/Snf inhibition 
between PSC+Dsp1 and PSC. 
 
When these factors were included in the pre-incubation of the 5S-G5bxd 
array with PSC, a similar trend to that observed with Zeste was seen for 
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all (Figure 2.4E), except Dsp1 (Figure 2.4F). Although the scale of the 
effect differed between the various PRE-binding proteins, each of the 
factors with DNA-binding sites on 5S-G5bxd increased the silencing 
activity of PSC at concentrations below the calculated array saturation 
threshold. The lack of effect seen with Dsp1 supports the model by 
which specific recruitment to the central nucleosomes on 5S-G5bxd is 
the basis for the increased activity of PSC on this template, because no 
binding sites for Dsp1 are present at this location. GAGA factor, which 
has previously been shown to be able to recruit PCC to nucleosomal 
arrays and to stimulate its activity (101) shows the strongest stimulatory 
effect, interestingly almost double the effect of Psq, which recognizes the 
same consensus sequence (95).  
This result suggests that the PSC interaction with GAGA is stronger than 
the interaction with Psq, possibly due to a direct interaction between 
GAGA and PSC (122). Together, these results show that multiple factors 
can contribute to the specificity of PRC1 localization at the appropriate 
targets. This information is consistent with what is known about the 
mechanism of PcG targeting in Drosophila. 
 
Zeste increases the occupancy of Ph targets 
As the previous experiments showed, each factor binding at a PRE has 
the potential to add a layer of specificity to PcG targeting, which could 
imply that, should all these effects be added up, a robust system for PcG 
recruitment would be in place. Given the strong, specific interaction 
between Zeste and Ph, we decided to test whether this close interaction 
would be sufficient to disrupt a resilient PcG targeting mechanism. To 
this end, we conducted Zeste overexpression experiments, combined 
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with ChIP to determine occupancy of defined targets. It has previously 
been shown that ectopic overexpression of Zeste leads to the 
appearance of hundreds of new Zeste bands on polytene chromosomes 
(123). Should the strong interaction with Ph be maintained under such 
circumstances, we would expect some of the available Ph to be brought 
along to these ectopic sites. 
To test this hypothesis, we used Sg4 cells, which express low levels of 
Zeste, and transfected them with a copper-inducible Zeste-FlagHA 
expression transgene. A small amount of protein is detected in 
transgenic, non-induced cells, with a large over-production after a 24 
hour induction with CuSO4 (Figure 2.5A). Using these starting materials, 
we studied the occupancy of known and potential Zeste targets by both 
transgenic Zeste and Ph. The most studied target of PcG proteins is the 
BX-C. In Sg4 cells, PRC1 has been shown to target the Ubx and abd-A 
regions, but not the abd-B region (59). Zeste targets both PREs and 
gene promoters, but PcG proteins are found mainly at PREs. We used 
primer pairs to detect the occupancy at two PREs which were expected 
to be Ph targets (bx and bxd) and one PRE which was not expected to 
be a Ph target in these cells (Fab-7); in parallel, we tested the 
occupancy at two promoters: the Ubx promoter, which is a prominent 
target of Zeste, and the white promoter, which contains Zeste binding 
sites, but which is a lesser Zeste target (Figure 2.5B). 
Wild type and Zeste-FlagHA (non-induced and induced) cells were 
cross-linked and ChIP was performed with polyclonal antibodies for the 
HA tag or Ph, along with control IgG. As expected, in wild type cells the 
HA tag antibody was not able to precipitate any of the target chromatin, 
whereas Ph was detected at bx and bxd (Figure 2.5C, first row). In the 
transgenic Zeste-FlagHA lines, the non-induced, low expressing Zeste 
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transgene was detected at varying amounts at the studied targets 
(excluding Fab-7), without showing the ability to recruit Ph to ectopic loci, 
but increasing the occupancy of Ph at wild-type targets by ~3-fold 
(Figure 2.5C, middle row). Upon transgene induction, Zeste becomes 
present at all targets tested, but the pattern of Ph localization doesn’t 
change appreciably (Figure 2.5C, bottom row). 
 
 
Figure 2.5: Chromatin-IP analysis of Zeste-HA and Ph occupancy at target loci. A. 
Western blot analysis of transgene Zeste-FlagHA (top) and total Zeste (bottom) protein 
levels in wild-type and Zeste-FlagHA transgenic lines (non-induced and induced with 
10mM CuSO4 for 24hr); B. Schematic of the target chromatin sites analyzed. PREs are 
represented by boxes and promoters by arrows. Shaded loci are expected non-targets 
for Ph and the grey lines under the loci represent the qPCR primer pairs used. The 
drawings are not to scale; C. Chromatin occupancy levels determined with IgG, α-HA 
and α-Ph at the indicated loci in wild-type Sg4 cells (top), Zeste-FlagHA non-induced 
transgenes (middle), and Zeste-FlagHA induced transgenes (bottom). Results are the 
average of 3 independent transfectios and error bars represent standard error. 
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Interestingly, the Ph occupancy at bx and bxd, though ~2-fold higher in 
the induced cells than in wild-type, is slightly lower than in the non-
induced cells. This might be due to the more widespread localization of 
Zeste throughout the genome and elsewhere in the cells when present in 
higher amounts. Although Ph is not found at the white promoter or Fab-
7, even when Zeste binds there in the induced cell lines, other genomic 
locations could presumably become Ph targets upon Zeste induction. In 
alternative, there might be a threshold above which the amount of Zeste 
acts as a dominant negative, sequestering Ph and/or other interacting 
partners, which are present in limiting amounts, from their chromatin 
locations. 
In summary, Zeste contributes to the fixation of higher amounts of Ph at 
its wild type locations, but ectopic recruitment, though possible, has not 
been detected at the sites tested. This activity is consistent with a role 
for Zeste in concentrating PcG activities at the appropriate targets, and 
suggests that the strength of the Zeste-Ph interaction is not sufficient to 
break the resilience of the PRC1 targeting mechanism. 
 
Discussion 
Zeste interacts specifically with Polyhomeotic 
We have described an interaction between Zeste and Ph, which 
depends on the Leucine-Zipper dimerization domain of Zeste. The lack 
of interaction between the isolated Leucine-Zipper and Ph suggests that 
an interaction surface forms upon dimerization, such that in the absence 
of the remaining protein, the Leucine-Zipper dimers alone don’t interact 
with Ph. Interestingly, even though there is a very long history in the 
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study of the interactions between the PcG machinery and Zeste, Ph had 
never been isolated as a physical or genetic interactor. This might be 
explained, in a small part, by the existence of 2 very similar ph genes in 
Drosophila – ph-p and ph-d – which might be able to compensate for 
each other’s loss. Of the remaining PRC1 proteins, Zeste has previously 
been shown to interact genetically with PSC, as well as with its close 
homolog Su(z)2 (124), and with the sub-stoichiometric PRC1-associated 
SCM (125). There are several peculiarities in the structural organization 
of these proteins, which are reflected in the way they interact with 
partner proteins and DNA. Zeste uses its Leucine-Zipper to self-interact 
and to contact Moira, in the Brahma complex (88), while apparently 
creating the surface to interact with Ph. Efficient binding to target DNA 
also requires the Leucine-Zipper domain (117), in addition to the DNA-
binding domain, suggesting that the functional Zeste unit is a dimer, or 
multimer. On the other hand, the H1 domain of Ph has been shown to 
interact with the HTH domain of PSC by yeast two-hybrid, but when the 
proteins are purified in isolation, the interaction can only be detected by 
GST-pulldown if a portion of the C-terminal region of PSC and the SAM 
domain of Ph are removed (126). This H1 region of Ph is also involved in 
controlling the extent of polymerization of the adjacent SAM domain 
(127). Together, these results show that there are shared surfaces on 
the PRC1 subunit protein structures and that these interactions are likely 
of key importance in regulating PRC1 functions. 
 
Implications for trans-interactions in chromatin 
An older model for Zeste function proposed that trans-regulation of 
targets is correlated with the capacity of the protein to form aggregates 
in vitro, suggesting that in vivo the protein forms high-molecular weight 
 Compositional and Functional Analysis of Polycomb Target Chromatin 
 
 
 49 
multimers (113). This mechanism could be the basis for the white 
silencing mechanism by zeste1, the neomorphic mutation in which paired 
copies of the white gene are silenced, in a PcG-dependent way, as well 
as for transvection at the Ubx locus. This model fails to provide any 
detailed information on the actual mechanism by which multimers of 
Zeste become functional, and later work has called into question that 
aggregation, per se, can be part of the mechanism, as mutants which 
aggregate more than wild-type Zeste fail to silence paired copies of 
white or to support transvection at Ubx (128). The notion that Zeste self-
interacts and that this interaction is required for its function, though, is 
valid. The reason for the correlation between aggregation potential and 
in vivo activity might be not that aggregation is the mechanism, but 
rather that in mutants that don’t aggregate (the ones missing the 
Leucine-Zipper domain) the interaction with both TrxG (Moira) and PcG 
(Ph) proteins is also defective, likely preventing transvection from 
occurring at Ubx (activating) and white (repressing), respectively. 
That Zeste interacts with Ph is an interesting fact on its own. Ph has 
been proposed to play a role on PcG activity spreading on chromatin, 
due to the suggestive helical polymers formed in vitro by its isolated 
SAM domain (104), which interacts with the SAM domain of SCM in a 
similar way (129). But importantly, Ph was also shown to play a crucial 
role on the in vitro PRC1-mediated recruitment of chromatin fibers in 
trans (85). The well-documented involvement of Zeste in trans-
interactions is consistent with this association with Ph being very 
important in the control of cis- and trans-spreading of silenced chromatin 
states. 
Further investigation into these Zeste, Ph, SCM and other associations 
will be useful to clarify these mechanisms. Interestingly, in S. pombe, the 
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Leucine-Zipper domain of the Ste4 protein has been shown to form a 
trimeric complex with the SAM domains of Ste4 itself and of Byr2 at high 
affinity (130), which could hint at a comparable interaction mode 
between Zeste, Ph, and eventually SCM. The implications of these 
associations would be better understood with structural data on these 
factors. 
 
Functional cooperation between Zeste and PCC 
Our inability to detect an interaction between the isolated Leucine-Zipper 
domain of Zeste and Ph might reflect a requirement for in vivo co-
assembly of the interacting pair, or for a post-translational modification 
on the native protein expressed in eukaryotic cells. These hypotheses 
also apply to the previously described interaction between PSC and Ph 
(126), and it could also help explaining why the effect of Zeste on PCC 
compaction activity is smaller when Zeste is isolated separately from 
PCC than when reconstituted as PCCZ (101): the interaction of Zeste 
with the pre-assembled complex might be weaker than when purified as 
part of PCCZ, or it could be of a different nature, precluding some 
structural change on the PRC1 core that would render the complex more 
active at compacting chromatin, independently of its targeting function. 
The DBD- and LZ-dependent functional interaction of Zeste with PCC is 
visible, though, and it shows that the DNA-binding function and the 
protein-protein interaction function of Zeste are required for the 
interaction. This effect is conserved when Ph or PSC are used as the 
compacting function. As is the case with another PRE-binding factor, 
Grainyhead (131), the homo-dimerization function of Zeste might 
strongly impair the DNA-binding ability, making the effect of the Zeste∆CT 
mutant difficult to interpret. 
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Redundant in vitro functions of PRE-binding proteins 
The poor biochemical stability of the purified Ph protein and the similar 
pattern of Zeste functional interaction with PSC led us to perform further 
analysis with PRE-binding proteins using PSC. Despite the different 
scale of effects on the PSC remodeling inhibition, all PRE-binding 
proteins with binding sites on the central nucleosomes of the 5S-G5bxd 
array increased the activity of PSC, as measured by the inhibition of 
DNA cutting by XbaI. The simplest explanation for these effects is that 
upon binding to their specific DNA motifs, PRE-binding proteins 
concentrate the available PSC protein at the central nucleosomes, which 
is the region in the array analyzed in the REA assay. The different levels 
of PSC “stimulation” might be due to the specificity of the association of 
each of these factors with PSC, or to different changes operated on the 
target chromatin structure by each factor, creating a more or less 
attractive environment for PSC. An alternative explanation would be that 
the association with these proteins makes PSC overall more active. 
Indeed, the increase in the activity of PSC at higher concentrations, 
though slight, is still visible for most factors (Figure 2.4E), suggesting 
targeting-independent activity. Overall this effect is reduced from the low 
PSC concentration points for most proteins, which is consistent with the 
main function for these proteins being the targeting of PRC1. These 
results thus suggest a functional overlap in the various PRE-binding 
proteins. 
The functions of Zeste and GAGA have been seen to overlap on other 
functions, such as on long-range interactions between enhancers and 
promoters in cis and in trans, a phenomenon typically associated with 
Zeste function, but which for some targets depends on GAGA (132). The 
seeming redundant functions of Zeste and GAGA, as well as other PRE-
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binding factors when studied in vitro or in transgenic reporter assays, lay 
behind an extremely well-orchestrated system to control embryo 
development in Drosophila.  
 
Figure 2.6: Model for the contribution of Zeste and other PRE-binding proteins to the 
activities of PRC1. A. In the absence of targeting factors, PRC1 has similar affinity for all 
potential chromatin locations available; B. In the nuclear context, multiple factors bind at 
PRC1 target chromatin and through interactions (black dotted lines) with any of its 
components contribute to increase the overall affinity of PRC1 for the site. Tri-methylated 
Lysine 27 at Histone H3 (K27) can add an extra level of specificity to this interaction, by 
providing a docking site for the chromodomain of Pc (dotted grey line). Zeste can 
associate directly with Ph and through Leucine-Zipper-mediated multimerization 
contribute to strengthen the anchoring of PRC1 at target PREs, while limiting the 
presence at non-target regions (shaded areas). 
 
For several of the DNA motifs at PREs there are at least 2 proteins with 
the ability to recognize them. GAGA, Zeste and Pho recognize the same 
consensus sequences as Pipsqueak (133), FSH-S (134) and Pho-like 
(94), respectively. Furthermore, there are close functional interactions 
between these factors: Zeste and GAGA binding to PRE chromatin 
facilitate the binding of Pho (135) which, in its turn associates with Pc 
and recruits it to chromatin (121), specifically to some consensus 
sequences where Pho and PCC bind cooperatively (136). Interestingly, 
though, in pho-/pho-like- double mutants, loss of PcG proteins from 
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chromosomal locations is minor (94), again suggesting that in vitro 
effects in reconstituted systems may not translate directly into in vivo 
effects, due to the resilience of the system. 
 
Resilience of the PcG targeting mechanism 
The PRC1 complex, and notably its subcomplex PCC, is a very tightly 
associated unit (83). Biochemical analysis of its isolated components is 
useful as a way to more rigorously study each of its activities, but in cells 
the complex is expected to work as a large toolbox of co-existing 
functions. This could be the reason for the long-known fact that PRC1 
components occur at overlapping locations on polytene chromosomes 
(137) and the more recent evidence that they localize at common loci 
(59-61,138). This is also evident in the remarkable maintenance of 
chromatin compaction activity in the mammalian PRC1 complex, despite 
the shuffling of the actual subunit that carries the compacting function, 
from the PSC to the Pc homolog (120), suggesting that the evolutionary 
pressures on this chromatin compaction function were exerted at the 
multi-protein complex level, rather than on the individual protein level. 
The tightness of this association provides a large surface for interaction 
with other proteins and complexes, making it possible for multiple DNA-
binding factors to find an anchoring point on the PRC1 complex and thus 
contributing for recruitment to targets (Figure 2.6). This might be the 
molecular basis for the multitude of PcG-recruiting factors and for the 
frequently reported apparent redundancy in their function. This model 
also provides an explanation for the increased occupancy of Ph target 
sites upon Zeste overexpression, but the lack of ectopic Ph recruitment 
to targets where it was not present in the basal state. If multiple PRE-
binding factors and H3K27me3 contribute to PRC1 recruitment, the 
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overexpression of just one of them might make the grip stronger at bona 
fide targets, but not be sufficient to, on its own, break the association 
with all other factors which help locking PRC1 (and hence Ph) in place. 
This model can help explaining previous data: When expressed 
ectopically as LexA fusion proteins, neither GAGA nor Pho are able to 
recruit PRC1 proteins to a transgenic target or to silence it, as opposed 
to Pc, which does both (122). In a very similar way, a P-element DNA-
binding domain fusion with Ph finds P-element targets in vivo and 
recruits the other PRC1 components (139). This is valid as well for the 
reverse, previously observed fact, that lack of Zeste-binding sites does 
not preclude Ph recruitment to the Fab-7 PRE (87). 
Together, these results show a direct physical interaction between Zeste 
and Ph and an in vitro targeting activity of PRC1 function by PRE-
binding proteins. Our Ph occupancy analysis in Zeste overexpression 
experiments suggest that PRC1 targeting is achieved by multiple 
stabilizing functions at the appropriate targets. 
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Abstract 
The specific set of proteins bound at each genomic locus contributes 
decisively to regulatory processes and to the identity of a cell. 
Understanding the function of a particular locus requires the knowledge 
of what factors interact with that locus, and how the protein composition 
changes in different cell types, or during the response to internal and 
external signals. Proteomics of Isolated Chromatin segments (PICh) was 
developed as a tool to target, purify, and identify proteins associated with 
a defined locus, and was shown to allow the purification of human 
telomeric chromatin. Here, we have developed this method to identify 
proteins that interact with the Drosophila Telomere-Associated 
Sequence (TAS) repeats. Several of the purified factors were validated 
as novel TAS-bound proteins using ChIP, and the Brahma complex was 
confirmed as a dominant modifier of Telomeric Position Effect through 
use of a genetic test. These results offer information on the efficacy of 
applying the PICh protocol to loci with sequence more complex than 
found at human telomeres and identify proteins that bind to the TAS 
repeats that might contribute to TAS biology and chromatin silencing. 
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Introduction 
Proteomics of Isolated Chromatin segments  was developed as an 
unbiased method to identify proteins that physically interact with a 
specific locus in the genome (80) and was developed using the 
telomeres of mammalian cells as a target. Telomeres are found in 
multiple copies of a simple repeat sequence, so do not offer the same 
challenge for the use of PICh as other genomic loci. In this work, we 
apply PICh to the Telomere-Associated Sequence (TAS) repeats of 
Drosophila to demonstrate the efficacy of the technology and to learn 
about the biology of these repeats. 
TAS repeats are found in the subtelomeric region of chromosomes 2, 3, 
and X, and nucleate a particular kind of heterochromatin, which is 
responsible for the Telomeric Position Effect [TPE; for a review, see 
(140)]. As also seen with pericentromeric heterochromatin-mediated 
Position Effect Variegation (PEV), reporter genes inserted at the TAS 
repeats, or between the TAS repeats and the telomeric retrotransposon 
(HTT) arrays, variegate. The extent of gene silencing depends on the 
size, and hence the strength of the transcription activating effect, of the 
HTT array and the transcription repressing activity of the TAS repeats 
(141). Interestingly, though, most modifiers of PEV [Mod(PEV)] have no 
effect on TPE, and in fact very few Mod(TPE)s have been 
unambiguously described so far. Among these are the Polycomb-group 
(PcG) genes, which in some studies have been proposed to act as 
dominant suppressors of TPE [Su(TPE)], and whose encoded proteins 
have been found to be located at the telomeric regions of polytene 
chromosomes (27). These findings indicate that TPE is a distinctive 
class of chromatin silencing, which shares mechanistic features with 
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both pericentromeric heterochromatin and PcG-mediated silencing of 
developmental regulators. 
The extent to which PcG proteins and other reported Su(TPE)s bind at 
TAS repeats and modify TPE, though, has become less clear since the 
finding of a high incidence of TPE-suppressing terminal deletions on the 
chromosome 2L in public Drosophila mutant stocks (142,143). This 
leads  to a high rate of false positive identifications of Su(TPE)s, in which 
the modifying activity is attributable to the 2L deletion, which eliminates 
the TAS repeats at that location and suppresses TPE in trans, rather 
than to the mutant gene being tested (142). The variability of results from 
genetic screens for Mod(TPE)s makes it difficult to advance hypotheses 
for the mechanisms working at TAS repeats. A possible way to 
understand these processes would be to identify which proteins can be 
found physically at the loci, and then study them in more detail. We thus 
decided to use PICh to identify candidates for binding at TAS repeats.  
The TAS repeats provide an excellent model for PICh development for 
several reasons. They are relatively large targets (~45Kb/variant) with 
abundant repeated sequence, yet there are 30-fold fewer target 
sequences for a 25-nt capture probe than in human telomeres. There 
are 2 families of TAS repeats, which provides not only different genomic 
locations to be targeted in parallel but also, due to differences of 
organization between the repeats, allows comparison of the efficiency of 
PICh with different densities of target sequences. Finally, TAS repeats 
have reported functional differences between somatic tissues and the 
female germline, where they function as piRNA-producing clusters 
(144,145). The future extension of findings with cell lines into different 
physiological states will be informative of the role of TAS repeats in 
Drosophila chromatin regulation. 
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With only one validated locus targeted by PICh to date (human 
telomeres), we considered the various challenges of applying the 
method to other loci. Multiple factors have the potential to contribute to 
the success of an experiment like PICh: the relative abundance of the 
targeted sequence, the chromatin architecture of the locus, the density 
of target sequence per DNA unit length, the design of the capture 
probe(s), and the balance between the stability of the crosslinks between 
proteins and DNA and the efficiency of the capture probe invasion of the 
target DNA double strand. We have implemented pre-enrichment steps 
to the PICh protocol and introduced a series of filters to the identified 
proteins to rank the most likely candidate TAS proteins. With these 
modifications, we identified over 70 candidate proteins for direct binding 
to the 2 families of TAS repeats, and validated 5 of these using ChIP. 
We find that the majority of the proteins identified are not dominant 
Su(TPE)s, but the Brahma complex is a dominant Mod(TPE). These 
results suggest the existence of a distinctive mode of regulation at TAS 
repeats, whereby chromatin silencing is less dependent on dose effects 
than in the case of PEV. 
 
Materials and Methods 
Capture probe design 
Oligo selection was done with the help of the Exiqon oligo tools found at 
http://www.exiqon.com/oligo-tools. Oligos were selected on the basis of 
their Tm (usually higher than 78ºC), the lowest possible self-annealing 
propensity, and the least homology to non-target regions in the genome, 
as determined by BLAST. No thresholds for self-hybridization and 
BLAST complementarity have been determined. Rather, for the locus of 
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interest, we looked for the region within this locus where these 
parameters are most favorable. This was done empirically. LNA-C bases 
were not included in the design of capture probes for several reasons: 
the difficulty in solubilizing the lyophilized reagent; the limitation of the 
synthesizer to hold 9 reagent bottles, making it possible to do the 
synthesis in one step when we exclude one of the LNA bases; the active 
search for regions in the target with a predominance of G over C (on one 
or the other strand), so that the self-annealing energies would be 
reduced; and the empirical evidence that capture probes with LNA-G 
work better than capture probes with LNA-C (when using the exact same 
target, with complementary capture probes targeting one or the other 
strand). The capture probe spacer is similar, but not identical to the 
design previously reported (80). The original protocol used a custom-
made 108-atom spacer; for this work, we used commercially available 
phosphoramidite spacer-18 monomers (4 units), plus the 
DesthiobiotinTEG phosphoramidite (Glen Research), bringing the total 
spacer length close to 100 atoms (comparable with the 108 atom length 
previously reported). We tested possible probe designs for their ability to 
enrich before arriving at the design described above. After showing that 
this design worked for TAS-R, we designed three other probes for this 
same region with similar success in enrichment (data not shown). Each 
of these TAS-R probes hybridized to sequences that clustered with the 
TAS-R region in a manner similar to the arrangement of clustered 
sequences that hybridize to the probe presented in the Results section. 
The TAS-L oligo was the only one tested for the TAS-L region. 
Capture probe synthesis 
DMT-LNA-T, DMT-LNA-ABz and DMT-LNA-GDMF phosphoramidites were 
obtained from Exiqon; CPG oligonucleotide synthesis columns, Spacer 
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18 and desthiobiotinTEG Phosphoramidites were obtained from Glen 
Research; dABz, dCBz, dT and dGDMF phosphoramidites were obtained 
from Applied Biosystems. Reagents were reconstituted into the 
recommended concentrations with acetonitrile and synthesis was done 
on an Expedite 8909 DNA synthesizer (Applied Biosystems), following 
recommended coupling conditions for each monomer. The capture 
probe was eluted from the resin with ammonium hydroxide, purified from 
a 15% acrylamide gel and the DMT removed with 80% acetic acid prior 
to a final ethanol precipitation and resuspension in 0.1% TE. 
A detailed capture probe synthesis protocol can be found at 
http://tiny.cc/h9356 
Proteomics of Isolated Chromatin Segments 
Drosophila S3 and Kc cells were grown in suspension in CCM3 medium 
(Hyclone), supplemented with Pen/Strep (Gibco), at 27ºC, 100rpm, in 
2.8L culture flasks, up to a density of 1-2X107/ml. For PICh experiments, 
typically 1011 cells were spun down at 4000rpm, room temperature, in a 
Beckman J6 centrifuge, washed with 400ml of 1X PBS, spun down 
4000g, at room temperature; washed once with 5pcv Hypotonic buffer 
(10mM HEPES, pH 7.9; 1.5mM MgCl2; 10mM KCl); resuspended with 
3pcv Hypotonic buffer and swelled 10 min. on ice in two 100ml dounce 
homogenizers (Kontes); added 37% Formaldehyde (Fisher) to a final 
concentration of 3% and immediately homogenized with 15 strokes of a 
tight pestle; spun down 10 min., at room temperature, 5000g; disposed 
of supernatant and resuspended pellets with a total of 400ml crosslinking 
solution (3% formaldehyde; 1X PBS); incubated 30 min. at room 
temperature, in a shaking platform; pellets were washed 3 times with 
PBS, then once with Sucrose buffer (0.3M Sucrose; 10mM HEPES, pH 
7.9; 1% Triton X-100; 2mM MgOAc), resuspended with 3pnv Sucrose 
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buffer and homogenized with 20 strokes of tight pestle in an 100ml 
homogenizer; pellets were kept after spinning chromatin down at 5000g, 
10 min. Chromatin was washed once with RNase buffer (0.5% Triton X-
100; 1X PBS) and resuspended with 5pnv RNase buffer; added 0.01pnv 
RNase A (Sigma) and incubated 5 hr., at room temperature, on a 
rotating wheel; kept overnight at 4ºC. Washed pellet twice with 6pnv 
PBS, once with 6pnv LB3JD buffer (10mM HEPES, pH 7.9; 0.1M NaCl; 
2mM EDTA, pH 8.0; 1mM EGTA, pH 8.0; 0.2% SDS; 0.1% Na-
Laurosylsarkosine), and resuspended with 3pnv LB3JD; split into 5ml 
aliquots in 15ml polystyrene tubes and sonicated each on ice, for a total 
processing time of 7 min., 15 sec. ON pulses, 45 sec. OFF pulses, in a 
Misonix sonicator, with the power level set to 7.0 (39-42W output); 
pooled the aliquots and spun down 25,000g, 1 hr., at room temperature; 
dialyzed chromatin against 30 volumes Buffer Y (5% Glycerol; 20mM 
HEPES, pH 7.9; 50mM NaCl; 0.05% SDS; 0.05% Na-Laurosylsarkosine; 
0.02% Triton X-100; 1mM EDTA, pH 8.0; 0.5mM EGTA, pH 8.0), through 
a CE-MWCO 1,000,000 dialysis membrane (Spectra/Por), for 4 hr. 
For pre-clearing biotinylated molecules from the mixtures, chromatin was 
incubated 5 min. in a water bath at 60ºC, in 50ml falcon tubes, mixing 
regularly to transfer heat uniformly; removed from water bath and added 
1:100 (v:v) Ultralink Plus Streptavidin beads slurry (Thermo Scientific); 
incubated on rotating wheel, at room temperature, 2 hr. and collected 
flow-through from Econo-pac column (Bio-Rad).  
For capture probe hybridization and purification, a 500-fold molar excess 
(to target copies) capture probe was added to 10mg chromatin (as 
determined by A260), in the case of TAS repeats, ~3nmol capture 
probe/10mg chromatin; the capture probe hybridization was carried out 
in 15ml polystyrene tubes: 6 min. at 70ºC; 1 hr. at 37ºC; 2.5 min. at 
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60ºC; 1 hr. at 37ºC; 2.5 min. at 60ºC; 2 hr. at 37ºC; the mixture was 
transferred into 1.5ml tubes and centrifuged 15 min., maximum speed in 
a microcentrifuge, at room temperature; supernatant was transferred into 
a new 15ml Falcon tube, added NaCl to 100mM and 300µl MyOne 
Magnetic Streptavidin beads (Invitrogen) in LB3JD buffer; incubated on 
rotating wheel, at room temperature, 2 hr.; beads were immobilized on 
magnetic stand, washed 7 times by gently resuspending with 8ml LB3JD 
buffer, transferred into a low-binding 1.5ml tube, washed twice for 5 min. 
with 1ml LB3JD buffer at 42ºC, 1000rpm in a Thermomixer (Eppendorf), 
then 1 hr., at room temperature, 1000rpm; elution was done for each 
sample with 1ml Elution Buffer (12.5mM Biotin; 7.5mM HEPES, pH 7.9; 
75mM NaCl; 1.5mM EDTA, pH 8.0; 0.75mM EGTA, pH 8.0; 0.15% SDS; 
0.075% Na-Laurosylsarkosine) at room temperature, 1000rpm, for 2 hr.; 
eluates were collected into a clean tube, centrifuged 1 min. to remove 
any magnetic beads that might have been carried over, and 
supernatants transferred to new tubes. 
Proteins were precipitated by adding 100% cold TCA to a final 
concentration of 20%. Samples were incubated 10 min. on ice, spun 
down 15 min., at room temperature, and supernatant carefully removed; 
pellet was washed twice with -20ºC Acetone, by vortexing a few seconds 
and centrifuging between washes; pellets were briefly air-dried and 
resuspended with 40µl crosslink reversal buffer (0.25M Tris, pH 8.8; 2% 
SDS; 0.5M β-Mercaptoethanol); crosslinks were reversed by incubating 
samples at 99ºC, 25 min. 
Samples were separated by SDS-PAGE (or stored at -20ºC); gels were 
stained with the SilverQuest kit (Invitrogen) or with Colloidal Blue 
(Invitrogen), according to the manufacturer’s instructions, and relevant 
regions of the gel were cut out of the TAS-specific and corresponding 
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regions of the negative control lanes and sent for analysis at the Taplin 
Mass Spectrometry Facility at the Harvard Medical School. 
Our decision to isolate large sections of the gel for mass spectrometry 
analysis was done to the detriment of deeper coverage, but with the 
advantage of providing an overview of the protein composition at 
reduced cost. The clean appearance of the negative control lane relative 
to the sample lanes indicates the extent to which we enriched for 
proteins with the specific capture probe. The number of peptides 
detected by mass spectrometry does not reflect the total amount of 
protein isolated by these two probes, given the mechanics of the 
LC/MS/MS tandem mass spectrometry apparatus, which discards a 
fraction of the injected peptides above its resolution power. For example, 
compare the number of bands detected by silver stain using specific vs. 
non-specific probes to the total number of proteins identified in each 
sample the protein enrichment with the specific capture probes. 
This technical consideration means that more dilute samples (such as 
the negative control) will have a deeper coverage than the more 
concentrated samples (such as the specific purifications), thus leading to 
a reduction in the difference between the number of proteins identified in 
these samples. Increased coverage from the material enriched with a 
specific probe might be obtained by performing mass spectrometry 
analysis using greater numbers of smaller slices from the gel. 
Drosophila embryo chromatin preparation 
For chromatin preparation from Drosophila embryos, 0-24 hr.-old 
embryos were collected from population cages, dechorionated in 50% 
bleach for 90 sec., washed with running water and transferred into 
Falcon tubes, at 1.5g dry embryos/50ml PBST. Let embryos settle for 5 
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min. and removed supernatant. Embryos were first cross-linked with 
10ml of 1.8% Formaldehyde in PBST, 30ml n-Heptane, for 15 min., 
shaking vigorously at room temperature. Pelleted embryos 1 min. at 
500g, room temperature; removed supernatant and washed twice with 
PBST; resuspended embryos in 10ml PBST and homogenized with 10 
strokes from a tight-fitting pestle to release the nuclei; centrifuged 1 min., 
400g, and collected supernatant into a new tube; centrifuged 10 min., 
1100g, and discarded supernatant. Cross-linked nuclei with 10ml of 3% 
Formaldehyde in PBST, at room temperature, 30 min. Washed the 
Chromatin 5 times with PBST. 
Bioinformatic Analysis of Candidate Proteins 
The total of proteins identified associated with TAS repeats by mass 
spectrometry were first filtered by removing the ones identified in the 
negative control PICh, then by removing proteins previously identified as 
the Drosophila TRAPome (146), which we called “common 
contaminants”. Thirdly, we removed proteins for which only 1 peptide 
was detected, due to the lower confidence in the detection. To sort the 
remaining candidates, we counted the peptides identified in each cell 
line for either TAS-L or TAS-R PICh experiments (PKc, PS3), and for each 
protein in the list we determined 2 normalizing parameters: 1) the 
Detectability Score (D), which represents a measure of the likelihood of 
a given protein being detected in a mass spectrometry experiment. To 
calculate it, we input the amino acid sequence of the largest isoform 
(when multiple isoforms exist) of each protein identified in the PICh 
experiments into the Peptide Detectability Predictor (147), and the 
number of peptides with a detectability score higher than 0.6 (on a 0-1 
scale) per 1000 amino acids in the sequence was determined. To 
determine D, we attributed the value 10 to the protein with the highest 
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density of detectable peptides, and normalized all the other proteins on 
the 0-10 scale. 2) the Normalized Gene Expression Score (EKc, ES3), 
which is a proxy for the protein abundance in the respective cell lines. 
We used raw expression data for Kc and S3 cells from the ModENCODE 
project (148) and attributed the value 10 to the highest gene expression 
level of all the factors identified as candidates with PICh. The remaining 
factors’ gene expression levels were normalized on the scale of 0-10. To 
calculate the Confidence Score (C), we used the following formula: 
𝐶 = 𝑃𝐾𝑐+𝑃𝑆3
�𝐷+�
𝐸𝐾𝑐+𝐸𝑆3
2
��
 . The candidate TAS-L and TAS-R proteins were 
ranked in Tables 3.2, 3.3, A5 and A6 according to this Confidence 
Score. 
GO Term analysis was performed on the FuncAssociate software (149), 
using the web interface. The following lists of proteins were used as 
input to calculate GO term enrichments (Table A3): 1) all the proteins 
identified in both TAS purifications from both cell lines (and that were not 
present in the negative control or “common contaminants” list, and that 
were identified through more than 1 peptide); 2) all the proteins identified 
associated with TAS-R (same filters); 3) proteins associated exclusively 
with TAS-R (same filters); 4) all the proteins associated with TAS-L 
(same filters); and 5) proteins associated exclusively with TAS-L (same 
filters, except for the “1 peptide” filter, because the number of exclusive 
TAS-L factors was too low to analyze GO term enrichment otherwise). 
Western Blot 
0.1%, 0.03% and 0.01% Input chromatin was separated along with 15% 
of the PICh-purified protein by SDS-PAGE and transferred onto a PVDF 
membrane. Membrane was blocked for 1 hr. with 5% milk in PBST, and 
incubated overnight with the following dilutions of the antibodies in 
 Compositional and Functional Analysis of Polycomb Target Chromatin 
 
 
 67 
PBST-3% milk at 4ºC: rabbit anti-Stromalin 1:2000 (gift from Dale 
Dorsett), rabbit anti-SMC1 1:2000 (150), mouse anti-BEAF-32 1:200 
(151), rabbit anti-Pontin 1:2000 and rabbit anti-Reptin 1:2000 (152), 
mouse anti-Modulo 1:1000 (153), rabbit anti-Polycomb 1:2000 (31), 
rabbit anti-dRING 1:1000 (154), rabbit anti-Moira 1:2000 (155), rabbit 
anti-Dsp1 1:2000 (156), rabbit anti-GAGAC-ter 581 1:1000 (157), rabbit 
anti-Woc 1:2000 (158), rat anti-Row 1:1000 and rat anti-HP1c 1:1000 
(159), rabbit anti-Sle 1:2000 (160), rabbit anti-gypsy/GAG 1:1000 (161). 
Membranes were washed 3 times, 15 min. each with PBST, and then 
incubated 1 hr. with a 1:10,000 dilution in PBST of HRP-conjugated 
secondary anti-rabbit (GE), anti-mouse (GE), or anti-rat (Abcam). 
Membranes were washed 3 times, 15 min. each with PBST, incubated 5 
min. with SuperSignal West Pico Chemiluminescent Substrate (Thermo 
Scientific), exposed and developed to Kodak Biomax film (PerkinElmer). 
Films were digitalized and images processed using Adobe Photoshop 
(Adobe Systems). 
Chromatin Immuno-precipitation 
Sg4 cells were grown in CCM3 medium, supplemented with Pen/Strep. 
Flag-HA tag expression vectors [pMK33-CFH-BD; (102)] were co-
transfected with pCoBlast (Invitrogen) using the FuGENE HD 
Transfection Reagent (Qiagen), following the manufacturer’s protocol. 
25µg/ml Blasticidin (Invivogen) was added to the medium 2 days after 
transfection. 24 hr. before crosslinking, transgene expression was 
induced by the addition of 1mM CuSO4 and ChIP was performed on all 
the transfected lines where transgene expression was detected by 
Western blot. ChIP experiments were performed essentially as 
described in Chapter 2 using the following primers: for TAS-R: 
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TAS_ChIP7 X TAS_ChIP8; for TAS-L: TAS3L_ChIP1 X TAS3L_ChIP2 
(primer sequences on Table A1). 
Mutant strains and genetic crosses 
Stocks were maintained and crosses made on cornmeal molasses 
medium with dry yeast added to the surface at 25ºC. 
Mutants defective in candidate genes were chosen because they have a 
strong lethal or sterile phenotype, or because they were described as 
null on FlyBase (162). One exception, XNPUY3132, is a gain of function 
mutation with no obvious phenotype. Stocks with a mutation in or 
deficiency for a candidate gene, and Mi{ET1} insertion stocks were 
obtained from the Bloomington Drosophila Stock Center. Depending on 
the affected chromosome, males from these stocks were crossed for 
four successive generations to either y w67c23; Sco/SM1 or y w67c23; 
Sb/TM6, Ubx females to remove extraneous modifiers of TPE. New 
stocks were established after these backcrosses and tested for TPE by 
crossing to y w67c23; P{wvar}11-5. Only stocks lacking a modifier of TPE 
were used for further analysis. As noted previously (142), many of the 
stocks from the stock center carried suppressors of TPE on 
chromosome 2. Thus, many of the chromosome 2 mutants were 
eliminated from further testing.  
In tests for TPE using a white transgene inserted into a telomere, 3-day 
old males were examined for eye color. Photographs were taken using a 
Nikon SMZ-U stereomicroscope with the diaphragm half open. 
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Results 
PICh optimization  
We have previously reported the development of PICh, a method to 
purify and identify proteins associated with a defined genomic location 
(80). The target sequences purified in that work (human telomeres) are 
highly abundant, and we were interested in determining whether less 
abundant genomic sequences can be isolated using this method. We 
chose to work with Drosophila cells, due to the availability of multiple 
well-established lines that can be grown in large amounts, the lower 
complexity of the genome (~20-fold smaller than the human genome), 
and the possibility of employing genetic assays to test candidates. As a 
target, we focused on the TAS repeats, a moderately repetitive group of 
genomic sequences. 
TAS repeats are subtelomeric satellite sequences which can be divided 
into at least 2 families: those found at the left ends of chromosomes 2 
and 3 (2L and 3L; TAS-L) and those at the XL, 2R and 3R telomeres 
(TAS-R). The TAS-L family is composed of a unique canonical 458bp 
sequence, tandemly arranged in 40-60 repeat units per chromosome. 
The TAS-R family is characterized by the presence of two classes of 
intercalated sub-repeats: a 440bp unit derived from the 3’ UTR of the 
Invader 4 retroelement, and a telomere-specific unit, which differs 
between the XL TAS and the autosomes [Figure 3.1A; for a review, see 
(140)]. TAS-L and TAS-R do not share significant homology at the 
sequence level, so they offered two related targets for PICh that could 
be purified using distinct and non-overlapping capture probes. We 
anticipated that purifying chromatin and identifying associated proteins 
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from the TAS repeats would face several challenges compared to 
purification of human telomeric chromatin.  
 
Figure 3.1: Structure of the TAS repeats and PICh capture probes. A. Schematic of the 
TAS repeats structure (see text for details): TAS repeats are adjacent to the telomeric 
retrotransposon arrays (TART, HeT-A), and are organized as a single repeat unit in 
Chromosomes 2L and 3L, or as a combination of 2 repeat units, one of which is common 
to Chromosomes 2R, 3R and XL, and the other one differing between the autosomes 
and the X. The black dots above the repeat blocks indicate the capture probe 
hybridization sequences. B. Sequence of the capture probes used. a. homology region of 
the capture probes, not including the desthiobiotin and spacers; DNA residues in lower-
case, LNA in upper-case. b. number of predicted targets in the haploid Drosophila 
genome. 
 
Compared to human telomeres, Drosophila TAS repeats comprise an 
equivalent percentage of the genome (~0.02%, compared to 0.01-0.07% 
for human telomeres), but given their longer repeat sequence, the 
number of target positions for a given capture probe is considerably 
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lower. Human telomeres are microsatellites, composed of the simple 
TTAGGG repeat, stretching for lengths ~5Kb per chromosome end. 
They contain a large number of hybridization positions (a 6-nucleotide 
sliding window along the chromosome ends) which significantly 
increases the opportunity for invasion by the capture probe when 
compared to other, non-microsatellite sequences, where the 
hybridization has to occur with a discrete position at the locus.  
 
Figure 3.2: TAS sequence unit repeats and probe hybridization sites. DNA sequence of 
a TAS-R repeat unit from Chromosome 3R (top) and a TAS-L repeat unit from 
Chromosome 2L (bottom). Capture probe hybridization sequences are highlighted in 
yellow and single mismatch in red. 
 
Thus, even though the abundance of TAS sequence is similar to the 
abundance of human telomeres, the possible hybridization positions are 
~30-fold less abundant. Also, in choosing to target both TAS-L and TAS-
R, we hoped to gain a better insight into the target constraints for PICh 
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to work successfully. The TAS-L capture probe hybridizes to one 
position within the 458bp repeat, whereas the TAS-R capture probe has 
three possible hybridization positions (one of which contains a single 
nucleotide change) within 300bp (Figure 3.2), which we refer to 
throughout as a cluster of hybridization sites. Clustered hybridization 
sequences are expected to increase the likelihood that one homologous 
sequence in the cluster will be available for efficient hybridization to the 
probe, as factors such as nucleosome location or local protein binding 
sites might impact hybridization. The relative success in purifying TAS-L 
versus TAS-R should inform concerning whether sequence abundance 
alone indicates a successful probe choice or whether the clustered 
target sequences are important to success. 
We altered the originally reported PICh protocol (see Figure 3.3) at 
specific steps to increase the efficiency of the method. One major 
consideration was the conditions used to prepare the sample for 
hybridization with the capture probe, as initial experiments indicated the 
importance of increasing the signal-to-noise ratio in this starting material. 
Attempts to purify TAS chromatin by the standard protocol yielded a 
large number of ribosomal proteins (data not shown). To combat this, we 
increased the RNase A incubation time (note that single-stranded 
nucleic acids will disproportionately contribute for background signal, 
because they are more easily available for spurious hybridization with 
the probe). Other abundant cytoplasmic proteins were also identified in 
the purified materials, so we isolated nuclei prior to crosslinking, rather 
than using whole cells, to limit contamination by cytoplasmic proteins. 
Finally, to remove non-crosslinked nucleic acids, proteins, and other 
components from the mixture, we dialyzed the solubilized chromatin 
through a high molecular weight cut-off (1MDa) membrane. With these 
combined steps, we achieved a chromatin sample that was enriched for  
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Figure 3.3: The optimized PICh protocol. Cell cultures are harvested and nuclei isolated 
(1); Nuclei are crosslinked, RNA digested, and chromatin is solubilized by sonication (2); 
chromatin is dialyzed through a 1MDa MWCO membrane, to obtain the substrate for 
hybridization (3); desthiobiotinylated capture probe (shown as a black/green line with a 
yellow star, representing the desthiobiotin) is hybridized to the target DNA in complex 
with the crosslinked associated proteins, including the histones (red) and non-
nucleosomal chromatin proteins (grey) (4); the nucleoprotein complex is captured with a 
streptavidin resin (lilac), and the non-associated proteins and DNA (white, outlined 
complexes) washed away (5); the specific complexes are isolated and the proteins are 
separated on a gel and subjected to mass spectrometric identification (6). 
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cross-linked nuclear complexes of nucleic acids and protein, with a 
reduced amount of contaminating materials. 
 
Purification of TAS repeats chromatin  
We designed PICh capture probes specific to the TAS-L and TAS-R 
families and used these to purify the chromatin from each version of TAS 
repeats. A scrambled capture probe, with approximately the same base 
composition as the specific probes but no homologies in the Drosophila 
genome, was used as a negative control (Figure 3.1B). The starting 
biological materials for these experiments were Kc167 (Kc) and S3 cell 
lines, which were chosen to obtain large quantities of homogeneous 
material, as well as to look at overlaps in the TAS protein composition in 
different biological contexts, and thus allow the identification of candidate 
constitutive TAS proteins with higher confidence. Kc and S3 cell lines 
display many similarities but have distinct embryonic origins, with Kc 
cells originating from young embryos and S3 cells from embryos on the 
verge of hatching (163), and distinct transcriptional profiles (148). By 
using these cell lines and capture probes that target the two different 
families of TAS repeats, we hoped to identify common themes and 
differences in the composition of the families of TAS repeats in different 
contexts. 
The PICh hybridization and capture protocol [(80); see details on 
Materials and Methods] was used to purify TAS-associated proteins from 
the modified starting material described above. Samples purified using 
TAS-specific capture probes yielded a higher amount of total protein 
when compared to samples purified with the control (scrambled) capture 
probe, with a markedly different profile from the input protein 
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composition, as determined by silver staining of the purified material 
(Figure 3.4A). We cut the control, TAS-L and TAS-R lanes of the protein 
gel into four slices and submitted each slice for mass spectrometry 
analysis. As expected, a much larger number of peptides was identified 
in the TAS-specific purifications, with ~300 peptides for the control and 4 
to 6.5-fold as many peptides for the specific purifications (see Table A2). 
 
Figure 3.4: TAS repeats chromatin purification. A. Silver-stained gels with input Kc 
nuclear chromatin (left) and 20% of the protein isolated from Kc nuclear chromatin using 
the indicated capture probes (right); Molecular weight (KDa) indicated on the left. B. 
Overlap between the factors identified associated with each capture probes, in Kc cells. 
The values between parentheses denote the number of proteins in the respective sector 
which are among the overall top 25% of proteins, by absolute number of identified 
peptides. C. Overlap between the factors identified associated with TAS-L and TAS-R 
capture probes, after removing proteins identified in the negative control and “common 
contaminants” (see text for details), using combined data from Kc and S3 cells. Values 
between parentheses as in B. 
 
PICh performed using the control capture probe yielded a mixture of 
highly abundant proteins, particularly histones, Topoisomerase II, 
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replication and transcription elongation factors and heat-shock proteins, 
most of which were also common to the TAS-specific purifications 
(Figure 3.4B, Table 3.1, left hand column). Many of these factors are 
likely to be present at TAS repeats, but not specific to the locus. In our 
effort to identify TAS-specific factors, we removed all of these proteins 
from the list of candidates. We also removed from the list of candidates 
proteins that had only one peptide observed following the mass 
spectrometry analysis (Table 3.1, right hand column). 
To confirm that the factors identified specifically in the TAS PICh 
experiments were indeed enriched in our purifications, we tested their 
abundance by Western blot (Figure 3.5). Despite high levels of 
enrichment being obtained for some factors, such as BEAF-32, Pontin or 
Osa, other proteins, such as SMC1, Stromalin and Dsp1, showed little or 
no enrichment. When we searched for these proteins through a list of 
common contaminants in proteomics analysis (146) we found a good 
correlation between lack of enrichment by Western blot and the 
presence of the protein in the TRAPome list (146). This prompted us to 
filter the proteins found in the TRAPome from our list of candidate TAS 
proteins (Table 3.1, middle column). After subtracting these common 
contaminants and low-confidence hits, the remaining proteins (Tables 
3.2, 3.3) showed GO terms anticipated to be associated with chromatin; 
among the top over-represented terms were the cellular components 
“nucleus” and “chromosome” and the activities “DNA binding”, 
“chromatin binding”, or “regulation of gene expression” (Table A3), 
consistent with the expected types of factors purified. 
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Table 3.1: Proteins removed from the final list of candidates 
 
a. proteins identified in the scrambled capture oligo purification. In the right column are 
proteins that are also listed as "common contaminants"; b. proteins considered "common 
contaminants", due to their identification associated with various resins used in 
proteomics studies (44); c. proteins which were not identified in the negative control, but 
for which only 1 peptide was identified in the specific PICh purifications, and thus having 
lower confidence. * proteins previously identified as Mod(PEV); ᵻ proteins previously 
identified as Mod(TPE) ‡ proteins previously identified as Mod(bwD). 
 
The application of filters to these datasets is inexact, so caution must be 
used in evaluating whether any individual protein might inappropriately 
be filtered out (see Discussion). Subtracting the proteins using the filters 
described above is expected to increase the likelihood of a remaining 
RpA-70 Top2 LamC pAbp lola mus309 *ᵻ GstD1 Map60
His H2B His H4 SMC2 l(3)72Ab Incenp Msh6 CG12592 exba
Ef1α48D CG1516 CG10576 SMC1 sle ‡ RpL10Ab CG15093 MAN1
gypsy\gag dre4 * Moe CG6084 RpII215 Ars2 mre11 grau
Ote Act88F tou porin dpa ATPsyn-b Dbp80 Hmu
row His H2Av * ATPsyn-β scu HP5 Mtor CG18292 Uch-L3
RfC3 Histone H1 glu * Hsp60C pds5 lid CkIα TfIIS
Nop60B Histone H3 RpL6 ATPsyn-γ lds Klp61F Orc4 l(2)35Df
mtSSB Lam Hsp60 WRNexo CG2982 mus209 * CG33523 Nurf-38
Nopp140 Hsc70-4 mxc Nup43 BRWD3 Acon lat ᵻ SsRβ
CtBP Gnf1 CG12288 RpS8 E(bx) RPA2 CG5703 Rab11
ZAM\gag CG13096 Hsp83 ncd hang Kap-α3 ᵻ cav * CG5857
Transpac\gag Hsp27 RpL8 Iswi RpL7A rept * CG7376 DNApol-α73
Gapdh1 Hsc70-5 l(2)03709 CG8677 mip130 CG9797 Past1
Hsp70Aa stwl sqd gkt Aldh CG9839 JIL-1 *
RpS2 Ssrp sesB eIF-4a RpI135 CG10139 Elf
Top1 CG6543 mod * βTub56D Mcm6 Hrb27C dalao
CG11180 HP1 * RpS3A Cap Mcm5 sxc Rpd3 *ᵻ
Dsp1 Act42A CG2199 RpS6 nonA Acn pic
CG13295 14-3-3ζ Ef2b Caf1-180 CG42232 DnaJ-1 hay
RfC4 Trap1 αTub84D CG2118 RpL13 phr Rcd1
Regucalcin Hrb87F RpII140 SA CG4747 l(1)G0004 RnrS
Taf6 CG30122 βTub60D kis ᵻ Nap1 CG12547 CG9135
CG3708 retn blw l(3)mbt CG5664 Caf1-105 CG9740
woc FK506-bp1 CG3680 su(Hw) brm ᵻ Klp10A Tbp
ball SF2 Ca-P60A Top3α DNApol-α180 lig3 TH1
CG8142 Fib kdn Rm62 *‡ Bap55 Fancd2 Transpac\pol
Mcm3 B52 bor CG17385 MBD-R2
msps Aly CTPsyn CG17896
Common Contaminants b
Proteins with only 1 Peptide 
detected cNegative control 
a
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candidate being a true positive; however, some of the removed 
candidates might turn out to be bona fide TAS factors. Possible 
examples include HP1, previously shown to associate with the TAS 
region (164); Woc, a transcription factor associated with telomeres and 
mutants of which display telomeric fusion phenotypes (158) and Row, its 
partner protein (159). Woc and Row associate with Hp1c (159,165), 
which was detected specifically at TAS-R in Kc cells (Tables 3.3, A2). 
Thus, though Woc and Row were seen in the control capture probe, they 
might be specifically enriched on TAS elements.  
 
Figure 3.5: Candidate TAS repeat factor enrichment levels by Western blot. A. 
Candidate enrichment on PICh-purified protein from S3 cells. Lanes contain 15% of the 
purified protein and 0.01% input; for Pc and dRING, 0.03% and 0.1% input lanes are 
shown. B. Negative control and TAS-R purifications from Kc cells. Lanes contain 15% of 
the purified protein. 
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Table 3.2: TAS-L proteins, ranked by confidence score 
 
* (-) tested, no effect; (+) tested, identified as Modifier; (+/-) tested, Modifier only in a 
subset of the studies, or only some of the alleles; (a) this study 
 
Also, among the factors filtered out are some that have previously been 
associated with chromatin silencing mechanisms (Table 3.3), which 
therefore might warrant further analysis to determine if they are true 
positives that should not have been filtered. The remaining proteins 
(Tables 3.2, 3.3) were ranked for the likelihood of being genuine TAS 
interacting proteins by several criteria. These were i) the number of 
peptides detected, ii) the relative expression levels of the genes in the  
 
TPE PEV bw D
1 XNP Chromatin remodeler - + + a, 166, 189
2 Rrp1 AP endonuclease - 142
3 Dip3 Myb/SANT-like domain; BESS motif - 142
4 CG8289 Chromodomain 
5 Bj1 RCC1 super family - a, 176
6 borr Chromosome Passenger Complex - a
7 ial Chromosome Passenger Complex
8 Trl GAGA factor, BTB/POZ domain - + a, 27, 167, 168, 142
9 CG8290 - 142
10 CG3163 myb/SANT-like domain
11 smt3 SUMO - 142
12 crol Zn-finger - + a, 142, 189
13 CG4004 Myb/SANT-like domain
14 Orc2 Origin recognition complex - + 142, 169
15 CG33691
16 D1 AT hook-like + 170
17 Mi-2 Chromatin remodeler + 176
18 Caf1 WD40 repeats; Histone-binding - a
19 GAG GAG protein of Gypsy element
20 Mcm2 minichromosome maintenance complex - 142
21 CG1240 SWIB/MDM2, Dek domains - a
22 mu2
23 psq BTB/POZ domain - + 142, 189
24 Su(var)2-10 Zinc fingers; SAP, PINIT domains +/- + 176, 172, 142, 171
25 LBR ICMT domain - 142
26 fbl6 F-box domain; Leucine Rich repeats - 142
27 Su(var)3-9 Chromodomain; SET domain +/- + 176, 187
28 ran GTPase
29 CG1910 - 142
ra
nk Name Domains/Function Modifier of silencing 
*
Reference
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Table 3.3: TAS-R proteins, ranked by confidence score 
 
* (-) tested, no effect; (+) tested, identified as Modifier; (+/-) tested, Modifier only in a 
subset of the studies, or only some of the alleles; (a) this study 
TPE PEV Others
1 Rrp1 AP endonuclease - 142
2 Bj1 RCC1 super family - a, 176
3 pont  AAA+ ATPase
4 Trl GAGA factor, BTB/POZ domain - + a, 27, 167, 168, 142
5 pita Zinc finger, C2H2 type - + 142, 189
6 CG8289 Chromodomain 
7 Mi-2 Chromatin remodeler + 176
8 crol Zn-finger - + a, 142, 189
9 D1 AT hook-like + 170
10 XNP Chromatin remodeler - + + a, 166, 189
11 LBR ICMT domain - 142
12 pzg - 142
13 CG7946 PWWP domain; LEDGF domain - 142
14 mor SANT, SWIRM, RSC8 domains +/- a, 27, 142
15 RfC38 AAA+ ATPase; RFC small subunit - 142
16 Kdm2 H3K4 demethylase
17 CG1240 SWIB/MDM2, Dek domains - a
18 Dref BED zinc finger - 142
19 Chro Chromodomain - 176
20 HP1c Chromodomain; Chromo Shadow +/- 176, 142
21 gp210 - 142
22 smt3 SUMO - 142
23 crp Helix-loop-helix domain - 142
24 borr Chromosome Passenger Complex - a
25 Ubqn Ubiquitin-like domain
26 ran GTPase
27 Klp3A Kinesin motor domain
28 BEAF-32 BESS motif; BED zinc finger - + 176, 173
29 Caf1 WD40 repeats; Histone-binding - a
30 Cp190 BTB/POZ domain
31 Cpr NADPH-dependent FMN reductase - 142
32 Parp PARP, WGR, Zn-finger, BRCT domains
33 Adf1 Myb/SANT-like domain - 142
34 osa ARID/BRIGHT DNA binding domain +/- a, 27, 142
35 Dek SAP domain + + 174, 189
36 Orc1 Origin recognition complex - 142
37 HP1b Chromodomain; Chromo Shadow
38 Rpb5 RNA polymerase II subunit - 142
39 bocksbeutel LEM domain - 142
40 Nipped-B Adherin - a, 142
41 ial Chromosome Passenger Complex
42 CG17078
43 GAG GAG protein of Gypsy element
44 CG1910 - 142
45 ham Zinc finger - 142
46 Dip3 Myb/SANT-like domain; BESS motif - 142
47 wds WD40 domain
48 zf30C + 142
49 Snr1 SNF5 superfamily - a, 142
ra
nk Name Domains/Function Modifier of silencing Reference
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cell line where peptides were identified (148), and iii) a measure of the 
“detectability” of each protein by mass spectrometry. For the latter 
criterion, the sequence of each protein identified by PICh was analyzed 
using the Peptide Detectability Predictor (PDP), an in silico tryptic 
digester (147), and the number of peptides with a ‘detectability score’ 
higher than 0.6 by the criteria of PDP was determined (1.0 is the 
maximum possible detectability on this scale, and 0.6 was chosen 
arbitrarily). This value was then adjusted for the size of the protein by 
expressing it per 1000 amino acids. The higher this value is, the more 
likely the protein is to be detected by mass spectrometry. Both the gene 
expression levels and the detectability score were normalized to a scale 
of 0-10, and the number of peptides identified was divided by the sum of 
these normalizing indexes. Highly expressing, highly detectable factors 
were thus brought to a lower confidence level than they would otherwise 
have had if the number of peptides identified were the only ranking 
factor. Tables 3.2 and 3.3 list the ranks for TAS-L and TAS-R proteins, 
respectively, down to the lowest-ranking candidate tested by ChIP for 
TAS-R (Table 3.3, see below), and the corresponding candidates to the 
same confidence level for TAS-L (Table 3.2). The complete lists, with the 
expression levels and detectability rank, are presented in supplemental 
information (Tables A5 and A6). 
A distinct issue concerns bona fide interacting proteins not being 
detected (i.e. false negatives). Possible reasons to miss a bona fide 
interaction include: the depth of proteomic coverage of the target loci by 
PICh; the extent to which proteins are difficult to identify due to low 
abundance; or low ability to be seen using mass spectrometry. One 
concern in our study was the complete absence of peptides for 
Polycomb-group proteins, which have previously been reported to be 
localized at TAS repeats (175), and to be modifiers of Telomeric Position 
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Effect (27,176); although the latter claim has been challenged for some 
of the PcG genes (142). We looked for enrichment of Polycomb and 
dRING, two members of the PRC1 complex, in the purified proteins by 
Western blot. There is a clear enrichment of Polycomb in the TAS-R 
purification, and also enrichment of dRING in both TAS-L and TAS-R 
purifications (Figure 3.5A). The false negative results for these proteins 
are therefore due to a failure in detection by mass spectrometry. This 
might be caused by a combination of low protein abundance [there is a 
very low amount of Pc transcript (148), as well as protein, as evidenced 
by the Western Blot input signal (Figure 3A)], shallower than ideal depth 
of coverage of the purified material (due to the isolation of proteins from 
4 sections of the gel, rather than using more discrete bands), and a low 
detectability of Polycomb and other Polycomb-Group proteins by mass 
spectrometry. The Polycomb protein has 19.2% of likely observable 
sequence coverage by mass-spec, compared to 81% of observable 
sequence for Topoisomerase II, a highly abundant protein in PICh 
experiments, according to the PeptideAtlas database (177). Using the 
criterion described above for peptide detectability, the density of highly 
detectable peptides for Polycomb is substantially lower than the average 
for detected proteins. 
We conclude that proteins can be missed using PICh due to the depth of 
coverage by mass spectrometry, and that the primary sequence of the 
protein, and the resultant ability to detect its peptides through mass 
spectrometry, might contribute to this issue. A straightforward way to 
alleviate this problem is by increasing the amount of protein isolated and 
analyzed. PICh can also be used, as above, with western analysis as a 
detection method for proteins captured by a specific probe. This might 
prove useful in detecting additional members of a protein complex when 
one or more members have been identified by mass spectrometry, or as 
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a positive control analysis method when optimizing PICh on a new 
sequence. 
 
Validation of new TAS candidates 
Having assembled lists of potential TAS repeat factors, we next chose to 
validate a subset of these by examining their localization in chromatin. 
To that end, we transfected HA-tagged expression vectors into Sg4 cells 
and performed ChIP from the expressing lines. We picked factors from 
different positions in the candidate lists to test the likelihood of finding 
true positive hits. We picked CG8289, a chromodomain protein ranked 
consistently high in all TAS purifications; Dip3 and Ial, found in both 
purifications but higher in the TAS-L rank (Tables 3.2 and 3.3); Klp3A, 
Zf30c and Snr1, all specific to the TAS-R purification, from further down 
in the rank (Table 3.3); Polycomb, not identified by mass spectrometry, 
but enriched at TAS-R (Figure 3.5A); Row, identified in the negative 
control (Table 3.3, Figure 3.5B), but which, as discussed above, 
represents a plausible candidate for being a TAS factor; and 
Topoisomerase 3α, a factor common to all TAS purifications (Table A2), 
but which is a highly expressed protein and previously identified as a 
common contaminant in proteomics studies (146). 
The tagged proteins were induced 24 hr. before Formaldehyde-
crosslinking and ChIP was performed with a polyclonal antibody for the 
HA tag. The binding at TAS repeats was determined by qPCR with 
primer pairs specific for TAS-L or TAS-R. The first observation was that 
the success rate for candidates as assessed by this approach was 
higher for TAS-R than for TAS-L (Figure 3.6). This was not surprising, 
given the higher number of specific candidates identified (Tables 3.3, 
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A2), and is consistent with the hypothesis that the PICh protocol works 
better with clustered capture probe hybridization sites. Second, the 
identification of proteins in the negative control should not be considered 
as a disqualifying parameter. An example of a protein that was found in 
the negative control yet shows binding by ChIP is Row: 4 total peptides 
were seen in the negative control, versus 35 in the TAS-R PICh; 
similarly, for its partner Woc, 1 peptide was detected in the control, 
versus 24 at TAS-R (Table A2).  
 
Figure 3.6: ChIP analysis of candidate TAS protein binding at TAS repeats. Sg4 cells 
were transfected with expression vectors for HA-tagged versions of the indicated 
proteins, and ectopic expression of the transgenes was induced by the addition of 
CuSO4. 24 hours post-induction, cells were crosslinked and ChIP performed. A. ChIP 
with primers specific for the TAS-L repeat, from cells transfected with expression vectors 
for the indicated tagged proteins; the 2 bars represent the average percentage of input 
DNA precipitated using a control IgG antiserum and an anti-HA polyclonal antibody and 
the error bars are the standard error from 2-3 independent transfections. CG8289 and Pc 
enrichments are significant (p <0.05) B. Same as A, but with primers specific for the 
TAS-R repeat family. Dip3 and Pc (p <0.05), CG8289 and Row (p <0.01) enrichments 
are significant. Schematic of the respective TAS repeat structures and primers used 
(arrows) below each graph. 
 
These significant differences in abundance in the TAS-specific vs. 
control purifications led to the possibility that these were true positives. 
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Additionally, for Woc-Row, prior information was available that 
connected Row to binding at the TAS repeats. As discussed earlier, Row 
and Woc are known to be in a complex with HP1c (159), woc mutants 
have a telomere fusion phenotype, and all of these proteins have shown 
an enrichment on the TAS-R purifications, relative to control and TAS-L 
(Table A2), as well as enrichment by Western blot for Woc and HP1c 
(Figure 3.5B). Consistently, when transfected into Sg4 cells, Row can be 
detected at TAS-R, but not at TAS-L (Figure 3.6). Top3α, on the other 
hand, as expected, was not detected at TAS repeats. The high-ranking 
candidate CG8289 was clearly detected at both TAS variants. CG8289 
was identified in the PICh experiments at TAS-L in S3 and Kc cells and 
at TAS-R in S3, Kc cells and embryos (Table A4). Dip3, surprisingly, was 
not found at TAS-L, but was detected at TAS-R, even though it ranked 
higher in the TAS-L list. Ial, the Drosophila homolog of the Aurora B 
Kinase, which came high on the TAS-L list and lower on the TAS-R list, 
was not found at either TAS repeats by ChIP. Of the other TAS-R 
candidates tested, Klp3A was not confirmed, Zf30c was confirmed and 
Snr1 was inconclusive (Figure 3.6B). It is known that performing ChIP 
with components of ATP-dependent remodeling enzyme complexes 
such as Snr1 is complicated, presumably due to their transient 
interactions with DNA as they function (178). The Zf30c result is 
particularly interesting, because its gene is deleted in a deficiency that 
has a dominant Su(TPE) phenotype (142). Given that it binds specifically 
at TAS-R and is associated with a Su(TPE), Zf30c is thus a good 
candidate for a chromatin regulation factor at TAS repeats. In addition to 
zf30c, the genes gkt and rpI135 (classified as “common contaminants”) 
are also removed in deficiencies with dominant Su(TPE) phenotype 
[(142); Table 3.4] and thus deserve special attention, as potential 
Su(TPE)s. 
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Table 3.4: Genes eliminated in dominant Su(TPE) deficiencies (142) 
 
(1) 1 of 3 Deficiencies is False Positive for missing the 2L tip. Does not invalidate the 
other 2 positive hits (region 2); (2) Region 1; (3) 2 of 4 Deficiencies are False Positive for 
missing the 2L tip. Does not invalidate the other 2 positive hits (regions 5, 6). Gkt and 
RpI135 were classified as “common contaminants”. 
 
Finally, Polycomb, found in the TAS-R purification by Western blot, is 
detected by ChIP on both TAS-L and TAS-R. Taken together, these 
results demonstrate a good rate of discovery for TAS-R candidates, with 
even proteins ranking at around #50 proving to be present at the locus, 
and a lower efficiency for TAS-L, with only one of the top hits being 
confirmed by using ChIP. This finding is consistent with the hypothesis 
that clustered target sequences might increase the efficiency of 
detection by PICh. As expected for a proteomic screening protocol, 
some non-specific contaminants appear to have eluded the filters we 
employed and are therefore false positives. Further information 
concerning non-specific proteins and success rates in purifying more loci 
are expected to help fine tune filters and thereby to increase the level of 
bona fide protein identification by PICh. 
 
The TrxG Brahma Complex is involved in the mechanism of 
TPE 
One use for a proteomic screen such as PICh is the identification of 
genes that can be tested using directed genetic protocols. This also 
Name Cytology Obs.
gkt 23D4-23D4 1
RpI135 21C2-21C2 2
zf30C 30C7-30C7 3
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serves as a form of validation, although not all mutations affecting bona 
fide interacting proteins will elicit a phenotype when tested by a specific 
genetic assay. Thus, such genetic assays cannot be used to remove 
candidates for interactions. The most studied biological phenomenon 
associated with TAS repeats is the chromatin silencing mechanism of 
TPE. The search for dominant suppressors of TPE has produced few 
results. A deficiency screen for dominant suppressors of TPE at the 2L 
telomere only identified a single gene, gpp, with mutations that could 
suppress TPE. Most of the suppressors identified in this screen were 
deficiencies for 2L TAS (142). Out of the genes identified by PICh, we 
tested five that had not been identified in the deficiency screen: sle, 
CG8289, rept, cap and smc1.  
Table 3.5: Mod(TPE) Screen  
Gene Allele Modifier 
 
Gene Allele Modifier 
Woc Df(3R)BSC497 No 
 
Osa 90 No 
" Df(3R)BSC739 Noa 
 
Mor Df(3R)Po4 Weakb 
" Df(3R)D605 Noa 
 
CAF1 Df(3R)BSC471 No 
WRNexo Dr(3R)Cha7 Weakb 
 
Borr Df(2L)TE30Cb No 
Sle 57 No 
 
Bj1 Df(3L)XAS96 No 
Brm 2 Yes 
 
XNP 1 No 
SMC1 exc46 No 
 
" UY3132 Noa 
su(Hw) 3 No 
 
CG1240 Df(3L)BSC119 No 
Rept 6945 No 
 
Crol 4418 Noc 
CG2199 Df(3L)Ar14-8 No 
 
" Df(2L)BSC243 No 
" Df(3L)BSC289 No 
 
Trl Df(3L)fz-M21 Nod 
Snr1 1319 No 
 
" Df(3L)XG3 No 
 
a A mutant was found, but it did not segregate with chromosome 3; b Efforts to map the 
modifier were unsuccessful, because the phenotype overlaps wildtype; c A mutant was 
found, but it did not segregate with chromosome 2; d A mutant was found, but it was 
deemed to be a fault positive, because a chromosome bearing another allele of the same 
gene did not carry a mutant. 
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None of the tested mutants showed suppression of TPE using the 
P{wvar}11-5 tester (179) (data not shown). 
As deficiencies of 2L TAS suppress TPE at a number of different 
chromosome ends (179), we next asked whether any of the factors 
identified by PICh could interfere with the TPE induced by Df(2L)M26 
[hereafter M26; (179)] on P{w+}39C-62 (hereafter C62), a mini-white 
insertion into 3R TAS (23). Flies with the C62 transgene alone exhibit an 
orange eye color due to TPE. In the presence of the M26 suppressor, 
silencing is lost and the eye color becomes red (Figure 3.7). To look for 
dominant modifiers of this M26-C62 interaction, we crossed y w67c23; 
M26; C62 females with males mutant for putative TAS-binding factors 
identified by PICh. The males were either y w67c23; mutant/SM1 or y 
w67c23; mutant/TM6, Ubx, depending on the location of the candidate 
gene. Tables 3.5 and A7 show the genes tested and the results. 
Whenever possible we tested multiple alleles, including deficiencies, for 
candidate genes; although in most cases, this was not possible. Two 
deficiency chromosomes, one for WRNexo and one for mor, showed a 
weak ability to suppress the suppression of TPE exhibited by M26. In 
these cases the phenotype overlapped wild type, and these effects were 
not pursued further. The brm2 chromosome exhibited a strong 
suppression of TPE suppression. It is well known that balancer 
chromosomes accumulate modifiers of PEV and TPE. We therefore 
repeated the assay of brm2 in the absence of the TM6 balancer by 
crossing y w67c23;brm2/TM6 males to y w67c23; Sb/TM6, then crossing the 
F1 y w67c23; brm2/Sb males to tester y w67c23; M26; C62 females. The 
result was essentially the same (Figure 3.7). 
To further verify that BRM plays a role in mediating TPE suppression, we 
mapped the genetic factor responsible for the suppression by meiotic 
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recombination. The simple question is: does this genetic factor map 
close to brm? One easy approach is to use a dominant genetic marker 
close to brm and monitor the frequency of recombination.  
 
Figure 3.7: brm2 effects on Df(2L)M26 suppression of TPE. A. Male progeny from a 
cross of y w67c23; +/Sb males to y w67c23; +; P{w+}39C-62 females are shown. There are 
no suppressors of TPE present in these males. Therefore, the mini-white insert in 3R 
TAS is repressed. B. Male progeny from a cross of y w67c23; +/Sb males to y w67c23; 
Df(2L)D26; P{w+}39C-62 females are shown. There are Df(2L)M26 is a deficiency for 2L 
TAS and a suppressor of TPE. Therefore, the silencing of the mini-white insert imposed 
by 3R TAS is repressed and the mini-white gene exhibits increased expression. C. Male 
progeny from a cross of y w67c23; brm2/Sb males to y w67c23; Df(2L)D26; P{w+}39C-62 
females are shown. Heterozygous Df(2L)M26/+; P{w+}39C-62/brm2 males exhibit 
silencing of the mini-white transgene similar to that seen when the Df(2L)M26 is absent. 
Control Df(2L)M26/+; P{w+}39C-62/Sb sibling males, however, exhibit high expression of 
the mini-white similar to that seen when silencing is suppressed. 
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To do this, we chose to use a Mi{3xP3-EGFP.ET1} element. There are 
2700 of these Mi{ET1} elements distributed randomly throughout the 
genome, which means that on average one of these elements is less 
than one map unit from any given gene. They all carry a GFP marker. 
The Mi{ET1}sffMB06603 element is in chromosome region 72A5, 70 kb, and 
we estimate approximately 1 map unit, from brm. We collected Ubx male 
progeny from y w67c23; Mi{ET1}/brm2 females crossed to y w67c23; 
Sb/TM6, Ubx males, tested them for GFP expression and crossed them 
to y w67c23; M26; C62 females to test for effects on M26 suppression of 
TPE. Of 216 males tested, three showed recombination between GFP 
and the suppressor of M26 suppression of TPE. This indicates that the 
genetic factor responsible for interference with M26 suppression is very 
close to brm and may, in fact, be the brm2 mutation. 
Some of the tested mutants showed an interaction with the M26; C62 
transgene combination (Table 3.5), but only the Mod(TPE) effect of the 
Brahma mutant brm2 (Figure 3.7) mapped back to the mutant locus. A 
deficiency eliminating the Brahma complex gene Moira also showed 
interaction in this assay, but the effect, though reproducible, was very 
subtle (Table A7). We conclude that Brahma is involved in regulation of 
TPE at TAS, consistent with our PICh analysis which identified several 
members of the Brahma complex as being physically associated with the 
TAS-R repeats (Table A2), and “Brahma complex” as the GO term with 
the highest over-representation in the list of purified candidate TAS-R 
proteins (LOD score of 2.106, Table A3). 
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Discussion 
We have isolated chromatin and identified proteins associated with the 
Drosophila TAS sequences present at the XL, 2R, 3R, 2L, and 3L 
telomeres. We validated the association of a subset of these factors by 
ChIP, and analyzed their involvement in TPE. We have identified ~70 
factors not previously associated with the TAS repeats and have used 
that information in a directed genetic test to demonstrate a role for 
Brahma in TPE. We conclude that PICh works for less abundant target 
sequences than human telomeres, and suggest that a close clustering of 
the capture probe targets might prove beneficial for PICh efficiency. 
These results represent a significant step in the direction of making PICh 
a universally applicable method, while pointing out the difficulties 
involved in isolating complex loci using PICh and in appropriately filtering 
the resultant data to avoid false positives and false negatives. 
 
Optimization of the PICh technology 
The first application of PICh was in the purification of proteins associated 
with human telomeres (80). Expansion of PICh to less abundant and 
more dispersed targets than the TAS repeats reported here will likely 
require the use of a combination of probes capable of hybridizing to 
closely spaced sequences, and would also benefit from further 
development of pre-enrichment strategies. Analysis of the resultant data 
will be made easier by the availability of an increasing number of public 
proteomics datasets of contaminating proteins and interaction networks, 
thus increasing the ability to filter the raw data and identify strong 
candidate proteins. Filtering out possible false positives using lists of 
common contaminants should nevertheless be used with caution: these 
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lists are under development and some common contaminants might 
prove to be important at the examined locus. 
We have identified strong candidate TAS-binding proteins using PICh, 
but a subset of these candidates will inevitably prove to be false 
positives. Given that PICh uses crosslinked material, a fraction of the 
false positives might be proteins that interact with a “common 
contaminant”, and are thus carried over in the purification. Protein-
protein interaction data is increasingly comprehensive, and recent work 
has added to the list of protein complexes isolated from Drosophila 
(180). Nineteen of the proteins identified in TAS purifications have been 
reported to be part of a complex in which a common contaminant or a 
protein identified in the control PICh experiment was identified. This is 
merely an indicative number of false positives, as we have seen that not 
all of the proteins filtered by “common contaminant” analysis – such as 
Brahma – are false positives. Likewise, such factors as Sle, Incenp, and 
Iswi, even though having been removed from the final list of TAS 
candidates by virtue of their classification as “common contaminants”, 
deserve some attention, given their high enrichment on the TAS 
purifications (Table A2). A careful analysis of all protein hits is thus 
required, in order to minimize both the false positive, as well as the false 
negative candidates. The most decisive advance in the applicability of 
PICh will come from the production of other PICh datasets from different 
tissues and different organisms. 
 
The chromatin at TAS repeats 
A key aspect of a developing methodology for performing proteomic 
screening, such as PICh, is to determine the fraction of identified 
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proteins that are likely to be ‘true’ interactors. These proteins can be 
determined retrospectively, by determining the proteins identified that 
have been shown to have interactions previously by other analyses, and 
can be determined prospectively by validating the association of novel 
candidates.  
At least 17 out of 74 (~23%) proteins identified associated with the TAS-
L/R purifications have previously been associated with some form of 
chromatin-mediated silencing, or to have a telomere-fusion phenotype 
when mutated. In contrast, only 8-12% of the factors in the negative 
control, “common contaminants” and proteins with one peptide identified 
have such phenotypes described. This implies enrichment for real TAS 
repeat associated factors. Additionally, as noted above, some of the 
factors filtered from our final lists might be true TAS repeat factors. In all, 
29 of the proteins detected (excluding the ones identified in the negative 
control) have been found to have a genetic interaction of some kind with 
heterochromatic silencing (Tables 3.1-3). 12 of these have been 
associated with TPE, but the prevalence of terminal deficiencies on 2L is 
a serious problem for the interpretation of TPE suppression data 
(142,143). Some of the putative Su(TPE) genes identified in numerous 
screens have later been shown to have a second-site mutation at the tip 
of 2L which segregates with the TPE effect (142). Nevertheless, 9 of the 
putative Su(TPE) genes found recently (176) have been identified in our 
experiments; others have not been identified in our experiments, 
including tefu (181) and gpp (182)  
Some relatively widespread factors were identified at the TAS repeats by 
PICh, but the specificity of these associations is not clear, as they are 
expected to be located at many regions in the genome. These include 
cohesin and condensin complex proteins, Modulo and Dsp1. 
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Interestingly, these factors have been implicated in the regulation of the 
human subtelomeric D4Z4 repeats, which share structural similarities 
with the Drosophila TAS repeats (183,184); likewise, cohesins have 
been implicated in the heterochromatin formation at yeast subtelomeres 
(185). Also, Rm62, which has ubiquitous expression and mutants of 
which interact genetically with dsp1 and pc, was detected on TAS-R in 
Kc cells only (Table A2). Multiple Rm62 bands are found in polytene 
chromosomes, some co-localizing with Dsp1, notably at the telomeric 
regions, but a physical interaction with Dsp1 is only seen in young 
embryos, not in older embryos (186). Despite Dsp1 having been 
discarded, because one peptide was identified in the negative control, 
this suggests that Dsp1 and Rm62 might have a role together at TAS 
repeats, and that there is specificity in PICh, as Kc cells are derived from 
young embryos and S3 cells from old ones (163). 
Finally, we have shown directly that CG8289, Dip3, Row, Zf30c, and Pc 
bind at least to one family of TAS repeats. These proteins have closer 
homologs in human than in yeasts, mostly in the conserved 
chromodomain of CG8289, and Zinc-finger protein homology regions of 
Zf30c and Row. The lists of likely candidates for TAS-L and TAS-R 
factors that we have compiled can help to unravel the biological roles of 
TAS repeats and the mechanism of TPE.  
 
Insights into the mechanism of TPE 
Drosophila assays for Mod(TPE) have proved to be prone to high 
incidence of false positive results (142). In addition to that, the 
occurrence of validated Mod(TPE)s in genetic screens is very low, 
according to what one would expect based on the screens for Mod(PEV) 
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(142,187). For these reasons, we used the candidates identified by PICh 
in functional tests in Drosophila. Out of the 45 genes from our candidate 
lists (Tables 3.2, 3.3) tested in this study or previously in a deficiency 
screen for dominant Mod(TPE) (142), mor, which is a weak modifier 
(Table 3.4), and zf30c, which is eliminated in one of the deficiencies 
which act as Su(TPE) (142), have a level of functional validation in 
addition to the more thoroughly validated brm (Figure 6). To this group, 
we can add gkt and rpl135 (Table 3.4), which, like zf30c, are eliminated 
in dominant Su(TPE) deficiencies (142). Brahma and Moira interact with 
each other as members of the Swi/Snf-family Brahma chromatin 
remodeling complex, emphasizing the role for this complex in TPE.  
There are three classes of explanation for why a low percentage of 
proteins found by PICh validate in this functional test: i) many of the 
proteins that bind to TAS repeats might be involved in functions that are 
unrelated to TPE and/or ii) PICh has been performed on cell lines, which 
may have different features (harbor distinct sets of factors) from tissues 
in which TPE is assayed and/or iii) the mechanism by which proteins 
function in TPE is not dose-dependent or involves redundant activities, 
and thus does not create a dominant phenotype. 
There is support for this latter possibility, in that screens for dominant 
modifiers in other specific silencing models in Drosophila have had very 
low success rates. For example, screens based upon the trans-
inactivation of bw+ by the bwD allele (188), and others based upon trans-
suppression of PEV associated with a terminal chromosome deletion 
(187), have not identified any such modifiers. In the case of bwD, there 
was evidence that at least some modifiers are recessive and X-linked 
(187). Comparable observations have been made for TPE, with loss of 
ATM causing a recessive suppressor phenotype (181), and for telomeric 
stability, with row mutants displaying a telomere fusion phenotype only 
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when the protein is eliminated completely (159).  Clustering of modifiers 
on the X, and/or predominantly recessive effects could be a reason for 
the low success rate of Mod(TPE) discovery. In fact, genetic screens for 
dominant Mod(TPE)s don’t usually contemplate X chromosome genes, 
because a non-functional white gene, which resides on the X 
chromosome, is required for the test, precluding the use of other mutant 
X chromosomes (142). The possibility that dominant Su(TPE)s cluster 
on the X chromosome exists, though, so we compiled the list of genes 
whose products were found by PICh for TAS sequences, but that haven’t 
been covered by deficiency screens or directed Mod(TPE) screens 
(Table A8). The majority of these factors are X-linked, including the PcG 
protein MXC, which could provide an extra link to the PcG machinery. 
While viable homozygous mutants for many genes in Drosophila are not 
readily available, one possible way to study genic modifiers is by looking 
at the effect of overexpression of such genes. Such a screen was 
conducted recently for Mod(bwD)s (189) and identified a plethora of new 
factors, some of which are identified here as candidate TAS-binding 
proteins (Tables 3.2, 3.3), and most of which have no effect on PEV. 
These findings suggest that some silencing mechanisms follow different 
rules from the well-studied PEV model. It is possible that modifiers of 
TPE, bwD, and TDA-PEV (187) are predominantly recessive. This would 
also be consistent with the findings on TPE in yeast, in which the study 
of heterochromatin, and notably of TPE, is done in the absence of the 
candidate modifier. Given that yeast is normally studied as a haploid, 
there is no distinction between dominant and recessive tests. 
One reason for TPE effects being recessive might be the presence of 
specific DNA-binding factors which bring silencers preferentially to TAS. 
In yeast, RAP1 plays such a role, sequestering SIR proteins at 
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telomeres (190,191). If factors with a similar function to RAP1 exist in 
Drosophila, a fraction of the proteins involved in TPE will not necessarily 
show a phenotype when reduced by 50%, as their depletion will 
predominantly happen from loci for which their affinity is lower. Thus, 
one might expect traditional dominant Mod(TPE) screens to yield a lower 
success rate than Mod(PEV) screens. Indeed that is what was observed 
historically and in this study.  
The potential issue of the suitability of modifier screens brings to light the 
usefulness of PICh. A more thorough analysis of these candidates might 
include the study of null mutants or the overexpression of such 
candidates when null mutants are not viable. The results obtained using 
PICh would help to direct such studies. In cases where limited 
information exists concerning the mechanism by which a given locus is 
regulated, knowing which factors bind to this locus will facilitate further 
genetic tests to validate function. Thus, in a genetically tractable 
organism, the application of PICh and genetic tests should synergize to 
more rapidly identify the full complement of proteins involved in a 
biological phenomenon.  
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A resilient system for targeting PRC1 
Of all the roughly 16 PcG proteins described so far in Drosophila, only 
Pho has a direct DNA-binding capability. Nevertheless, a double mutant 
eliminating both pho and its homolog pho-like, which binds the same 
sequence, has a limited effect on the recruitment of other PcG proteins 
to chromatin targets (94). Likewise, other DNA-binding factors which 
recognize PcG targets and recruit PcG proteins don’t seem to cause 
major PcG displacement when eliminated. In addition, perturbation of the 
methylation of K27 on histone H3, frequently considered the hallmark of 
PRC1 targets, does not necessarily lead to striking changes in PRC1 
recruitment (43,192). These observations suggest, collectively, that the 
PcG targeting system in Drosophila is either extremely redundant, or that 
it has a high level of sophistication, with high plasticity and resilience.  
Many of the PRE-binding, PcG-recruiting factors bind not only at PREs, 
but elsewhere in the genome. GAGA factor, for instance, besides PREs 
(53,193), is also found at boundary-elements (194-196) and at 
heterochromatic satellite regions (197-199). Zeste is found very 
prominently associated with the Ubx (200) and other gene promoters, 
working as a transcriptional activator (86). Dsp1, whose target sequence 
has been determined as GAAAA, a very frequent motif, is found at many 
more locations on polytene chromosomes than Ph (91). These 
observations are consistent with a mechanism in which only certain 
combinations of PRE-binding proteins and chromatin environments are 
conducive to the recruitment of the PcG machinery. 
Interestingly, several of these factors also form homo-dimers. Zeste 
dimerizes through its Leucine-Zipper domain, GAGA dimerizes through 
the POZ domain (201) and Grainyhead also self-interacts through a 
specific domain (131). That these three factors also bind the Ubx 
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promoter (202) is interesting and suggestive of a mechanism for 
mediating the looping of PREs, where PcG proteins accumulate, into the 
gene promoters controlled by them, where PcG accumulation is minor. 
Can, under these models, the reported lack of phenotype of zeste 
mutants (90) be explained? A likely explanation is that this “lack of 
phenotype” is a symptom of the resilient PcG targeting system. During 
early Drosophila embryo development, cell cycles are extremely quick, 
and only slow down progressively, as cellularization takes place and 
zygotic transcription takes hold. The zeste transcript is found 
predominantly in the early embryo developmental stages and decays 
only after Gap and Pair-rule genes do (203). During this period, the PcG 
machinery takes over from the segmentation genes, so their correct 
targeting is crucial for normal embryo development. Despite the 
widespread notion that PcG-bound chromatin is a stably silenced 
structure, PRC1 protein dynamics is very high, with the residence time at 
targets much shorter than the cell cycle (204) and apparently complete 
disassembly from chromosomes at mitosis (28). Also, histone turnover 
rates at genome regions containing Zeste binding sites are particularly 
high (205). Together, these results suggest a fast and continuous 
chromatin sampling process happening during early embryo 
development, which allows the rapid progression of embryogenesis, 
without loss of fidelity in segment identity maintenance. Disturbances in 
this mechanism can probably lead to major complications in embryo 
development, which could explain the low ecclosion rates of zeste-
deleted flies (90). The small percentage of survivors which do not die 
during embryogenesis, when zeste transcripts are high, then resist 
adulthood, when zeste transcription is low, as nearly normal individuals, 
although neurological defects have been described (202). This is 
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consistent with the relatively high zeste transcript levels in the larval 
central nervous system and in the adult brain (206). 
 
Common features of repressed chromatin in Drosophila 
The zeste1-white interaction presents some of the hallmarks of PRE-
mediated silencing: it is mediated by the PcG machinery (207), is 
dependent on the pairing of white genes (208) and on the presence of 
Zeste binding sites (209). Furthermore, the PSS effect seen with the 
Fab-7 PRE is responsive to the zeste1 mutation in much the same way 
as paired white copies are (54). On the other hand, the topological 
constraints for white silencing in the zeste1 background are reminiscent 
of the communication between homologs in transvection. Transvection, 
PcG-mediated silencing and the zeste1-white interaction, thus, share at 
least a few common chromatin characteristics.  
A possible way to identify genomic region where the chromatin structure 
might be similar is to move the white locus into different regions and 
analyze the maintenance of the characteristic zeste1-white interaction. In 
fact, when this experiment is done only a subset of the ectopic insertion 
sites maintain the zeste1-white interaction, suggesting that a particular 
environment is common to the original locus (210,211). Interestingly, 
insertions near the telomeres of the chromosomes 2R and 3R show 
variegating white expression, which is enhanced in zeste1 mutants. The 
TAS repeats have been identified as PcG targets and to induce PSS of a 
mini-white transgene (27), both of which are hallmarks of PRE 
sequences. Telomeric regions in Drosophila have also been 
demonstrated to pair with homologous and non-homologous regions in 
the genome (212) and the TPE mechanism was shown to be dependent 
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on trans interactions between TAS sequences on different chromosomes 
(142). We have thus decided that Drosophila TAS sequences would be a 
good target for determining associated proteins. Importantly, for PICh 
technical optimization, TAS repeats presented an ideal target, because 
their abundance is considerably higher than single-copy elements, such 
as individual PREs, and a variable architecture of the target sequences 
allowed a better development of the technical protocol (see chapter 3). 
Given the aforementioned commonalities between PRE-mediated 
silencing, zeste1-white interaction and TPE, we anticipated that a subset 
of the factors identified by PICh at TAS repeats would possibly be 
present at other PcG targets as well. In accordance with that prediction, 
Woc, one of the most abundant TAS-R factors, has been recently found 
to interact with the silencing mechanism through the engrailed PRE 
(213). Further investigation of other factors identified by PICh will likely 
elucidate the mechanisms of PcG-mediated chromatin silencing and 
long-range communication. This will be relevant for TPE, PSS, 
transvection, and probably other trans-interaction phenomena, such as 
bwD and TDA-PEV. 
 
Recessive modification of TPE 
Position Effect Variegation is the quintessential chromatin silencing 
model system. The vast majority of its protein modifiers have been 
identified in dominant screens, where the protein dosage is diminished to 
one half of the wild-type amount. This historic fact has shaped our view 
of chromatin silencing mechanisms in general. For the PcG system, the 
model can be readily adapted because, despite some important 
differences, the system is also dosage-dependent: typically, 
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homozygous PcG mutants are lethal, but heterozygotes are viable, with 
a few non-lethal homeotic transformations, such as the ectopic sex 
combs on the 2nd and 3rd pairs of legs (as opposed to just the 1st pair of 
legs in the wild type). For TPE, though, most tested genetic mutants do 
not show dominant modification [(142); Chapter 3]. As discussed 
previously, this is also the case for other gene silencing models, such as 
bwD and TDA-PEV. It is tempting to speculate that part of the reason 
might be that these are all phenomena that involve chromatin 
interactions in trans. A simpler explanation has to do with the ratios of 
target chromatin and modifier protein. 
The TAS repeats, as mentioned before, are approximately 0.02% of the 
genome, while the total Drosophila heterochromatin is roughly 30% of 
the genome (214). Given this scale difference, it is plausible that the 
reduction of any associated protein’s dosage by one half will impact 
differently each of these targets. For proteins which might be shared 
between pericentric heterochromatin and the TAS repeats, the impact on 
PEV versus the impact on TPE will depend on the relative affinities for 
each of the shared targets. But even for eventual TAS-specific factors, 
the dosage effects are difficult to ascertain, not least because of the 
polymorphism resultant from frequent chromosomal terminal deficiencies 
(215). The frequent deletion of terminal chromosomal regions, including 
TAS sequences, means that Drosophila needed to adapt to frequent 
changes in the DNA target/silencer protein ratios. Proteins involved in 
the control of TPE can, thus, have varying ratios to their TAS target 
sequences between individuals and strains. In this context, shared 
targets elsewhere in the genome, such as pericentric heterochromatin 
and PcG targets, can function as buffer regions for TAS repeats factors. 
Furthermore, most of the identified cases of perturbation of TPE result 
from expansion or contraction of the TAS DNA sequence itself (142). 
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This is most studied in the TAS repeats of Drosophila, but similar 
phenomena are seen in a relatively well studied sub-telomeric satellite in 
humans, the D4Z4 repeats, as well. In this latter case, contraction of the 
repeat block to less than 10 copies can lead to Fascioscapulohumeral 
Dystrophy, with the subjacent molecular cause being the loss of the 
silencing ability, and thus the de-repression of a transcription factor gene 
(81). These observations suggest that the DNA dose component of the 
heterochromatin is dominant over the effect of single proteins’ doses, 
maybe because it is the limiting factor, as opposed to PEV, where the 
DNA component of heterochromatin is large, and hence the protein 
components can be made limiting more easily. 
 
The work reported here has revealed mechanistic information on the 
interaction of PRE-binding proteins with the PcG silencing activity, and 
has identified a list of factors which physically associate with PcG 
targets. Some of these new factors might also contribute to the targeting 
and activity of the PcG machinery. The described advances in the 
development of the PICh technology let foresee a future application of 
PICh to other target genomic regions in Drosophila and in mammalian 
systems, where PcG mechanisms are more poorly understood. 
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Primer name Sequence
NdeDBD TTTCATATGTATCCGTACAGGGATGGC
Zeste-CT TAGAATTCCATGGTTGAAGCGATC
Zeste-CTFlag TAGAATTCCTACTATTTATCGTCATCGTCTTTGTAGTCTGAAGTGGAGCACTTCCGCAG
Zeste-NT CGCGGATCAGATCCATGGGC
BssHII-N2 TAGCGCGCCTGTTGTGGCACCGCCGACG
BssHII-C TATGCGCGCCAGCAGCAGCAACAGCAGC
BlpCT CTGAATTCCTACTGCTGAGCCTGGTACTGGG
ZPst429F GGTTAAGATGCAACTAACTGCAGCCACGCCCACGTTTACC
ZPst429R GGTAAACGTGGGCGTGGCTGCAGTTAGTTGCATCTTAACC
ZPstLeu ATGCGTCTGCAGCCGCTGCG
ProCT CTGAATTCCTAAGCAGACGCATTAGTGGCTCC
ZK425M2F GCGGCGGCGGCGGTTATGATGCAACTAACCGCC
ZK425M2R GGCGGTTAGTTGCATCATAACCGCCGCCGCCGC
ProFlag2 CTGAATTCCTACTTATCATCATCATCATCCTTGTAATCAGCAGACGCATTAGTGGCTCC
BlpFlag2 CTGAATTCCTACTTATCATCATCATCATCCTTGTAATCCTGCTGAGCCTGGTACTGGG
Dsp1-NT TAACTAGTGCCACCATGGAACACTTTCATCAAATACAGC
Dsp1Flag-CT TTCTCGAGCTACTATTTATCGTCATCGTCTTTGTAGTCTTGGTTCTCGTCATCATCTC
Psq-NT TTGCGGCCGCGCCACCATGGCAGCGGTTCGAGGA
PsqFlag-CT TTGGTACCCTACTATTTATCGTCATCGTCTTTGTAGTCACTACGCTCCGGCGTC
Pho-NT TTGAATTCGCCACCATGGCATACGAACGTTTTGG
PhoFlag-CT TTTCTAGACTACTATTTATCGTCATCGTCTTTGTAGTCGTCTGCATATACCACAAACG
GAGA-NT TTACTAGTGCCACCATGTCGCTGCCAATGAATTCGC
GAGAFlag-CT TTTCTAGACTACTATTTATCGTCATCGTCTTTGTAGTCCTGCGGCTGCGGCTGTT
G5E4mutSalIA GAGCTGGTGCCGTGTCGACTGGTGTTTTTTTAATAGG
G5E4mutSalIB CCTATTAAAAAAACACCAGTCGACACGGCACCAGCTC
G5E4mutEagIA TTGTTATACCTCCTATGGCGGCCGTAATCTCGAGCTCGCTG
G5E4mutEagIB CAGCGAGCTCGAGATTACGGCCGCCATAGGAGGTATAACAA
bxdSal AAGTCGACGGAAGCCATAACGGCAG
bxdEag AACGGCCGCGACTGCGCCGCGACT
ZesteLZBam AAGGATCCGCGGACAGTTTCGAAGAGCG
ZesteLZEco AATTAGAATTCTCATGAAGTGGAGCACTTCC
F5-fwd AAGGCGAAAGAGAGCACCAA
F5-rev CGTTTTAAGTGCGACTGAG
F9-fwd TCCAATCCGTTGCCATCGAACGAAT
F9-rev TTAGGCCGAGTCGAGTGAGTTGAGT
F13-fwd CCATAAGAAATGCCACTTTGC
F13-rev CTCTCACTCTCTCACTGTGAT
F18-fwd GGAATACCGCACTGTCGTAGG
F18-rev GCAGCCATCATGGATGTGAA
wp1 AGTCAGCGCTGTTTGCCTC
wp2 CCTCTTGGCCCATTGCCG
TAS_ChIP7 GATGACAATGTAGTGAACGC 
TAS_ChIP8 GCGCTCGACAGAATTTTCAT 
TAS3L_ChIP1 TGACTGCCTCTCATTCTGTC 
TAS3L_ChIP2 TATCATCTCGTTCATCCGCC
Table A1: List of primers
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FBgn0003732 Top2 7 5 25 19 99 54 29 26 56 26 132 59
FBgn0051611 Histone H4 14 8 41 13 35 10 17 8 28 9 32 9
FBgn0027580 CG1516 19 12 0 0 1 1 9 7 3 3 7 7
FBgn0010173 RpA-70 13 9 13 6 47 22 9 7 13 6 41 20
FBgn0061209 Histone H2B 6 4 28 8 27 8 14 8 21 8 23 7
FBgn0000556 Ef1α48D 7 3 28 12 37 12 10 5 28 13 36 13
FBgn0002183 dre4 7 5 22 13 48 29 9 9 36 17 49 26
FBgn0000047 Act88F 4 3 8 6 20 6 10 8 7 4 20 14
FBgn0001197 Histone H2Av 5 2 9 2 12 2 5 2 8 2 11 3
FBgn0034962 Histone H1 3 3 19 10 15 9 4 4 11 6 9 9
FBgn0034961 Histone H3 1 1 8 3 15 5 5 4 17 5 15 4
FBgn0014965 gypsy\gag 0 0 0 0 0 0 6 5 17 6 17 6
FBgn0002525 Lam 2 2 6 5 23 12 3 3 4 3 22 13
FBgn0003022 Ote 1 1 4 4 12 12 4 3 10 8 12 6
FBgn0033998 row 2 2 5 5 20 15 2 2 4 3 15 8
FBgn0001219 Hsc70-4 3 2 23 15 33 17 1 1 11 6 12 6
FBgn0032244 RfC3 0 0 1 1 5 5 4 4 3 3 2 2
FBgn0004913 Gnf1 0 0 3 3 19 15 3 3 9 8 29 17
FBgn0032050 CG13096 3 3 5 3 10 6 0 0 3 2 3 3
FBgn0001226 Hsp27 0 0 0 0 0 0 2 2 3 3 6 5
FBgn0001220 Hsc70-5 2 2 3 2 3 2 0 0 0 0 0 0
FBgn0003459 stwl 1 1 1 1 2 1 1 1 2 1 3 2
FBgn0010278 Ssrp 1 1 18 12 29 17 1 1 11 7 26 14
FBgn0033879 CG6543 1 1 2 2 2 2 1 1 1 1 1 1
FBgn0003607 Su(var)205 1 1 35 18 22 13 1 1 19 12 6 6
FBgn0259937 Nop60B 2 2 1 1 1 1 0 0 0 0 0 0
FBgn0010438 mtSSB 2 2 1 1 3 3 0 0 0 0 3 3
FBgn0037137 Nopp140 2 1 1 1 3 2 0 0 0 0 0 0
FBgn0020496 CtBP 0 0 12 8 12 8 2 2 0 0 3 1
FBgn0024271 ZAM\gag 2 2 3 1 6 4 0 0 2 2 0 0
FBgn0040266 Transpac\gag 0 0 0 0 0 0 2 2 8 7 4 4
FBgn0000043 Act42A 1 1 2 2 1 1 0 0 2 1 4 4
FBgn0001091 Gapdh1 0 0 0 0 0 0 1 1 0 0 0 0
FBgn0004907 14-3-3ζ 0 0 2 2 2 2 1 1 0 0 0 0
FBgn0013275 Hsp70Aa 0 0 0 0 1 1 1 1 0 0 0 0
FBgn0026761 Trap1 0 0 1 1 2 1 1 1 0 0 0 0
FBgn0004867 RpS2 1 1 1 1 1 1 0 0 0 0 0 0
FBgn0004924 Top1 1 1 0 0 3 2 0 0 0 0 2 2
FBgn0004237 Hrb87F 0 0 1 1 0 0 1 1 2 1 2 1
FBgn0050122 CG30122 0 0 0 0 1 1 1 1 0 0 3 2
Proteins identified in the Scramble purifications
Kc S3
Scramble TAS-L
Table A2: Total peptides identified in PICh experiments
TAS-R Scramble TAS-L TAS-R
Flybase ID Name
peptides peptides peptides peptides peptides peptides
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FBgn0004795 retn 1 1 0 0 1 1 0 0 0 0 3 1
FBgn0013269 FK506-bp1 0 0 4 4 4 4 1 1 9 7 3 3
FBgn0040284 SF2 0 0 0 0 2 2 1 1 0 0 1 1
FBgn0003062 Fib 1 1 3 3 5 5 0 0 2 2 2 2
FBgn0034528 CG11180 1 1 0 0 0 0 0 0 0 0 0 0
FBgn0011764 Dsp1 1 1 1 1 3 1 0 0 2 1 1 1
FBgn0035674 CG13295 1 1 0 0 0 0 0 0 0 0 0 0
FBgn0260985 RfC4 0 0 2 2 4 4 1 1 1 1 5 4
FBgn0030362 Regucalcin 0 0 0 0 0 0 1 1 1 1 4 4
FBgn0010417 Taf6 1 1 0 0 0 0 0 0 0 0 0 0
FBgn0040345 CG3708 1 1 0 0 0 0 0 0 0 0 0 0
FBgn0010328 woc 1 1 0 0 14 8 0 0 4 3 10 8
FBgn0027889 ball 0 0 1 1 8 7 1 1 2 2 0 0
FBgn0030871 CG8142 0 0 0 0 2 2 1 1 0 0 2 2
FBgn0010397 LamC 0 0 0 0 1 1 0 0 0 0 0 0
FBgn0027783 SMC2 0 0 0 0 1 1 0 0 0 0 0 0
FBgn0035630 CG10576 0 0 0 0 1 1 0 0 0 0 0 0
FBgn0011661 Moe 0 0 2 2 0 0 0 0 0 0 2 2
FBgn0033636 tou 0 0 0 0 2 2 0 0 0 0 0 0
FBgn0010217 ATPsyn-β 0 0 2 2 1 1 0 0 0 0 0 0
FBgn0015391 glu 0 0 0 0 1 1 0 0 0 0 1 1
FBgn0039857 RpL6 0 0 0 0 1 1 0 0 0 0 0 0
FBgn0015245 Hsp60 0 0 0 0 1 1 0 0 0 0 0 0
FBgn0260789 mxc 0 0 0 0 3 3 0 0 0 0 0 0
FBgn0032620 CG12288 0 0 0 0 1 1 0 0 0 0 0 0
FBgn0001233 Hsp83 0 0 2 2 0 0 0 0 0 0 0 0
FBgn0024939 RpL8 0 0 0 0 1 1 0 0 0 0 0 0
FBgn0010551 l(2)03709 0 0 1 1 1 1 0 0 0 0 0 0
FBgn0086897 sqd 0 0 0 0 1 1 0 0 0 0 0 0
FBgn0003360 sesB 0 0 6 6 10 9 0 0 0 0 0 0
FBgn0002780 mod 0 0 2 2 4 4 0 0 5 5 3 3
FBgn0017545 RpS3A 0 0 0 0 1 1 0 0 0 0 0 0
FBgn0035213 CG2199 0 0 2 1 4 2 0 0 3 1 1 1
FBgn0000559 Ef2b 0 0 4 3 2 2 0 0 0 0 0 0
FBgn0003885 αTub84D 0 0 6 4 8 3 0 0 1 1 0 0
FBgn0003276 RpII140 0 0 1 1 3 3 0 0 0 0 3 3
FBgn0003888 βTub60D 0 0 3 3 7 7 0 0 0 0 0 0
FBgn0011211 blw 0 0 3 3 2 2 0 0 0 0 0 0
FBgn0037027 CG3680 0 0 2 2 1 1 0 0 0 0 0 0
FBgn0004551 Ca-P60A 0 0 1 1 3 3 0 0 0 0 0 0
FBgn0086133 kdn 0 0 0 0 1 1 0 0 0 0 0 0
FBgn0024332 Mcm3 0 0 2 2 0 0 0 0 0 0 0 0
TAS-R Scramble TAS-L TAS-R
Flybase ID Name
peptides peptides peptides peptides peptides peptides
Proteins identified as non-specific (146)
Kc S3
Scramble TAS-L
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FBgn0027948 msps 0 0 0 0 1 1 0 0 0 0 0 0
FBgn0003031 pAbp 0 0 1 1 0 0 0 0 0 0 0 0
FBgn0036548 l(3)72Ab 0 0 0 0 0 0 0 0 1 1 0 0
FBgn0040283 SMC1 0 0 1 1 0 0 0 0 0 0 0 0
FBgn0086254 CG6084 0 0 2 2 4 4 0 0 0 0 0 0
FBgn0004363 porin 0 0 0 0 1 1 0 0 0 0 0 0
FBgn0021765 scu 0 0 0 0 1 1 0 0 0 0 0 0
FBgn0031728 Hsp60C 0 0 1 1 2 2 0 0 0 0 0 0
FBgn0020235 ATPsyn-γ 0 0 1 1 1 1 0 0 0 0 0 0
FBgn0038608 WRNexo 0 0 2 2 4 3 0 0 2 2 1 1
FBgn0038609 Nup43 0 0 1 1 0 0 0 0 0 0 0 0
FBgn0039713 RpS8 0 0 0 0 3 3 0 0 0 0 0 0
FBgn0002924 ncd 0 0 0 0 0 0 0 0 0 0 1 1
FBgn0011604 Iswi 0 0 3 2 17 15 0 0 2 2 11 8
FBgn0026577 CG8677 0 0 0 0 1 1 0 0 1 1 0 0
FBgn0260817 gkt 0 0 0 0 2 1 0 0 0 0 0 0
FBgn0001942 eIF-4a 0 0 1 1 1 1 0 0 0 0 0 0
FBgn0003887 βTub56D 0 0 2 1 3 2 0 0 1 1 0 0
FBgn0015615 Cap 0 0 0 0 5 5 0 0 0 0 2 1
FBgn0004922 RpS6 0 0 1 1 2 2 0 0 0 0 0 0
FBgn0030054 Caf1-180 0 0 2 1 2 2 0 0 0 0 0 0
FBgn0039877 CG2118 0 0 0 0 1 1 0 0 0 0 0 0
FBgn0085261 SA 0 0 3 3 4 4 0 0 0 0 0 0
FBgn0086902 kis 0 0 0 0 1 1 0 0 0 0 0 0
FBgn0002441 l(3)mbt 0 0 0 0 0 0 0 0 0 0 1 1
FBgn0003567 su(Hw) 0 0 0 0 3 3 0 0 0 0 3 3
FBgn0040268 Top3α 0 0 1 1 3 3 0 0 3 3 4 4
FBgn0003261 Rm62 0 0 0 0 4 4 0 0 0 0 0 0
FBgn0004587 B52 0 0 0 0 0 0 0 0 1 1 2 1
FBgn0010774 Aly 0 0 1 1 0 0 0 0 0 0 0 0
FBgn0005630 lola 0 0 1 1 0 0 0 0 1 1 0 0
FBgn0260991 Incenp 0 0 28 13 20 9 0 0 11 5 1 1
FBgn0037810 sle 0 0 32 15 22 15 0 0 10 8 2 2
FBgn0003277 RpII215 0 0 0 0 6 6 0 0 0 0 2 2
FBgn0015929 dpa 0 0 2 2 1 1 0 0 0 0 0 0
FBgn0030301 HP5 0 0 4 3 0 0 0 0 1 1 1 1
FBgn0260012 pds5 0 0 1 1 1 1 0 0 2 2 0 0
FBgn0002542 lds 0 0 0 0 1 1 0 0 0 0 0 0
FBgn0029704 CG2982 0 0 0 0 3 3 0 0 0 0 0 0
FBgn0011785 BRWD3 0 0 0 0 0 0 0 0 0 0 1 1
FBgn0000541 E(bx) 0 0 0 0 4 4 0 0 1 1 3 3
FBgn0026575 hang 0 0 0 0 0 0 0 0 0 0 1 1
FBgn0014026 RpL7A 0 0 1 1 0 0 0 0 0 0 0 0
peptides peptides peptides
Flybase ID Name
peptides peptides peptides
Kc S3
Scramble TAS-L TAS-R Scramble TAS-L TAS-R
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FBgn0023509 mip130 0 0 0 0 1 1 0 0 0 0 0 0
FBgn0012036 Aldh 0 0 0 0 1 1 0 0 0 0 0 0
FBgn0003278 RpI135 0 0 0 0 1 1 0 0 0 0 0 0
FBgn0025815 Mcm6 0 0 2 2 0 0 0 0 0 0 0 0
FBgn0017577 Mcm5 0 0 5 5 3 3 0 0 0 0 0 0
FBgn0004227 nonA 0 0 0 0 0 0 0 0 0 0 1 1
FBgn0250754 CG42232 0 0 0 0 0 0 0 0 0 0 3 3
FBgn0011272 RpL13 0 0 0 0 0 0 0 0 0 0 1 1
FBgn0043456 CG4747 0 0 3 3 17 11 0 0 2 1 11 7
FBgn0015268 Nap1 0 0 0 0 1 1 0 0 0 0 0 0
FBgn0037082 CG5664 0 0 1 1 0 0 0 0 0 0 0 0
FBgn0000212 brm 0 0 0 0 3 3 0 0 0 0 1 1
FBgn0259113 DNApol-α180 0 0 0 0 5 5 0 0 0 0 0 0
FBgn0025716 Bap55 0 0 0 0 5 4 0 0 0 0 0 0
FBgn0040237 bor 0 0 1 1 0 0 0 0 0 0 0 0
FBgn0036478 CTPsyn 0 0 1 1 0 0 0 0 0 0 0 0
FBgn0002906 mus309 0 0 0 0 1 1 0 0 0 0 1 1
FBgn0036486 Msh6 0 0 0 0 1 1 0 0 0 0 0 0
FBgn0036213 RpL10Ab 0 0 1 1 1 1 0 0 0 0 0 0
FBgn0033062 Ars2 0 0 0 0 1 1 0 0 0 0 0 0
FBgn0019644 ATPsyn-b 0 0 0 0 1 1 0 0 0 0 0 0
FBgn0013756 Mtor 0 0 0 0 1 1 0 0 0 0 0 0
FBgn0031759 lid 0 0 0 0 4 4 0 0 0 0 2 2
FBgn0004378 Klp61F 0 0 0 0 1 1 0 0 0 0 1 1
FBgn0005655 mus209 0 0 0 0 2 2 0 0 0 0 0 0
FBgn0010100 Acon 0 0 0 0 1 1 0 0 0 0 0 0
FBgn0032906 RPA2 0 0 0 0 6 6 0 0 1 1 2 2
FBgn0027338 Kap-α3 0 0 0 0 1 1 0 0 0 0 0 0
FBgn0040075 rept 0 0 1 1 5 5 0 0 2 2 1 1
FBgn0001149 GstD1 0 0 0 0 0 0 0 0 1 1 0 0
FBgn0037811 CG12592 0 0 1 1 0 0 0 0 0 0 0 0
FBgn0034390 CG15093 0 0 1 1 0 0 0 0 0 0 0 0
FBgn0020270 mre11 0 0 1 1 0 0 0 0 0 0 0 0
FBgn0024804 Dbp80 0 0 0 0 0 0 0 0 1 1 0 0
FBgn0030269 CG18292 0 0 1 1 0 0 0 0 0 0 0 0
FBgn0002872 mu2 0 0 2 2 0 0 0 0 0 0 0 0
FBgn0015024 CkIα 0 0 0 0 0 0 0 0 1 1 0 0
FBgn0023181 Orc4 0 0 1 1 0 0 0 0 0 0 0 0
FBgn0015270 Orc2 0 0 2 2 0 0 0 0 0 0 0 0
FBgn0032988 Tif-IA 0 0 1 1 0 0 0 0 1 1 0 0
FBgn0053523 CG33523 0 0 1 1 0 0 0 0 0 0 0 0
FBgn0005654 lat 0 0 1 1 0 0 0 0 0 0 0 0
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FBgn0030853 CG5703 0 0 1 1 0 0 0 0 0 0 0 0
FBgn0026257 cav 0 0 1 1 0 0 0 0 0 0 0 0
FBgn0003600 Su(var)3-9 0 0 4 4 0 0 0 0 0 0 0 0
FBgn0035689 CG7376 0 0 1 1 0 0 0 0 0 0 0 0
FBgn0026573 CG8290 0 0 8 6 0 0 0 0 0 0 0 0
FBgn0037621 CG9797 0 0 1 1 0 0 0 0 0 0 0 0
FBgn0037633 CG9839 0 0 1 1 0 0 0 0 0 0 0 0
FBgn0033951 CG10139 0 0 0 0 1 1 0 0 0 0 0 0
FBgn0026196 Nop5 0 0 1 1 0 0 0 0 0 0 1 1
FBgn0004838 Hrb27C 0 0 0 0 0 0 0 0 0 0 1 1
FBgn0261403 sxc 0 0 0 0 1 1 0 0 0 0 0 0
FBgn0086441 Acn 0 0 0 0 0 0 0 0 0 0 1 1
FBgn0015657 DnaJ-1 0 0 0 0 1 1 0 0 0 0 0 0
FBgn0003082 phr 0 0 0 0 1 1 0 0 0 0 0 0
FBgn0027334 l(1)G0004 0 0 0 0 1 1 0 0 0 0 0 0
FBgn0250830 CG12547 0 0 0 0 1 1 0 0 0 0 0 0
FBgn0040465 Dip3 0 0 10 5 1 1 0 0 0 0 0 0
FBgn0033526 Caf1-105 0 0 0 0 1 1 0 0 0 0 0 0
FBgn0033609 fbl6 0 0 0 0 0 0 0 0 2 2 1 1
FBgn0038964 Nop56 0 0 1 1 1 1 0 0 0 0 0 0
FBgn0030268 Klp10A 0 0 0 0 1 1 0 0 0 0 0 0
FBgn0038035 lig3 0 0 0 0 0 0 0 0 0 0 1 1
FBgn0038827 Fancd2 0 0 0 0 1 1 0 0 0 0 0 0
FBgn0033934 CG17385 0 0 0 0 0 0 0 0 0 0 1 1
FBgn0023537 CG17896 0 0 0 0 1 1 0 0 0 0 0 0
FBgn0010342 Map60 0 0 0 0 1 1 0 0 0 0 0 0
FBgn0033107 koi 0 0 1 1 1 1 0 0 0 0 0 0
FBgn0004399 psq 0 0 0 0 0 0 0 0 2 2 1 1
FBgn0250753 exba 0 0 0 0 1 1 0 0 0 0 0 0
FBgn0034962 MAN1 0 0 0 0 1 1 0 0 0 0 0 0
FBgn0001133 grau 0 0 0 0 0 0 0 0 0 0 1 1
FBgn0015737 Hmu 0 0 0 0 1 1 0 0 0 0 0 0
FBgn0011327 Uch-L3 0 0 0 0 1 1 0 0 0 0 0 0
FBgn0010422 TfIIS 0 0 0 0 1 1 0 0 0 0 0 0
FBgn0030418 CG4004 0 0 4 1 1 1 0 0 0 0 0 0
FBgn0001986 l(2)35Df 0 0 0 0 1 1 0 0 0 0 0 0
FBgn0004926 eIF-2β 0 0 1 1 1 1 0 0 0 0 0 0
FBgn0015546 spel1 0 0 1 1 0 0 0 0 0 0 1 1
FBgn0016687 Nurf-38 0 0 0 0 0 0 0 0 0 0 1 1
FBgn0020633 Mcm7 0 0 2 2 1 1 0 0 0 0 0 0
FBgn0000566 Eip55E 0 0 3 3 1 1 0 0 0 0 0 0
FBgn0011016 SsRβ 0 0 0 0 1 1 0 0 0 0 0 0
FBgn0011236 ken 0 0 1 1 1 1 0 0 0 0 0 0
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FBgn0015790 Rab11 0 0 0 0 1 1 0 0 0 0 0 0
FBgn0039125 CG5857 0 0 0 0 1 1 0 0 0 0 0 0
FBgn0005696 DNApol-α73 0 0 0 0 1 1 0 0 0 0 0 0
FBgn0016693 Past1 0 0 0 0 1 1 0 0 0 0 0 0
FBgn0020412 JIL-1 0 0 0 0 0 0 0 0 0 0 1 1
FBgn0020443 Elf 0 0 0 0 1 1 0 0 0 0 0 0
FBgn0024227 ial 0 0 5 5 1 1 0 0 1 1 0 0
FBgn0030093 dalao 0 0 0 0 1 1 0 0 0 0 0 0
FBgn0015805 Rpd3 0 0 0 0 1 1 0 0 0 0 0 0
FBgn0014861 Mcm2 0 0 3 2 1 1 0 0 0 0 0 0
FBgn0025457 Bub3 0 0 1 1 1 1 0 0 0 0 0 0
FBgn0260962 pic 0 0 0 0 1 1 0 0 0 0 0 0
FBgn0039697 CG7834 0 0 1 1 1 1 0 0 0 0 0 0
FBgn0026373 RpII33 0 0 1 1 0 0 0 0 0 0 1 1
FBgn0001179 hay 0 0 0 0 1 1 0 0 0 0 0 0
FBgn0033897 Rcd1 0 0 0 0 0 0 0 0 0 0 1 1
FBgn0011704 RnrS 0 0 0 0 1 1 0 0 0 0 0 0
FBgn0031769 CG9135 0 0 0 0 1 1 0 0 0 0 0 0
FBgn0037669 CG9740 0 0 0 0 1 1 0 0 0 0 0 0
FBgn0003687 Tbp 0 0 0 0 1 1 0 0 0 0 0 0
FBgn0004925 eIF-2α 0 0 2 2 1 1 0 0 0 0 0 0
FBgn0010416 TH1 0 0 0 0 1 1 0 0 0 0 0 0
FBgn0040265 Transpac\pol 0 0 0 0 0 0 0 0 0 0 1 1
FBgn0011715 Snr1 0 0 0 0 2 1 0 0 0 0 0 0
FBgn0022772 Orc1 0 0 0 0 2 1 0 0 0 0 0 0
FBgn0033571 Rpb5 0 0 0 0 2 2 0 0 0 0 0 0
FBgn0000054 Adf1 0 0 0 0 2 2 0 0 0 0 0 0
FBgn0086855 CG17078 0 0 0 0 1 1 0 0 0 0 1 1
FBgn0040066 wds 0 0 0 0 1 1 0 0 0 0 1 1
FBgn0051363 Jupiter 0 0 1 1 2 2 0 0 0 0 0 0
FBgn0034961 CG3163 0 0 12 7 2 2 0 0 2 1 0 0
FBgn0045852 ham 0 0 1 1 2 1 0 0 0 0 0 0
FBgn0064122 CG33691 0 0 3 1 2 1 0 0 1 1 0 0
FBgn0003507 srp 0 0 1 1 2 1 0 0 0 0 0 0
FBgn0022720 zf30C 0 0 0 0 2 2 0 0 0 0 0 0
FBgn0029798 CG4078 0 0 0 0 2 2 0 0 0 0 0 0
FBgn0011823 Pen 0 0 0 0 2 2 0 0 0 0 0 0
FBgn0004106 cdc2 0 0 0 0 2 2 0 0 0 0 0 0
FBgn0011703 RnrL 0 0 1 1 2 1 0 0 0 0 0 0
FBgn0039019 HP1c 0 0 0 0 2 2 0 0 0 0 0 0
FBgn0030082 HP1b 0 0 0 0 1 1 0 0 0 0 1 1
FBgn0031977 baf 0 0 1 1 1 1 0 0 1 1 1 1
FBgn0003013 osa 0 0 0 0 2 2 0 0 0 0 0 0
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FBgn0003612 Su(var)2-10 0 0 3 2 2 2 0 0 0 0 0 0
FBgn0000289 cg 0 0 0 0 2 2 0 0 1 1 0 0
FBgn0022764 Sin3A 0 0 0 0 1 1 0 0 0 0 1 1
FBgn0037719 bocksbeutel 0 0 0 0 2 2 0 0 1 1 0 0
FBgn0026401 Nipped-B 0 0 0 0 3 3 0 0 0 0 0 0
FBgn0022349 CG1910 0 0 1 1 1 1 0 0 2 1 2 1
FBgn0010247 Parp 0 0 0 0 1 1 0 0 0 0 2 2
FBgn0032105 borr 0 0 10 6 3 3 0 0 0 0 0 0
FBgn0001224 Hsp23 0 0 0 0 0 0 0 0 1 1 3 3
FBgn0026533 Dek 0 0 0 0 1 1 0 0 1 1 2 1
FBgn0000283 Cp190 0 0 0 0 0 0 0 0 0 0 3 3
FBgn0011606 Klp3A 0 0 0 0 1 1 0 0 0 0 2 2
FBgn0015602 BEAF-32 0 0 0 0 4 3 0 0 0 0 0 0
FBgn0035370 CG1240 0 0 1 1 2 2 0 0 1 1 2 2
FBgn0034878 pita 0 0 0 0 2 1 0 0 0 0 2 1
FBgn0015610 Caf1 0 0 2 2 2 2 0 0 1 1 2 1
FBgn0027381 Idefix\gag 0 0 3 3 4 4 0 0 2 2 0 0
FBgn0044324 Chro 0 0 0 0 2 2 0 0 0 0 3 2
FBgn0037659 Kdm2 0 0 0 0 2 2 0 0 0 0 3 2
FBgn0002783 mor 0 0 0 0 5 4 0 0 0 0 0 0
FBgn0001994 crp 0 0 0 0 5 3 0 0 0 0 0 0
FBgn0039743 CG7946 0 0 0 0 0 0 0 0 1 1 5 4
FBgn0015623 Cpr 0 0 0 0 1 1 0 0 0 0 5 4
FBgn0031057 Ubqn 0 0 0 0 6 5 0 0 0 0 0 0
FBgn0039338 XNP 0 0 14 11 6 6 0 0 3 3 0 0
FBgn0015664 Dref 0 0 1 1 4 4 0 0 0 0 2 1
FBgn0259785 pzg 0 0 0 0 4 4 0 0 0 0 2 2
FBgn0033039 gp210 0 0 1 1 4 4 0 0 0 0 2 2
FBgn0028700 RfC38 0 0 0 0 5 5 0 0 1 1 2 2
FBgn0000412 D1 0 0 0 0 4 3 0 0 3 2 3 3
FBgn0020309 crol 0 0 5 2 7 4 0 0 1 1 1 1
FBgn0034657 LBR 0 0 3 2 6 3 0 0 0 0 2 2
FBgn0013591 Mi-2 0 0 0 0 5 4 0 0 3 3 3 3
FBgn0030854 CG8289 0 0 7 4 7 6 0 0 10 6 1 1
FBgn0020255 ran 0 0 4 3 6 6 0 0 1 1 4 4
FBgn0013263 Trl 0 0 9 3 9 3 0 0 3 2 2 1
FBgn0026170 smt3 0 0 17 5 11 4 0 0 5 1 1 1
FBgn0040078 pont 0 0 0 0 6 5 0 0 0 0 7 5
FBgn0038016 MBD-R2 0 0 0 0 0 0 0 0 0 0 1 1
FBgn0002638 Bj1 0 0 18 9 14 10 0 0 5 3 9 7
FBgn0004584 Rrp1 0 0 7 7 13 13 0 0 7 6 14 9
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Embryo *
TAS-R
peptides
 to
ta
l
 u
ni
qu
e
 to
ta
l
 u
ni
qu
e
 to
ta
l
 u
ni
qu
e
 to
ta
l
 u
ni
qu
e
 to
ta
l
FBgn0037810 sle 32 15 22 15 10 8 2 2 0
FBgn0002638 Bj1 18 9 14 10 5 3 9 7 4
FBgn0004584 Rrp1 7 7 13 13 7 6 14 9 8
FBgn0260991 Incenp 28 13 20 9 11 5 1 1 0
FBgn0043456 CG4747 3 3 17 11 2 1 11 7 0
FBgn0011604 Iswi 3 2 17 15 2 2 11 8 2
FBgn0026170 smt3 17 5 11 4 5 1 1 1 0
FBgn0030854 CG8289 7 4 7 6 10 6 1 1 3
FBgn0013263 Trl 9 3 9 3 3 2 2 1 0
FBgn0002780 mod 2 2 4 4 5 5 3 3 4
FBgn0020255 ran 4 3 6 6 1 1 4 4 0
FBgn0040268 Top3α 1 1 3 3 3 3 4 4 0
FBgn0020309 crol 5 2 7 4 1 1 1 1 0
FBgn0035213 CG2199 2 1 4 2 3 1 1 1 0
FBgn0038608 WRNexo 2 2 4 3 2 2 1 1 0
FBgn0040075 rept 1 1 5 5 2 2 1 1 3
FBgn0015610 Caf1 2 2 2 2 1 1 2 1 3
FBgn0035370 CG1240 1 1 2 2 1 1 2 2 0
FBgn0031977 baf 1 1 1 1 1 1 1 1 0
FBgn0022349 CG1910 1 1 1 1 1 1 1 1 0
peptides
* PICh experiment performed on chromatin from 0-24hr old embryos; red background: factors 
identified as non-specific (146); yellow background: no enrichment seen by Western blot.
Flybase ID Name
peptides peptides peptides
Kc S3
TAS-L TAS-R TAS-L TAS-R
Table A4: Proteins common to TAS-L/R in S3, Kc, embryos
| Compositional and Functional Analysis of Polycomb Target Chromatin
137
K
c
S3
K
c
S3
total
unique
total
unique
total
unique
total
unique
1
17
.5
4
3.
29
0.
89
1.
22
72
6
10
72
3.
92
FB
gn
00
39
33
8
XN
P
14
11
6
6
3
3
0
0
2
14
.1
6
2.
65
1.
17
1.
35
95
1
11
81
3.
58
FB
gn
00
04
58
4
R
rp
1
7
7
13
13
7
6
14
9
3
14
.3
7
2.
69
0.
19
0.
14
15
5
11
9
3.
50
FB
gn
00
40
46
5
D
ip
3
10
5
1
1
0
0
0
0
4
20
.8
3
3.
90
0.
94
1.
09
76
4
95
6
3.
46
FB
gn
00
30
85
4
C
G
82
89
7
4
7
6
10
6
1
1
5
25
.5
9
4.
79
2.
85
1.
55
23
27
13
56
3.
29
FB
gn
00
02
63
8
B
j1
18
9
14
10
5
3
9
7
6
15
.6
7
2.
94
0.
84
0.
87
68
7
76
7
2.
64
FB
gn
00
32
10
5
bo
rr
10
6
3
3
0
0
0
0
7
9.
12
1.
71
0.
50
0.
74
40
7
64
7
2.
58
FB
gn
00
24
22
7
ia
l
5
5
1
1
1
1
0
0
8
12
.0
3
2.
25
3.
40
4.
41
27
74
38
68
1.
95
FB
gn
00
13
26
3
Tr
l
9
3
9
3
3
2
2
1
9
20
.8
5
3.
90
0.
53
0.
82
43
5
71
7
1.
75
FB
gn
00
26
57
3
C
G
82
90
8
6
0
0
0
0
0
0
10
19
.0
2
3.
56
5.
10
5.
03
41
58
44
13
1.
62
FB
gn
00
34
96
1
C
G
31
63
12
7
2
2
2
1
0
0
11
33
.3
3
6.
24
9.
65
6.
72
78
73
58
94
1.
52
FB
gn
00
26
17
0
sm
t3
17
5
11
4
5
1
1
1
12
9.
36
1.
75
4.
45
3.
59
36
29
31
49
1.
04
FB
gn
00
20
30
9
cr
ol
5
2
7
4
1
1
1
1
13
17
.7
0
3.
31
0.
29
1.
49
23
9
13
05
0.
95
FB
gn
00
30
41
8
C
G
40
04
4
1
1
1
0
0
0
0
14
12
.9
4
2.
42
0.
34
0.
37
27
7
32
3
0.
72
FB
gn
00
15
27
0
O
rc
2
2
2
0
0
0
0
0
0
15
28
.4
7
5.
33
1.
87
0.
92
15
25
80
6
0.
59
FB
gn
00
64
12
2
C
G
33
69
1
3
1
2
1
1
1
0
0
16
11
.2
7
2.
11
2.
81
3.
09
22
94
27
10
0.
59
FB
gn
00
00
41
2
D
1
0
0
4
3
3
2
3
3
17
19
.1
6
3.
59
1.
44
2.
00
11
71
17
54
0.
57
FB
gn
00
13
59
1
M
i-2
0
0
5
4
3
3
3
3
18
16
.2
8
3.
05
2.
49
2.
63
20
29
23
02
0.
54
FB
gn
00
15
61
0
C
af
1
2
2
2
2
1
1
2
1
19
25
.9
4
4.
86
5.
10
5.
03
41
58
44
13
0.
50
FB
gn
00
27
38
1
G
AG
3
3
4
4
2
2
0
0
20
25
.9
3
4.
86
1.
08
1.
20
88
5
10
50
0.
50
FB
gn
00
14
86
1
M
cm
2
3
2
1
1
0
0
0
0
21
4.
10
0.
77
3.
23
3.
40
26
34
29
81
0.
49
FB
gn
00
35
37
0
C
G
12
40
1
1
2
2
1
1
2
2
22
19
.5
3
3.
66
0.
67
0.
56
54
9
48
9
0.
47
FB
gn
00
02
87
2
m
u2
2
2
0
0
0
0
0
0
23
12
.2
2
2.
29
1.
46
2.
61
11
89
22
89
0.
46
FB
gn
00
04
39
9
ps
q
0
0
0
0
2
2
1
1
24
21
.8
8
4.
10
2.
15
2.
66
17
55
23
32
0.
46
FB
gn
00
03
61
2
Su
(v
ar
)2
-1
0
3
2
2
2
0
0
0
0
25
32
.3
9
6.
07
0.
87
1.
00
71
0
87
7
0.
43
FB
gn
00
34
65
7
LB
R
3
2
6
3
0
0
2
2
26
20
.8
3
3.
90
0.
51
1.
06
41
3
92
9
0.
43
FB
gn
00
33
60
9
fb
l6
0
0
0
0
2
2
1
1
pe
pt
id
es
pe
pt
id
es
pe
pt
id
es
Ta
bl
e 
A5
: T
A
S
-L
 p
ro
te
in
s,
 ra
nk
ed
 b
y 
co
nf
id
en
ce
 s
co
re
K
c
S3
rank
detectable 
peptides/ 1000 
a
detectability score 
b
N
or
m
al
iz
ed
 G
en
e 
Ex
pr
es
si
on
 S
co
re
 
c
Ex
pr
es
si
on
 le
ve
l d
Confidence score 
e
Fl
yb
as
e 
ID
N
am
e
TA
S_
L
TA
S_
R
TA
S_
L
TA
S_
R
pe
pt
id
es
| Compositional and Functional Analysis of Polycomb Target Chromatin
138
K
c
S3
K
c
S3
total
unique
total
unique
total
unique
total
unique
27
17
.3
2
3.
24
7.
55
5.
47
61
59
47
97
0.
41
FB
gn
00
03
60
0
Su
(v
ar
)3
-9
4
4
0
0
0
0
0
0
28
27
.7
8
5.
20
10
.0
0
6.
31
81
60
55
29
0.
37
FB
gn
00
20
25
5
ra
n
4
3
6
6
1
1
4
4
29
22
.4
9
4.
21
1.
85
6.
03
15
13
52
87
0.
37
FB
gn
00
22
34
9
C
G
19
10
1
1
1
1
2
1
2
1
30
14
.6
6
2.
75
3.
19
3.
00
26
05
26
29
0.
34
FB
gn
00
04
92
5
eI
F-
2α
2
2
1
1
0
0
0
0
31
27
.7
8
5.
20
1.
04
1.
22
84
7
10
71
0.
32
FB
gn
00
20
63
3
M
cm
7
2
2
1
1
0
0
0
0
32
31
.1
0
5.
82
1.
45
1.
64
11
85
14
41
0.
27
FB
gn
00
32
98
8
Ti
f-I
A
1
1
0
0
1
1
0
0
33
25
.4
5
4.
77
5.
37
8.
18
43
80
71
70
0.
26
FB
gn
00
00
56
6
Ei
p5
5E
3
3
1
1
0
0
0
0
34
20
.0
5
3.
75
0.
83
0.
50
67
4
44
0
0.
23
FB
gn
00
37
71
9
bo
ck
sb
eu
te
l
0
0
2
2
1
1
0
0
35
21
.0
5
3.
94
0.
55
1.
10
45
2
96
6
0.
21
FB
gn
00
39
74
3
C
G
79
46
0
0
0
0
1
1
5
4
36
44
.4
4
8.
32
2.
62
1.
70
21
35
14
87
0.
19
FB
gn
00
31
97
7
ba
f
1
1
1
1
1
1
1
1
37
24
.3
7
4.
56
1.
99
0.
03
16
24
29
0.
18
FB
gn
00
45
85
2
ha
m
1
1
2
1
0
0
0
0
38
18
.4
7
3.
46
2.
30
2.
68
18
80
23
53
0.
17
FB
gn
00
11
70
3
R
nr
L
1
1
2
1
0
0
0
0
39
13
.4
5
2.
52
2.
00
5.
44
16
30
47
69
0.
16
FB
gn
00
26
53
3
D
ek
0
0
1
1
1
1
2
1
40
26
.8
0
5.
02
1.
16
1.
31
95
0
11
48
0.
16
FB
gn
00
15
66
4
D
re
f
1
1
4
4
0
0
2
1
41
33
.7
1
6.
31
0.
49
0.
46
39
8
40
0
0.
15
FB
gn
00
28
70
0
R
fC
38
0
0
5
5
1
1
2
2
42
26
.6
5
4.
99
1.
66
2.
09
13
51
18
34
0.
15
FB
gn
00
33
03
9
gp
21
0
1
1
4
4
0
0
2
2
43
9.
49
1.
78
3.
47
6.
94
28
29
60
83
0.
14
FB
gn
00
03
50
7
sr
p
1
1
2
1
0
0
0
0
44
15
.7
6
2.
95
5.
07
4.
22
41
39
37
01
0.
13
FB
gn
00
00
28
9
cg
0
0
2
2
1
1
0
0
45
53
.7
6
10
.0
7
1.
49
9.
26
12
17
81
22
0.
06
FB
gn
00
01
22
4
H
sp
23
0
0
0
0
1
1
3
3
46
43
.2
7
8.
10
9.
64
5.
89
78
66
51
63
0.
06
FB
gn
00
51
36
3
Ju
pi
te
r
1
1
2
2
0
0
0
0
pe
pt
id
es
pe
pt
id
es
Fl
yb
as
e 
ID
N
am
e
TA
S_
L
TA
S_
R
TA
S_
L
a.
 n
um
be
r o
f p
ep
tid
es
 w
ith
 a
 d
et
ec
ta
bi
lit
y 
>0
.6
, c
al
cu
la
te
d 
us
in
g 
th
e 
P
ep
tid
e 
de
te
ct
ab
ili
ty
 p
re
di
ct
or
 a
t h
ttp
://
bi
t.l
y/
gr
3j
K
R
 (1
47
); 
b.
 n
um
be
r o
f d
et
ec
ta
bl
e 
pe
pt
id
es
/1
00
0 
no
rm
al
iz
ed
 to
 a
 s
ca
le
 o
f 0
-1
0,
 w
he
re
 1
0 
is
 th
e 
va
lu
e 
fo
un
d 
fo
r t
he
 p
ro
te
in
 w
ith
 th
e 
hi
gh
es
t d
et
ec
ta
bl
e 
pe
pt
id
es
/1
00
0 
(H
sp
23
, 5
3.
76
); 
c.
 th
e 
N
or
m
al
iz
ed
 G
en
e 
E
xp
re
ss
io
n 
S
co
re
 is
 th
e 
re
la
tiv
e 
ge
ne
 e
xp
re
ss
io
n,
 o
n 
a 
sc
al
e 
of
 0
-1
0,
 w
he
re
 1
0 
is
 th
e 
va
lu
e 
of
 th
e 
hi
gh
es
t e
xp
re
ss
in
g 
ge
ne
 in
 th
e 
re
sp
ec
tiv
e 
ce
ll 
lin
e 
(K
c:
 ra
n,
 8
16
0;
 S
3:
 c
pr
, 8
79
6)
; 
d.
 e
xp
re
ss
io
n 
da
ta
 o
bt
ai
ne
d 
fro
m
 th
e 
m
od
E
N
C
O
D
E
 d
at
ab
as
e 
(1
48
); 
e.
  v
al
ue
 re
su
lti
ng
 fr
om
 th
e 
di
vi
si
on
 o
f t
he
 n
um
be
r o
f p
ep
tid
es
 d
et
ec
te
d 
in
 b
ot
h 
ce
ll 
lin
es
 b
y 
th
e 
su
m
 
of
 th
e 
D
et
ec
ta
bi
lit
y 
S
co
re
 a
nd
 th
e 
av
er
ag
e 
of
 th
e 
N
or
m
al
iz
ed
 G
en
e 
E
xp
re
ss
io
n 
S
co
re
s 
fro
m
 th
e 
2 
ce
ll 
lin
es
; R
ed
 fo
nt
: e
xp
re
ss
io
n 
le
ve
ls
 n
ot
 a
va
ila
bl
e;
 a
ttr
ib
ut
ed
 a
ve
ra
ge
 
ex
pr
es
si
on
 le
ve
l o
f a
ll 
fa
ct
or
s 
de
te
ct
ed
.
Ta
bl
e 
A5
, c
on
tin
ue
d
K
c
S3
rank
detectable 
peptides/ 1000 
a
detectability score 
b
N
or
m
al
iz
ed
 G
en
e 
Ex
pr
es
si
on
 S
co
re
 
c
Ex
pr
es
si
on
 le
ve
l d
Confidence score 
e
TA
S_
R
pe
pt
id
es
pe
pt
id
es
| Compositional and Functional Analysis of Polycomb Target Chromatin
139
K
c
S3
K
c
S3
total
unique
total
unique
total
unique
total
unique
1
14
.1
6
2.
65
1.
17
1.
35
95
1
11
81
6.
91
FB
gn
00
04
58
4
R
rp
1
7
7
13
13
7
6
14
9
2
25
.5
9
4.
79
2.
85
1.
55
23
27
13
56
3.
29
FB
gn
00
02
63
8
B
j1
18
9
14
10
5
3
9
7
3
32
.8
9
6.
16
0.
79
1.
13
64
1
99
1
1.
83
FB
gn
00
40
07
8
po
nt
0
0
6
5
0
0
7
5
4
12
.0
3
2.
25
3.
40
4.
41
27
74
38
68
1.
79
FB
gn
00
13
26
3
Tr
l
9
3
9
3
3
2
2
1
5
8.
78
1.
65
0.
61
0.
71
49
8
62
6
1.
73
FB
gn
00
34
87
8
pi
ta
0
0
2
1
0
0
2
1
6
20
.8
3
3.
90
0.
94
1.
09
76
4
95
6
1.
63
FB
gn
00
30
85
4
C
G
82
89
7
4
7
6
10
6
1
1
7
19
.1
6
3.
59
1.
44
2.
00
11
71
17
54
1.
51
FB
gn
00
13
59
1
M
i-2
0
0
5
4
3
3
3
3
8
9.
36
1.
75
4.
45
3.
59
36
29
31
49
1.
39
FB
gn
00
20
30
9
cr
ol
5
2
7
4
1
1
1
1
9
11
.2
7
2.
11
2.
81
3.
09
22
94
27
10
1.
38
FB
gn
00
00
41
2
D
1
0
0
4
3
3
2
3
3
10
17
.5
4
3.
29
0.
89
1.
22
72
6
10
72
1.
38
FB
gn
00
39
33
8
XN
P
14
11
6
6
3
3
0
0
11
32
.3
9
6.
07
0.
87
1.
00
71
0
87
7
1.
14
FB
gn
00
34
65
7
LB
R
3
2
6
3
0
0
2
2
12
20
.0
8
3.
76
0.
92
2.
17
75
3
19
06
1.
13
FB
gn
02
59
78
5
pz
g
0
0
4
4
0
0
2
2
13
21
.0
5
3.
94
0.
55
1.
10
45
2
96
6
1.
05
FB
gn
00
39
74
3
C
G
79
46
0
0
0
0
1
1
5
4
14
16
.5
4
3.
10
0.
95
2.
41
77
8
21
15
1.
05
FB
gn
00
02
78
3
m
or
0
0
5
4
0
0
0
0
15
33
.7
1
6.
31
0.
49
0.
46
39
8
40
0
1.
03
FB
gn
00
28
70
0
R
fC
38
0
0
5
5
1
1
2
2
16
22
.3
0
4.
18
0.
71
0.
88
58
1
76
9
1.
01
FB
gn
00
37
65
9
K
dm
2
0
0
2
2
0
0
3
2
17
4.
10
0.
77
3.
23
3.
40
26
34
29
81
0.
98
FB
gn
00
35
37
0
C
G
12
40
1
1
2
2
1
1
2
2
18
26
.8
0
5.
02
1.
16
1.
31
95
0
11
48
0.
96
FB
gn
00
15
66
4
D
re
f
1
1
4
4
0
0
2
1
19
16
.2
0
3.
03
1.
74
2.
87
14
21
25
15
0.
94
FB
gn
00
44
32
4
C
hr
o
0
0
2
2
0
0
3
2
20
8.
44
1.
58
0.
67
0.
53
54
7
46
5
0.
92
FB
gn
00
39
01
9
H
P1
c
0
0
2
2
0
0
0
0
21
26
.6
5
4.
99
1.
66
2.
09
13
51
18
34
0.
87
FB
gn
00
33
03
9
gp
21
0
1
1
4
4
0
0
2
2
22
33
.3
3
6.
24
9.
65
6.
72
78
73
58
94
0.
83
FB
gn
00
26
17
0
sm
t3
17
5
11
4
5
1
1
1
23
26
.9
4
5.
05
0.
73
1.
31
59
9
11
50
0.
82
FB
gn
00
01
99
4
cr
p
0
0
5
3
0
0
0
0
24
15
.6
7
2.
94
0.
84
0.
87
68
7
76
7
0.
79
FB
gn
00
32
10
5
bo
rr
10
6
3
3
0
0
0
0
25
27
.4
2
5.
14
2.
39
2.
70
19
53
23
69
0.
78
FB
gn
00
31
05
7
U
bq
n
0
0
6
5
0
0
0
0
26
27
.7
8
5.
20
10
.0
0
6.
31
81
60
55
29
0.
75
FB
gn
00
20
25
5
ra
n
4
3
6
6
1
1
4
4
pe
pt
id
es
pe
pt
id
es
pe
pt
id
es
Ta
bl
e 
A6
: T
A
S
-R
 p
ro
te
in
s,
 ra
nk
ed
 b
y 
co
nf
id
en
ce
 s
co
re
K
c
S3
rank
detectable 
peptides/ 1000 
a
detectability score 
b
N
or
m
al
iz
ed
 G
en
e 
Ex
pr
es
si
on
 S
co
re
 
c
Ex
pr
es
si
on
 le
ve
l d
Confidence score 
e
Fl
yb
as
e 
ID
N
am
e
TA
S_
L
TA
S_
R
TA
S_
L
TA
S_
R
pe
pt
id
es
| Compositional and Functional Analysis of Polycomb Target Chromatin
140
K
c
S3
K
c
S3
total
unique
total
unique
total
unique
total
unique
27
18
.9
8
3.
55
0.
43
0.
79
34
7
69
6
0.
72
FB
gn
00
11
60
6
K
lp
3A
0
0
1
1
0
0
2
2
28
24
.7
3
4.
63
0.
88
1.
00
71
7
87
3
0.
72
FB
gn
00
15
60
2
B
EA
F-
32
0
0
4
3
0
0
0
0
29
16
.2
8
3.
05
2.
49
2.
63
20
29
23
02
0.
71
FB
gn
00
15
61
0
C
af
1
2
2
2
2
1
1
2
1
30
18
.2
5
3.
42
1.
09
2.
36
89
2
20
70
0.
58
FB
gn
00
00
28
3
C
p1
90
0
0
0
0
0
0
3
3
31
25
.0
4
4.
69
2.
18
10
.0
3
17
82
87
96
0.
56
FB
gn
00
15
62
3
C
pr
0
0
1
1
0
0
5
4
32
21
.1
3
3.
96
1.
64
1.
43
13
36
12
54
0.
55
FB
gn
00
10
24
7
Pa
rp
0
0
1
1
0
0
2
2
33
15
.2
7
2.
86
0.
82
0.
97
66
7
85
1
0.
53
FB
gn
00
00
05
4
Ad
f1
0
0
2
2
0
0
0
0
34
10
.6
8
2.
00
1.
60
2.
36
13
05
20
66
0.
50
FB
gn
00
03
01
3
os
a
0
0
2
2
0
0
0
0
35
13
.4
5
2.
52
2.
00
5.
44
16
30
47
69
0.
48
FB
gn
00
26
53
3
D
ek
0
0
1
1
1
1
2
1
36
19
.4
8
3.
65
0.
56
0.
68
45
9
60
0
0.
47
FB
gn
00
22
77
2
O
rc
1
0
0
2
1
0
0
0
0
37
16
.6
7
3.
12
1.
22
1.
16
99
2
10
19
0.
46
FB
gn
00
30
08
2
H
P1
b
0
0
1
1
0
0
1
1
38
19
.0
5
3.
57
0.
56
0.
93
45
9
81
3
0.
46
FB
gn
00
33
57
1
C
G
11
97
9
0
0
2
2
0
0
0
0
39
20
.0
5
3.
75
0.
83
0.
50
67
4
44
0
0.
45
FB
gn
00
37
71
9
bo
ck
sb
eu
te
l
0
0
2
2
1
1
0
0
40
23
.1
1
4.
33
3.
15
1.
93
25
71
16
92
0.
44
FB
gn
00
26
40
1
N
ip
pe
d-
B
0
0
3
3
0
0
0
0
41
9.
12
1.
71
0.
50
0.
74
40
7
64
7
0.
43
FB
gn
00
24
22
7
ia
l
5
5
1
1
1
1
0
0
42
21
.3
1
3.
99
0.
89
0.
99
72
3
86
4
0.
41
FB
gn
00
86
85
5
C
G
17
07
8
0
0
1
1
0
0
1
1
43
25
.9
4
4.
86
5.
10
5.
03
41
58
44
13
0.
40
FB
gn
00
27
38
1
G
AG
3
3
4
4
2
2
0
0
44
22
.4
9
4.
21
1.
85
6.
03
15
13
52
87
0.
37
FB
gn
00
22
34
9
C
G
19
10
1
1
1
1
2
1
2
1
45
24
.3
7
4.
56
1.
99
0.
03
16
24
29
0.
36
FB
gn
00
45
85
2
ha
m
1
1
2
1
0
0
0
0
46
14
.3
7
2.
69
0.
19
0.
14
15
5
11
9
0.
35
FB
gn
00
40
46
5
D
ip
3
10
5
1
1
0
0
0
0
47
24
.9
3
4.
67
0.
99
1.
18
81
0
10
37
0.
35
FB
gn
00
40
06
6
w
ds
0
0
1
1
0
0
1
1
48
23
.1
7
4.
34
0.
91
1.
93
74
3
16
90
0.
35
FB
gn
00
22
72
0
zf
30
C
0
0
2
2
0
0
0
0
49
27
.0
3
5.
06
0.
66
0.
76
53
5
66
2
0.
35
FB
gn
00
11
71
5
Sn
r1
0
0
2
1
0
0
0
0
50
18
.4
7
3.
46
2.
30
2.
68
18
80
23
53
0.
34
FB
gn
00
11
70
3
R
nr
L
1
1
2
1
0
0
0
0
51
29
.4
4
5.
51
0.
54
0.
66
43
7
58
3
0.
33
FB
gn
00
29
79
8
C
G
40
78
0
0
2
2
0
0
0
0
52
20
.3
7
3.
81
1.
57
3.
78
12
84
33
12
0.
31
FB
gn
00
22
76
4
Si
n3
A
0
0
1
1
0
0
1
1
pe
pt
id
es
pe
pt
id
es
Fl
yb
as
e 
ID
N
am
e
TA
S_
L
TA
S_
R
TA
S_
L
Ta
bl
e 
A6
, c
on
tin
ue
d
K
c
S3
rank
detectable 
peptides/ 1000 
a
detectability score 
b
N
or
m
al
iz
ed
 G
en
e 
Ex
pr
es
si
on
 S
co
re
 
c
Ex
pr
es
si
on
 le
ve
l d
Confidence score 
e
TA
S_
R
pe
pt
id
es
pe
pt
id
es
| Compositional and Functional Analysis of Polycomb Target Chromatin
141
K
c
S3
K
c
S3
total
unique
total
unique
total
unique
total
unique
53
21
.8
8
4.
10
2.
15
2.
66
17
55
23
32
0.
31
FB
gn
00
03
61
2
Su
(v
ar
)2
-1
0
3
2
2
2
0
0
0
0
54
28
.4
7
5.
33
1.
87
0.
92
15
25
80
6
0.
30
FB
gn
00
64
12
2
C
G
33
69
1
3
1
2
1
1
1
0
0
55
30
.3
0
5.
67
0.
77
1.
67
63
2
14
61
0.
29
FB
gn
00
04
10
6
cd
c2
0
0
2
2
0
0
0
0
56
9.
49
1.
78
3.
47
6.
94
28
29
60
83
0.
29
FB
gn
00
03
50
7
sr
p
1
1
2
1
0
0
0
0
57
15
.7
6
2.
95
5.
07
4.
22
41
39
37
01
0.
26
FB
gn
00
00
28
9
cg
0
0
2
2
1
1
0
0
58
17
.7
0
3.
31
0.
29
1.
49
23
9
13
05
0.
24
FB
gn
00
30
41
8
C
G
40
04
4
1
1
1
0
0
0
0
59
19
.0
2
3.
56
5.
10
5.
03
41
58
44
13
0.
23
FB
gn
00
34
96
1
C
G
31
63
12
7
2
2
2
1
0
0
60
12
.2
2
2.
29
1.
46
2.
61
11
89
22
89
0.
23
FB
gn
00
04
39
9
ps
q
0
0
0
0
2
2
1
1
61
20
.8
3
3.
90
0.
51
1.
06
41
3
92
9
0.
21
FB
gn
00
33
60
9
fb
l6
0
0
0
0
2
2
1
1
62
53
.7
6
10
.0
7
1.
49
9.
26
12
17
81
22
0.
19
FB
gn
00
01
22
4
H
sp
23
0
0
0
0
1
1
3
3
63
44
.4
4
8.
32
2.
62
1.
70
21
35
14
87
0.
19
FB
gn
00
31
97
7
ba
f
1
1
1
1
1
1
1
1
64
30
.6
5
5.
74
7.
54
4.
23
61
54
37
07
0.
17
FB
gn
00
11
82
3
Pe
n
0
0
2
2
0
0
0
0
65
14
.6
6
2.
75
3.
19
3.
00
26
05
26
29
0.
17
FB
gn
00
04
92
5
eI
F-
2α
2
2
1
1
0
0
0
0
66
25
.9
3
4.
86
1.
08
1.
20
88
5
10
50
0.
17
FB
gn
00
14
86
1
M
cm
2
3
2
1
1
0
0
0
0
67
27
.7
8
5.
20
1.
04
1.
22
84
7
10
71
0.
16
FB
gn
00
20
63
3
M
cm
7
2
2
1
1
0
0
0
0
68
43
.2
7
8.
10
9.
64
5.
89
78
66
51
63
0.
13
FB
gn
00
51
36
3
Ju
pi
te
r
1
1
2
2
0
0
0
0
69
25
.4
5
4.
77
5.
37
8.
18
43
80
71
70
0.
09
FB
gn
00
00
56
6
Ei
p5
5E
3
3
1
1
0
0
0
0
pe
pt
id
es
pe
pt
id
es
pe
pt
id
es
Ta
bl
e 
A6
, c
on
tin
ue
d
K
c
S3
rank
detectable 
peptides/ 1000 
a
detectability score 
b
N
or
m
al
iz
ed
 G
en
e 
Ex
pr
es
si
on
 S
co
re
 
c
Ex
pr
es
si
on
 le
ve
l d
Confidence score 
e
Fl
yb
as
e 
ID
N
am
e
TA
S_
L
TA
S_
R
TA
S_
L
TA
S_
R
pe
pt
id
es
a.
 n
um
be
r o
f p
ep
tid
es
 w
ith
 a
 d
et
ec
ta
bi
lit
y 
>0
.6
, c
al
cu
la
te
d 
us
in
g 
th
e 
P
ep
tid
e 
de
te
ct
ab
ili
ty
 p
re
di
ct
or
 a
t h
ttp
://
bi
t.l
y/
gr
3j
K
R
 (1
47
); 
b.
 n
um
be
r o
f d
et
ec
ta
bl
e 
pe
pt
id
es
/1
00
0 
no
rm
al
iz
ed
 to
 a
 s
ca
le
 o
f 0
-1
0,
 w
he
re
 1
0 
is
 th
e 
va
lu
e 
fo
un
d 
fo
r t
he
 p
ro
te
in
 w
ith
 th
e 
hi
gh
es
t d
et
ec
ta
bl
e 
pe
pt
id
es
/1
00
0 
(H
sp
23
, 5
3.
76
); 
c.
 th
e 
N
or
m
al
iz
ed
 G
en
e 
E
xp
re
ss
io
n 
S
co
re
 is
 th
e 
re
la
tiv
e 
ge
ne
 e
xp
re
ss
io
n,
 o
n 
a 
sc
al
e 
of
 0
-1
0,
 w
he
re
 1
0 
is
 th
e 
va
lu
e 
of
 th
e 
hi
gh
es
t e
xp
re
ss
in
g 
ge
ne
 in
 th
e 
re
sp
ec
tiv
e 
ce
ll 
lin
e 
(K
c:
 ra
n,
 8
16
0;
 S
3:
 c
pr
, 8
79
6)
; 
d.
 e
xp
re
ss
io
n 
da
ta
 o
bt
ai
ne
d 
fro
m
 th
e 
m
od
E
N
C
O
D
E
 d
at
ab
as
e 
(1
48
); 
e.
  v
al
ue
 re
su
lti
ng
 fr
om
 th
e 
di
vi
si
on
 o
f t
he
 n
um
be
r o
f p
ep
tid
es
 d
et
ec
te
d 
in
 b
ot
h 
ce
ll 
lin
es
 b
y 
th
e 
su
m
 
of
 th
e 
D
et
ec
ta
bi
lit
y 
S
co
re
 a
nd
 th
e 
av
er
ag
e 
of
 th
e 
N
or
m
al
iz
ed
 G
en
e 
E
xp
re
ss
io
n 
S
co
re
s 
fro
m
 th
e 
2 
ce
ll 
lin
es
; R
ed
 fo
nt
: e
xp
re
ss
io
n 
le
ve
ls
 n
ot
 a
va
ila
bl
e;
 a
ttr
ib
ut
ed
 a
ve
ra
ge
 
ex
pr
es
si
on
 le
ve
l o
f a
ll 
fa
ct
or
s 
de
te
ct
ed
.
| Compositional and Functional Analysis of Polycomb Target Chromatin
142
Table A7: Eye color phenotypes on Mod(TPE) Screen
+c + + red + orange Negative control
+ red + brown
Ubx red Ubx dark orange
+ orange + brown
Ubx orange Ubx orange
+ orange + orange
Ubx orange Ubx orange
+ bright red + red
Ubx red Ubx brown
+ bright red + red
Ubx red Ubx dark orange
+ dark orange + orange
Ubx red Ubx red
+ red + ND
Ubx red Ubx ND
+ orange + orange
Ubx red Ubx red
+ red + ND
Ubx red Ubx ND
+ red + ND
Ubx red Ubx ND
+ red + ND
Ubx red Ubx ND
+ red + ND
Ubx red Ubx ND
+ red + ND
Ubx red Ubx ND
+ red + ND
Ubx red Ubx ND
+ red + ND
Ubx red Ubx ND
+ red + orange
Ubx red Ubx dark orange
+ red + red
Ubx red Ubx dark red
+ red + ND
Cy red Ubx ND
+ red + orange
Ubx red Ubx brown
+ red + ND
Ubx red Ubx ND
+ dark orange + ND
Ubx dark orange Ubx ND
+ red + ND
Ubx red Ubx ND
Eye color
+; C62b
Eye color
M26; C62a
CG1240 Df(3L)BSC119 Negative
XNP 1 Negative
" UY3132 Mutant not on III
borr Df(2L)TE30Cb Negative
Bj1 Df(3L)XAS96 Negative
mor Df(3R)Po4 Mutant, but too weak to map.
CAF1 Df(3R)BSC471 Negative
Snr1 1319 Negative
osa 90 Negative
CG2199 Df(3L)Ar14-8 Negative
" Df(3L)BSC289 Negative
su(Hw) 3 Negative
rept 6945 Negative
brm 2 Mutant on III
SMC1 exc46 Negative
WRNexo Df(3R)Cha7 Mutant, but too weak to map.
sle 57 Negative
mod 7570 Su(TPE)e
" Df(3R)04661 Su(TPE)e
" Df(3R)BSC739 Mutant not on III
" Df(3R)D605 Mutant not on III
Gene Allele Interpretation
woc Df(3R)BSC497 Negative
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+ orange + ND
Cy dark orange Ubx ND
+ red + ND
Cy red Ubx ND
+ brown + ND Mutant on III;
Ubx red Ubx ND False positivef
+ red + ND
Ubx w5 Ubx ND
a y w67c23; Df(2L)M26; P{w+}39C-62 females were crossed to y w67c23; mutant/SM1, Cy or y w67c23;
mutant/TM6, Ubx. F1 males were aged for three days, then examined for eye color. Males without the balancer
constitute the test for suppressors of the Su(TPE) activity of M26 on the C62 telomeric insert. Males with the
balancer act as a sibling control.
b y w67c23; P{w+}39C-62 females were crossed to y w67c23; mutant/SM1, Cy or y w67c23; mutant/TM6, Ubx.
F1 males were aged for three days, then examined for eye color. Males without the balancer constitute the test
for suppressors of the Su(TPE) activity of M26 on the C62 telomeric insert. Males with the balancer act as a
sibling control.
c Oregon R was a negative control.
d ND indicates not done.
e Mutant is a dominant suppressor of TPE at C62, in 3R TAS, but not at 11-5, in 2LTAS. Df(3R)04661 removes
part of 3R TAS. Deficiencies for 3R TAS are known to be dominant suppressors of TPE at the 3R telomere
(Laurenti et al, 1995). The apparent enhancement of the suppression caused by M26 is likely due to a
combination of suppression due to M26 with suppression due to the mod mutant.
f The Df(3L)fz-M21 chromosome carries a suppressor of the M26 suppressor, but the Df(3L)XG3 chromosome
does not. The simplest explanation is that the observed effect is due to a genetic factor at an unrelated site.
Gene Allele
Eye color Eye color
M26; C62a +; C62b
Trl Df(3L)fz-M21
" Df(3L)XG3 Negative
Interpretation
crol 4418 Mutant not on II
" Df(2L)BSC243 Negative
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